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ABSTRACT
Cerebrovascular Dysfunction in Metabolic Syndrome and Depression: Mechanisms and
Implications for Neurovascular Disease
Steven D. Brooks
Cerebrovascular diseases are any pathological conditions that are caused by disruptions
or alterations in the blood supply to the brain. The brain, which is only 2% of body mass,
constantly requires a minimum of 20% of cardiac output to meet its unique metabolic demands.
Cerebral tissue relies on aerobic respiration and therefore requires a constant, steady supply of
blood to provide oxygen and glucose to make ATP. Insufficient perfusion of the brain, which
occurs as a result of reduced or obstructed blood flow, results in cerebral ischemia; ischemic
neurons quickly deplete their available ATP and die if blood flow is not restored. Disruptions in
the delivery of blood to the brain, either acutely or chronically, can lead to impairment of
neurological function, neuronal cell death, and even death.
Metabolic Syndrome (MetSyn) is the comorbid presence of three or more risk factors,
including: central obesity, hypertriglyceridemia, high cholesterol, hypertension, and
hyperglycemia. Data from the NHANES study reports that over 35% of all adults, and over 50%
of adults over 60, are estimated to have MetSyn. MetSyn is a risk factor for almost every major
cardiovascular disease, and causes well-defined impairments in the peripheral circulation.
However, its effects on regulation of cerebral blood flow are not well understood. The primary
aim of this dissertation is to study the functional and structural alterations cause by MetSyn in
the cerebral circulation, utilizing the obese Zucker rat (OZR), a translationally relevant model for
studying the vascular complications of MetSyn, and to interrogate how vascular and neurological
outcomes to cerebrovascular disruptions are influenced by pre-existing cerebral vasculopathies
associated with MetSyn in OZR. The specific aims are as follows:
1. Define and characterize structural and functional changes in vascular reactivity, vessel wall
mechanics, and vascular remodeling in middle cerebral arteries (MCA) of OZR, and evaluate
changes in microvascular density throughout the cerebral microcirculation.
2. Determine the contribution of each constituent pathology of MetSyn on the development of
cerebrovascular impairments in OZR, and identify mechanisms through which these
pathologies are progressing in the cerebral circulation.
3. Interrogate the mechanisms of stroke-induced vascular dysfunction in lean Zucker (LZR) and
OZR, and determine how pre-existing vascular dysfunction in OZR changes outcomes and
pathological mechanisms following ischemic stroke.
4. Investigate the effects of chronic stress/ depression on cerebrovascular function in LZR and
OZR, assess efficacy of exercise as a prophylactic anti-depressant treatment, and evaluate
mechanisms through which impairments, and exercise-based recovery, are occurring.
The results of these studies have helped to establish the prominent driving mechanism of
cerebrovascular dysfunction in MetSyn, and defined the functional impacts these impairments
have on outcomes to ischemic stroke and stress-induced depression. By thoroughly interrogating
these mechanisms and evaluating functional outcomes of relevant disease states, this dissertation
hopes to lay the groundwork for a new approach to understanding the relationship between
MetSyn, cerebrovascular dysfunction, and neurological outcomes.
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CHAPTER 1: REVIEW OF THE LITERATURE
Part 1: Introduction to Cerebrovascular Disease
Cerebrovascular diseases are any pathological conditions that are caused by disruptions
or alterations in the blood supply to the brain [1]. The brain, which is only 2% of body mass,
constantly needs 20% of cardiac output to meet its unique metabolic demands [2, 3]. Cerebral
tissue does not store glucose, and relies principally on aerobic respiration, so the brain requires a
constant, steady supply of blood to provide the necessary oxygen and glucose needed to make
ATP [4, 5]. Insufficient perfusion of the brain, which occurs as a result of reduced or obstructed
blood flow, results in cerebral ischemia[6]; ischemic neurons quickly deplete their available ATP
and will rapidly die if blood flow is not restored[3, 5]. Such disruptions in the delivery of blood
to the brain, either acutely or chronically, can lead to impairment of neurological function,
neuronal cell death, and even death [7].
Acute cerebrovascular diseases, such as ischemic stroke and transient ischemic attack
(TIA), occur as a result of a sharp decrease in blood flow to a region of the brain, causing an area
of cerebral tissue to become ischemic [1, 3, 8]. The most common etiology of acute ischemia is
arterial blockage by a blood clot, but can also result from hypoperfusion due severe hypotension
or cerebral hemorrhage [3, 7]. Neurons have a critical oxygen tension of 25-40mmHg; when P02
drops below this threshold, aerobic production of ATP can decline by over 90% within 5 minutes
[4]. Neurons depend on a constant supply of ATP, and cannot produce ATP via anaerobic
respiration in sufficient amounts to survive. Within minutes of the ischemic onset, ATP
starvation will cause hypoxic neurons to depolarize, allowing an influx of Ca++ that triggers
ejection of neurotransmitters like glutamate, and lysis of the cell, releasing large amounts of
reactive oxygen species (ROS) [4, 9, 10]. Glutamate binds neighboring NMDA receptors, exiting
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these neurons and stimulates an excitatory injury through neighboring neurons, and oxidative
damage inflicted by ROS can induce apoptosis in these neighboring cells as well [4, 9]. The
ischemic core of infarcted neurons will die as a result of the acute hypoxia; however, the
spreading nature of the excitotoxic and oxidative damage can induce necrosis and apoptosis of
neurons in neighboring neurons that were otherwise adequately perfused, an area of at-risk
neurons known as the penumbra[6, 9, 11] The physical symptoms that define stroke and TIA,
such as facial dropping, impaired motor control/weakness of the limbs, and slurred or difficult
speech, are caused by the immediate dysfunction of hypoxic neurons. If the hypoxic neurons
become necrotic, the symptoms may become permanent long-term disabilities [6, 8, 11, 12].
However, during a TIA, the hypoxic neurons recover due to rapid restoration of blood flow, and
no infarction or penumbra will develop.

The neurological symptoms will resolve, and no

permanent lasting damage occurs [7, 13].
The principal difference between ischemic stroke and TIA is the ability of the patient’s
body to quickly restore blood flow to the ischemic area [13]. Time is the most crucial factor in
this equation, as reflected by the American Stroke Association’s mantra of “Time is Brain” [12].
Mechanistically, the ability to restore blood flow involves rapid dissolution of the blood clot
and/or diversion of blood into the ischemic region via collateral vessels [6, 7, 12]. Restoration of
blood flow is also critical in enhancing the survival of the at-risk neurons populating the
penumbra [14, 15]. The most active areas of stroke research therefore have historically centered
on ways to lyse or remove clots, improve collateral blood supply, reduce the spread of excitotoxic injury, or prolong the ability of hypoxic neurons to survive and therefore lengthen the gap
between onset of hypoxia and infarction [7, 11, 12, 14, 15].
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Figure 1: Schematic Representation of Ischemic Stroke
Chronic cerebrovascular disease
is the accumulated effects of neuronal
injury over time, due to repeated periods
of hypoxia, the aggregation of many
small infarctions deep within the brain,
and consistent hypoperfusion stemming
Cerebral Blood Supply
Figure Adapted From Creighton University SOM Stroke Program

from arterial stiffening, rarefaction, and
dysfunction [1, 3, 16-18]. The exact

mechanisms vary by patient, but the general result is loss of mental ability including clarity of
executive thought (mild cognitive impairment, or MCI) [3, 17, 18], impairments to memory
formation and memory recall, and gradual impairments in motor and sensory function [1, 3, 19].
The most prominent chronic cerebrovascular disease is dementia, which includes both
Alzheimer’s and vascular dementia [3, 16, 20]. Both vascular dementia and MCI are
characterized clinically by the presence of small infarcts throughout the brain, often observable
via MRI [17, 21]. While each small infarct on its own may have not caused noticeable
symptoms, their accumulation over time results in cognitive impairments and symptoms of
dementia [21, 22].
A third type of cerebrovascular disease is intracranial aneurysm. An intracranial
aneurysm is a disorder in which a weak or malformed cerebral artery balloons out due to its
structural weakness, and may eventually rupture, leading to intracranial hemorrhage [215, 216].
The largest and most common intracranial aneurysm is the saccular aneurysm, which typically
arise in or immediately adjacent to the Circle of Willis [217]. The etiology of saccular aneurysms
are almost always hereditary [215, 218], and therefore do not neatly fit the definition of acute or
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chronic cerebrovascular disease as defined here. Because of its genetic components, aneurysm
will not be included or discussed alongside the other cerebrovascular diseases listed in this
dissertation. Cardiovascular risk factors, such as hypertension and smoking, can increase risk of
aneurysm rupture and vasospasm [215, 218]; however, these mechanisms are common to the
pathways through with CV risk factors affect cerebrovascular circulation in general. For
simplification and topicality, the discussion of these mechanisms on post-aneurysm outcome will
be omitted as well.
While both ischemic stroke and cognitive vascular diseases represent distinct
pathological conditions, they share a common etiology rooted in the dysregulation of cerebral
blood flow [23, 24]. This review will present the structure and regulation of the cerebral
circulation in the condition of health, and then explore how the individual components of the
cerebral vasculature malfunction under pathological conditions. As both ischemic stroke and
vascular cognitive impairments are rooted in underlying vascular comorbidities, it is important to
first characterize the nature of cerebrovascular dysfunction in the metabolic syndrome, a
prevalent condition that is strongly linked as a risk factors for stroke and vascular dementia due
to its constituent underlying pathologies [25-29]. The mechanisms of vessel function and blood
flow regulation during ischemic stroke will then be detailed, with emphasis on differences
between healthy and cardiovascular disease (CVD) comorbid studies. Lastly, the mechanisms of
cerebrovascular dysfunction and cognitive impairments will be discussed. By highlighting the
mechanisms and identifying commonalities between these conditions, this reviews aims to
establish a robust framework from which to further explore how mechanisms of cerebrovascular
dysfunction impact highly relevant health outcomes in several common disease states.
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Part 2: Public Health and Disease Burden

of Cerebrovascular Disease and Metabolic

Syndrome
Ischemic Stroke is among the leading causes of death and disease burden worldwide.
According to the AHA’s 2016 Heart Disease and Stroke Statistics update, around 800,000 people
will experience a stroke every year in the US; a stroke occurs on average every 40 seconds, and
approximately 15 people die every hour from stroke [30, 31]. While overall mortality has
improved in the past 6 years, the prevalence of stroke has not decreased, and the total number of
strokes is expected to double by 2050 as the population continues to age. Stroke is therefore one
of the leading causes of serious long-term disability and decreased quality of life, and alone is
responsible for a disease cost burden of over $34 billion in the US annually [8, 12, 30]. Stroke
also disproportionately affects the most vulnerable and disadvantaged of our population, as
stroke death rates are highest in African Americans and Hispanics, and also greatly elevated in
Appalachia and throughout the southeastern US [8, 30, 31].
Despite the prevalence of ischemic stroke, treatment options for patients are very limited.
Currently, there are only two FDA-approved treatments for ischemic stroke [7, 12]. The “gold
standard” treatment is intravenous recombinant tissue plasminogen activator (IV tPA), first
approved for use in 1996, which works to dissolve the blood clot and restore blood flow to the
ischemic area [12, 32]. However, IV tPA usage is restricted by a narrow treatment window (0 to
3-4.5 hours after symptom onset), as well as contra-indicated for use in many patients due to
elevated hemorrhage risk. As a result, IV tPA is vastly under-utilized, with estimates of usage
ranging from only 3%-7.0% of stroke patients [32-34]. The second most common treatment for
stroke is endovascular surgery, in which a clot is either retrieved or directly aspirated with tPA
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[7, 12, 34]. Usage of endovascular treatment for stroke is low, however, due to the specialization
of the procedure and the stringent inclusion criteria for treatment.
While stroke research has been a priority of both national funding agencies and
pharmaceutical companies, no new drugs have been approved since tPA first gained approval in
1996. Intravenous tPA’s benefit is solely derived from its ability to more quickly restore
perfusion, and many other drugs have been sought to improve this strategy [15, 35]. Other
strategies have focused on improving collateral blood flow to ischemic areas, enhancing the
ability of neurons to survive under hypoxia to extend the effective window for reperfusion-based
recovery, and limiting the spreading excito-toxic effects that often cause larger infarctions during
ischemic stroke [36, 37]. Clearly, novel strategies are needed to expand treatment options and
efficacies for stroke patients, and chapter 4 of this dissertation will addresses such an approach.
The US Centers for Disease Control names high blood pressure, high cholesterol, heart
disease, and diabetes as significant independent risk factors for stroke, with hypertension being
the most significant [8, 38]. The metabolic syndrome, which encompasses each of these risk
factors as constituents, is also itself a significant risk factor for stroke [38-40]. The metabolic
Syndrome is defined as the presence of three or more risk factors, including: central obesity,
hypertriglyceridemia, high cholesterol, hypertension, and hyperglycemia [25, 26, 38]. Data from
the NHANES study reveals that over 35% of all adults, and over 50% adults aged 60 or older,
are estimated to have the metabolic syndrome [25]. The conditions that underlie the metabolic
syndrome, including most types of cardiovascular disease, have a cumulative cost of over $300
billion in the US annually, which comprises the largest financial burden on the US healthcare
system. For contrast, the annual cost of all types of cancer is just under $90 billion [25, 26].
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Treatment of patients with the metabolic syndrome focuses on managing and reducing
the individual risk factors themselves [25, 26]. Notably, however, each of these risk factors has a
distinct impact on the regulation and delivery of blood flow [41-44]. Each constituent pathology
is linked to impairments arterial function, and the resultant restrictions in blood flow lead to
increased incidence of heart attack and stroke [41, 45, 46]. Studying these underlying
mechanisms, and how they interact with each other, can provide valuable insight into the
progression of vascular disease, and help identify potential areas for therapeutic development.
The relevant pathophysiological mechanisms that underlie the metabolic syndrome, and their
specific effects in the cerebrovasculature, will be detailed in the fourth part of this introduction.
Chronic impairments in blood flow delivery to the brain often manifest as cognitive
impairments [17, 21]. The CDC estimates that over 16 million adults currently suffer from some
form of cognitive impairment, ranging from Mild Cognitive Impairment (MCI) to more advances
dementias, such as Alzheimer’s disease and vascular dementia [47]. The direct and indirect costs
of caring for these patients as their symptoms worsen has been estimated as high as $144 billion
annually, and is expected to rise as the population continues to age [16, 21, 48, 49]. Currently, no
FDA-approved treatments are available to treat or reverse these cognitive conditions; only drugs
which slow the onset are available. While not all dementia or cognitive impairments are strictly
vascular-derived, blood flow related issues are thought to be amongst the most common
underlying factors, and patients with heart disease, stroke, and other types of CVD are all at
elevated risk of developing cognitive impairments later in life [17, 22, 29, 31, 48-50].
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Table 1: Lifetime Prevalence of Stroke, Dementia, and other Cerebrovascular Pathologies
among all US adults age 60 or older
Lifetime Prevalence of Cerebrovascular Disease in the United States
Adults (>60 years)

Men (>60 years)

Women (>60 years)

Ischemic Cerebrovascular
Events

22%

17%

21%

Ischemic Stroke

18%

15%

19%

Transient Ischemic Attack (TIA)

3%

2%

3%

Mild Cognitive Impairment
(MCI)

20%

18%

20%

All Dementia

16%

13%

19%

Alzheimer's Disease

11%

10%

17%

Vascular Dementia

4%

~4%

~4%

Stroke or Dementia

~40%

35%

50%

Sources: [16, 17, 31, 40, 48, 49, 51]

Table 2: Prevalence of Metabolic Syndrome and Depression in US Adults
Lifetime Prevalence of Metabolic Syndrome and Depression in the US
All Adults

Men

Women

Metabolic Syndrome (All Adults)

35%

37%

33%

Metabolic Syndrome (>60 years)

50%

44%

54%

All Depressive Mood Disorders

21%

15%

27%

Major Depressive Disorder

16%

8-12%

20-26%

Sources: [25, 27, 39, 52-56]

Depression is another independent risk factor for development of MCI and dementia [20,
54, 57, 58]. Interestingly, depression is also an established risk factor for developing CVD, and
inversely, CVD is an independent risk factor for developing depression [59-67]. While a strong
causal mechanism defining the relationship between depression and CVD is unknown,
depression has been shown to have direct effects on vascular function. Patients with depression
exhibit impaired flow-mediated dilation and endothelium-dependent dilation, as well as
8

decreased plasma nitric oxide (NO) and endothelial nitric oxide synthase (eNOS) activity [60,
68-70]. Additionally, obesity, a major CVD risk factor and component of the metabolic
syndrome, is also directly associated with depression [68, 71, 72]. As over 15% of adults will
suffer from depression [53, 54, 58, 73, 74], a large number of patients will suffer comorbidity
between depression and CVD, depression and the metabolic syndrome, and depression and
stroke [55, 58]. A potential linking pathway between these conditions may involve regulation of
the Sympathetic-Adrenal-Medullary (SAM) axis and the hypothalamic-pituitary-adrenal (HPA)
axis [68, 75-79]; chronic stress, which is among the most well-established etiological triggers for
depression, is known to cause hyper-activation of the SAM and HPA axes, leading to enhanced
catecholamine release, elevated glucocorticoid levels, increased chronic inflammation,
hyperglycemia, and risk of oxidative stress [61, 65, 71, 80, 81].
The HPA axis modulates the neuroendocrine stress response by stimulating production of
glucocorticoids, such as cortisol, and activating the SAM axis to ready the fight-or-flight
response. However, chronic stress causes long term elevation of stress hormones, which
overwhelm the endogenous negative feedback mechanisms of the hypothalamus and pituitary
[65, 79, 82-87]. Clinically, hypercortisolemia stemming from HPA axis over-activation [88] is
one among the most common biomarkers found in depressed patients [89, 90]. Cortisol
dysregulation has direct consequences for vascular health, contributing to impairment of
vasomotor responses and promoting endothelial dysfunction [66, 86, 88, 90, 91]. Glucocorticoids
can directly reduce endothelial NO bioavailability by limiting tetrahydrobiopterin (BH4) and
eNOS gene transcription, and also by affecting pathways of reactive oxygen species production
[76, 86], and studies that have found treatment with an inhibitor of glucocorticoid production
results in improved endothelial dysfunction in depressed patients [92, 93]. Chronic
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hypercortisolemia also promotes low-grade, chronic inflammation [94, 95], and cortisol
insensitivity develops in lymphocytes of depressed patients [91, 94], impairing their ability to
attenuate immune responses and leading to chronic inflammation [95]. Hyperactivity of SAM
axis is also observed in depressed patients, causing an increase in catecholamine hormone release
[96-98] [e.g. norepinephrine (NE) and epinephrine (Epi), as well as the monoamine serotonin (5HT)] that is associated with several CVD risk factors, including congestive heart failure [97, 99102] and diabetes [103]. In the peripheral circulation, these hormones innervate vascular smooth
muscle cells and endothelial cells and alter vascular reactivity [43, 98, 104-106].

Figure 2: Pathways Linking Chronic Stress and Depression with Vascular Dysfunction

Each subset of cerebrovascular disease is characterized by distinct pathophysiological
pathways that impact the function of the vascular endothelium, vascular smooth muscle, and/or
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cerebral vessel mechanics. Specific examples of these impairments have been previously
identified in hypertension, hypercholesterolemia, diabetes, the metabolic syndrome, and
depression [2, 3, 22, 23, 36]. Impaired regulation of cerebral blood flow has clear implications
for prevention, acute treatment, and long-term recovery in patients at risk of ischemic stroke, and
improved cerebral blood flow may have clear implications for patients with depression, or at risk
of developing cognitive impairments later in life [24, 27, 45, 107]. This aim of this review is to
examine the known mechanisms of cerebrovascular dysfunction inherent in CVD and in
cerebrovascular disease, in order to better identify and define a vascular linkage between each of
them.

Part 3: The Arterial Components of the Cerebral Circulation- Structure, regulation, and
mechanisms of function in health
The cerebral circulation is the unique and critical system through which the body supplies
the brain with nutrients and regulates perfusion to the different regions of the brain based on
metabolic demand. The brain, which represents only approximately 2% of total body mass, is
comprised of some of the body’s most constitutively active tissue in terms of oxygen and glucose
consumption, and therefore consistently receives 15-20% of the blood flow from the heart [2,
108]. The arterial component of the cerebral circulation has a unique anatomy to help ensure
constant blood flow to the brain, and given its critical importance, contains inherent
redundancies governed to ensure adequate blood flow [2, 3, 45, 108]. The arteries and arterioles
of the cerebrovasculature are also uniquely regulated, with extrinsic, intrinsic, and autoregulatory
mechanisms exerting different levels of control, depending on the size and function of the vessel.
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Anatomy of the Cerebrovasculature
The main conduit arteries supplying the cerebral circulation are the left and right internal
carotid arteries, and the basilar artery, which arises when the two vertebral arteries coalesce into
a single conduit along the brain stem. These three large arteries each merge into a looping
network of communicating arteries, known as the circle of Willis, providing excellent
redundancy of blood flow [2, 107]. The majority of the blood that circulates throughout the
cerebrum comes from the two internal carotids, while the basilar artery also serves as a branch
point for the main arteries supplying the cerebellum and brain stem. However, the anastomotic
ring structure of the circle of Willis ensures distribution of blood flow from all three major
conduits is maintained throughout the brain, so that reduction of loss of blood supply from either
of the carotids or the basilar artery is compensated completely by blood supply from the other
two [2, 107, 109].
Figure 3: Arterial Circulation of the Brain
Branching from the circle of Willis,

Circle of Willis and Branching Arterial Blood Supply

there are three main hemispheric pairs of
large pial (surface) arteries; the anterior,
middle, and posterior cerebral arteries
(ACA, MCA, and PCA respectively); that
form that beginning of branching arterial
networks supplying blood to each region of
the
Figure adapted from
Grey’s Anatomy

brain.

These

pial

arteries

each

progressively split into smaller daughter

arteries, which lay across the exterior surface of the brain in the pia-arachnoid space or within
the glia limitans [2, 110-112]. Pial arteries are surrounded by cerebrospinal fluid (CSF), and
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narrow as they become more distal to the circle of Willis. Redundancy of blood flow is again
observed in the spatial alignment of the pial arteries, which are located in close enough proximity
to be capable of supplying overlapping perfusion territories of sister arteries with blood flow.
This phenomenon is known as collateral blood supply; functionally, blockages or reductions in
flow of a single pial artery can often be compensated for by the neighboring pial arteries [2,
109]. Penetrating arterioles branch off of the pial arteries and begin the descent into the cortex,
occupying spatial invaginations known as the Virchow-Robin space.

Once the penetrating

arterioles enter the cortical tissue, they continue to narrow and form into the smallest resistance
arterioles of the brain, called parenchymal arterioles [2, 110, 113]. In contrast to pial arteries,
parenchymal arterioles are almost completely surrounded by astrocytes, a hallmark feature of the
cerebral blood-brain barrier (BBB), and reflective of their tight regulation by the surrounding
neuropil. Lastly, these parenchymal arterioles perfuse a highly interconnected network lattice of
capillaries, supplying blood throughout the cerebrum [2, 110, 113].
Each artery and arteriole of the cerebrovascular circulation is composed of three
concentric layers- the tunica intima, comprised of an endothelial cell layer and the internal elastic
lamina; the tunica media, comprised of vascular smooth muscle cells; and the tunica adventitia,
comprised of a collagen fiber network, peripheral or perivascular nerve termini, fibroblasts,
and/or astrocytic end feet [2, 107, 108]. The endothelial cell layer in these cerebral vessels is
unique compared to endothelium in most other vascular beds, and forms the bedrock of the BBB.
Each endothelial cell is joined to its neighbors by specialized tight junctions which greatly limit
diffusion and transport from the blood into the cerebral interstitial fluid [114, 115]. The BBB
also includes the cerebral arteries and arterioles, and their surrounding astrocytic end feet which
provide biochemical support and moderate control of diffusion between neuronal tissue and the
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cerebrovasculature [2, 45, 108]. Despite structural similarities, however, pial arteries, penetrating
arterioles, and parenchymal arterioles each have varying structural and regulatory components
that inform their different functions in regulating cerebral blood flow.
Conduit and pial arteries have multiple layers of vascular smooth muscle cells, ranging
from 20 layers thick in the internal carotids down to 3 layers thick in the smallest pial arteries [2,
112, 116]. The well-developed smooth muscle layer allows the pial artery network to
significantly regulate bulk blood flow by controlling resistance, making the cerebrovasculature
unique from most peripheral vascular beds, in which resistance is more highly impacted by
smaller arterioles. Pial arteries are extrinsically innervated by the nervous system, with
neurotransmitters such as Nitric Oxide (NO), acetylcholine (ACh), norepinephrine (NE), and
serotonin (5-hydroxytryptophan, or 5-HT) each having vasoactive effects on vessel diameter.
They are also responsive to circulating factors [2, 108, 112]. Mechanisms of vascular regulation
will be discussed in greater detail in the next section.
The penetrating and parenchymal arteries exhibit only a single layer of vascular smooth
muscle cells, and are not extrinsically innervated by perivascular nerves. Instead, these arterioles
are intrinsically innervated by the neurons and glial cells in which they are embedded [2, 116]. In
further contrast to pial arteries, penetrating and parenchymal arterioles exhibit vastly different
responses to neurotransmitters (e.g. NE and 5-HT), and possess higher levels of basal vascular
tone [109, 117, 118]. Metabolic and endothelial factors also play an important role in regulation
of these vessels. In contrast to pial arteries, penetrating and parenchymal arterioles do not
typically branch laterally. Occlusions or blockages are not easily compensated by collateral flow,
and therefore, narrowing or occlusion of these vessels frequently leads to ischemia and infarction
of the immediate surrounding cerebral tissue [109].
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Figure 4: Schematic Representation of Cerebral Arteries and Arterioles
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endothelium of cerebral capillaries forms the distinct BBB, and the capillaries are all always
open and perfused. Perfusion pressure within the capillaries is governed by flow from the
feeding arterioles; as arterioles dilate, perfusion pressure increases, driving increased capillary
flow [112, 116]. The brain is extraordinarily rich in capillarity, with some estimates stating that
every neuron may have its own capillary. The proximity and importance of blood flow to each
neuron lends further credence to the hypothesis that regulation of cerebral blood flow may be
directly linked to the performance of neurons at the individual and population level [119].
Cerebral capillary density is also variable depending on environmental or pathological
stimuli. Growth and development result in neovascularization, with the density of cerebral
capillaries increasing in response to rising activity levels in the brain [2, 120-122]. Chronic
hypoxia also activates angiogenic pathways, regulated by VEGF and HIF-1, which increase
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capillarity in the brain [123]. On the other hand, pathological conditions such as hypertension
have been linked with rarefaction of cerebral microvessels [124, 125], as well as with impaired
angiogenic pathways which hamper the formation of new arterioles and capillaries [120, 121].
In other disease states, such as diabetes, the effect is less clear. Dr. Fagan’s research team reports
that type 2 diabetic rats display increased neovascularization in the cerebral cortex [33, 121, 122,
126], but that these new vessels were often non-viable or non-perfused, resulting proliferation of
small vessels but functionally demonstrating perfusion deficits.
The mechanisms of endothelial dysfunction and oxidative damage discussed in this
dissertation focus on the arterial circulation; however there are important differences between the
cerebral venous system and the peripheral venous system that should be briefly discussed. The
cerebral venous system is comprised of larger superficial veins and dural sinuses, and deep
central veins which drain the white matter and deeper brain structures [2, 219, 220]. In contrast
to peripheral veins, cerebral veins lack valves and do not have a tunica media layer [2, 219, 220].
They are mostly imbedded in the dura mater, protecting them from compression, and due to their
lack of tunica media, the cerebral veins remain perpetually dilated to enhance drainage into the
jugular veins [219, 220]. An additional difference is that the cerebral veins form a tight blood
brain barrier [219, 221], similar to the cerebral arterial side. While peripheral veins exhibit
varying levels of permeability, and are the primary site of leukocyte invasion of tissue, the BBB
of the cerebral veins is known to prevent these events in the cerebral circulation [221, 222].
Some evidence shows that in conditions of chronic disease and inflammation, BBB breakdown
may lead to some permeability of cerebral veins [223]; otherwise, cerebral veins, like their
arterial counterparts, protect the brain from direct interaction with the leukocytes of the systemic
immune system [221, 222]. In terms of thrombosis, Virchow’s Triad stipulates clot formation is
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most likely in states of 1) hypercoagulability, 2) venous stasis, or 3) endothelial
injury/dysfunction [224]. In comparing the periphery with cerebral venous circulation, condition
1 is universal and related mostly to circulating clotting factors. Condition 2, however, will differ
between central and peripheral veins, in that the lack of valves and structural protection of
vertebral veins helps prevent venous stasis [2, 222, 224]. Lastly, until very recently, it was not
believed that the brain possessed any lymphatic drainage [225]; this discovery has revolutionized
our understanding of lymphatic clearance from the brain, but is yet to be well-characterized.
Regulation of the Cerebrovasculature
Given the brain’s substantial basal metabolic rate, and the ubiquitous perfusion of all
arterioles and capillaries, precise regulation of blood flow is critical for neuronal function and
survival. As discussed previously, perfusion of cerebral capillaries is primarily influenced by the
diameter of the proximal parenchymal arteriole. In turn, the upstream penetrating arteriole and
pial arteries must also dilate or constrict to optimize blood flow and perfusion pressure across the
whole network. The cerebral circulation uses mechanisms of extrinsic and intrinsic innervation,
along with metabolic, myogenic, and neurogenic autoregulation to ensure that blood flow is
tightly regulated throughout the entire brain [2, 108, 116]. Autoregulation in particular is critical
for maintaining cerebral perfusion pressure (CPP) within a physiological zone- if CPP drops too
low (<50mmHg), neurons will quickly become ischemic; if CPP becomes too high
(>160mmHg), BBB integrity may become compromised, elevated hydrostatic pressure may
hamper diffusion and ion exchange, and cerebral edema can develop [2, 108, 116]. It is therefore
critical that regulatory mechanisms integrate across all levels of circulation to ensure that
perfusion is maintained and able to respond to specific increases in metabolic demand.
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The networks of pial arteries across the surface of the cortex are extrinsically innervated
by perivascular nerve terminals. The density of these nerve bundles is higher in the larger,
proximal pial arteries, and decreases in density as the pial arteries narrow in diameter;
perivascular nervous synapses are almost completely absent at the point where penetrating
arterioles dive down into the cortex [2, 116, 119]. Sympathetic innervation by these nerves on
pial arteries with NE or 5-HT can cause acute vasoconstriction via α1-adrenoceptors and 5HT1B receptors, respectively. During conditions of health/normal blood flow, such induced
constriction beyond basal vessel tone is not necessary, and therefor plays little to no role in
regulating resting cerebral blood flow. However, sympathetic innervation becomes a fail-safe
mechanism against chronic hypertension, shifting the myogenic tone curve upward to protect
against edema and prevent so-called autoregulatory breakthrough [108, 127]. Parasympathetic
innervation of pial arteries results in vasodilation through neurotransmitters such as NO, from
neuronal NO synthase (nNOS), and ACh. These pathways help increase bulk blood flow during
periods of heightened awareness, and also to help compensate/increase collateral flow during
cerebral ischemia [2, 109, 118].
Penetrating and parenchymal arterioles lack the nerve bundles found in pial arteries are
therefore not affected by extrinsic stimuli in the same manner as pial arteries. The α1adrenoceptors and 5-HT1B receptors are absent, replaced by β1 adrenoceptors and other 5-HT
receptor subtypes [108, 113, 119]. Instead of constricting to NE and 5-HT as pial arteries do, the
smaller arterioles will actually dilate in the presence of these neurotransmitters. Penetrating and
parenchymal arterioles are instead more heavily innervated by intrinsic stimuli coming from the
surrounding astrocytes, glial cells, and interneurons in their immediate vicinity [2, 128, 129].
Release of GABA, nNOS –produced NO, ACh, and even 5-HT can each induce vasodilation in
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penetrating and parenchymal arterioles, and brain slice culture studies have shown that simply
increasing neuronal firing by electrical stimulation was sufficient to induce vasodilation through
a calcium mediated pathway [2, 113, 119, 129].
Autoregulation through myogenic tone and myogenic reactivity are important
mechanisms of blood flow control at all levels of the cerebrovasculature. Cerebral myogenic tone
allows cerebral arteries to dilate or constrict to maintain constant perfusion at different levels of
blood pressure and maintain a constant vessel luminal diameter at basal blood pressure [2].
Myogenic reactivity allows the vessels to respond to acute changes in cerebral perfusion pressure
and blood flow; increases in perfusion pressure are sensed by stretch receptors in the vascular
endothelium and vascular smooth muscle, which then stimulate vasoconstriction to maintain
constant blood flow [2, 129]. Decreases in perfusion pressure, in turn, activate pathways that
cause vasodilation. At the pial level, myogenic autoregulation is able to adjust blood flow
appropriately across a wide range of pressures [130], estimated generally to be ~50mmHg to
~160mmHg. Myogenic autoregulation is perhaps strongest in the penetrating and parenchymal
arterioles [2, 117, 128, 131-133], and helps to closely regulate perfusion in lieu of intrinsic or
metabolic signaling for increased blood flow. CPP beyond this physiologic range, however, can
cause vessels to lose their myogenic tone and become passive, resulting in dangerously high
levels of cerebral perfusion [2, 117].
Autoregulation based on metabolic demand is another significant factor in controlling
cerebral blood flow. This mechanism, also commonly referred to as flow-metabolism coupling or
functional hyperemia, utilizes increases in H+, K+, and adenosine that occur as a result of
increased neuronal firing/activation to induce vasodilation [2, 107, 113, 134, 135]. Adenosine
levels rise as a result of increased neuronal activity, with evidence linking glutamate signaling to
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adenosine release [136]. H+ and K+ are also known byproducts of synaptic activity in neurons
[128, 134, 135, 137]. Increases in each of these molecules are therefore reflective of neuronal
activity, and blood flow increases to provide the necessary increases in O 2 and glucose. Acute
hypoxia, which causes a reduction in oxidative respiration and a decrease in ATP levels, causes
KATP channels to activate in vascular smooth muscle [123, 138]. Opening of KATP channels
allows an efflux of K+, resulting in hyperpolarization of the smooth muscle cells and causing
vasodilation of the vessel. Hypoxia has also been shown to stimulate NO production within the
endothelium, further promoting vasodilation. Similarly, increases in circulating H+ as a result of
hypercapnia will also cause vasodilation of cerebral vessels [2, 108]. While NO-mediated
vasodilation in response to shear stress can temporarily overcome myogenic constriction,
autoregulation by myogenic forces is stronger and will restore vessel diameter to baseline [2,
117].
Lastly, the cerebral vascular endothelium produces several vasoactive substances that
help regulate cerebral blood flow. Because of its immediate proximity to the blood, circulating
factors, endocrine signaling molecules, and leukocyte-derived signaling molecules each can act
through the endothelium to dilate or constrict vessels [2, 108, 114, 135]. The most potent
vasodilatory mechanism is that of nitric oxide (NO), produced by endothelial NO synthase
(eNOS) [108, 109, 139]. Cerebral eNOS oxidizes l-Arginine into l-Citrulline and NO, and has
repeatedly been shown to be an important mediator of vasodilation in pial arteries, penetrating
arterioles, and parenchymal arterioles [2, 24, 36, 45, 107, 108, 140]. The endothelium also
enables vasodilation through the production of endothelium-derived hyperpolarizing factors
(EDHF), such as the COX metabolites prostacyclin and prostaglandin E2, and hydrogen peroxide
[24, 115, 116]. Each of these signaling pathways induces hyperpolarization of the vascular
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smooth muscle, resulting in relaxation of the muscle and dilation of the blood vessel. Cerebral
endothelial cells also synthesize and release endothelin-1, a potent vasoconstrictor by biding the
ETA receptor on cerebral vascular smooth muscle cells [2, 108, 141]. Endothelin-1, in conditions
of health, affects remarkably long periods of constriction, and contributes to maintenance of
vascular tone. However, in conditions of vascular dysfunction or cerebral hemorrhage, increased
release of endothelin-1 can lead to hypertension and cerebral vasospasm [108].
In sum, the cerebrovasculature is responsible for the regulation and delivery of consistent
blood flow to the entire brain. Blood flow is tightly regulated by a system of extrinsic, intrinsic,
autoregulatory, metabolic, and endothelium-derived factors, which under conditions of health
work together to ensure constant, uninterrupted blood flow throughout the brain, and increases
flow to areas of increased neuronal activity.
Part 4: Mechanisms of Cerebrovascular Disease- Metabolic Syndrome, Ischemic Stroke,
Vascular Cognitive Impairments
The multitude of regulatory and autoregulatory mechanisms regulating healthy cerebral
blood flow provides numerous potential points for pathological disruption. Indeed, each category
of cerebrovascular disease is characterized by distinct pathophysiological deviations that impact
the function of the vascular endothelium, vascular smooth muscle, and mechanics of the cerebral
vessels. To properly contextualize the role each of these pathways play in affecting
cerebrovascular disease progression, it is important to first characterize the cerebrovascular
dysfunction and remodeling that is inherent to the constituent pathologies underlying metabolic
syndrome, as these mechanisms are the driving factors that place patients at risk of
cerebrovascular disease in the first place.
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Pre-clinical investigations of vascular function in metabolic syndrome often utilize rodent
models of this disease, including the obese Zucker rat (OZR), Zucker diabetic fatty (ZDF), and
Goto-Kakizaki (GK) rat [142-144]. OZR and ZDF, which possess a truncated leptin receptor,
both are hyperphagic and rapidly develop moderate hypertension, hyperglycemia, elevated lipids
and cholesterol, and insulin insensitively as a consequence of overeating [142, 143]. GK is a
non-obese model of type 2 diabetes, which derives from genetic mutations affecting pancreatic B
cells and insulin receptors in peripheral tissues [144]. While the etiology of metabolic syndrome
in Zucker-derived animals more closely mirrors the human condition, all three of these models
have been used to make translationally-relevant observations of vascular dysfunction [41-43,
121, 122, 145, 146]. Consequently, these rats, and related leptin receptor modified mice, are also
popularly used to study ischemic stroke and vasculopathy-associated cognitive decline.
Mechanisms of Cerebrovascular Dysfunction
While rodent models of diabetes had been popular models for studying diabetesassociated vascular dysfunction in the peripheral circulation, Mayhan’s 1989 paper was the first
to denote a specific impairment of dilation in pial arteries of diabetic rats [147]. Despite
utilization of a type-1 diabetic model, he reported an endothelial etiology for cerebrovascular
dysfunction that would serve as a basis for investigation in other models. Building on this work,
Schwaninger et al. found that pial arteries in OZR demonstrated impaired vasodilation to ACh
and adenosine, but normal dilation to nitroglycerin [146]. They also reported elevated protein
expression of eNOS in pooled pial arteries of OZR; together, their results suggested that a
mechanism specifically impairing endothelium-dependent NO production was causing the
vascular dysfunction. Erdos et al. reported that dilation to ACh and PGI2 was impaired in basilar
arteries of OZR, but not to an exogenous NO donor [148]. They then treated the basilar artery
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with SOD and observed total recovery of vasodilation, indicating that ROS, specifically
superoxide, was limiting bioavailability of endothelial NO. Phillips et al. confirmed vascular
dysfunction in ex vivo MCA from OZR, and further reported increased oxidative stress,
increased sensitivity to sympathetic vasoconstrictors, and elevated basal vascular tone [149].
However, Phillips et al reported only partial restoration of dilator activity after treatment with
TEMPOL, a potent ROS scavenger, and that TEMPOL treatment did not ameliorate increased
myogenic reactivity or hyperconstriction to 5-HT. Additionally, they reported that no significant
changes in vessel morphology or distensibility had developed, in stark contrast with skeletal
muscle arterioles from OZR [149]. Overall, a significant body of research supports that acute
scavenging of ROS by SOD, TEMPOL, or other antioxidants results in improved NO
bioavailability and vasodilation, both in the peripheral and cerebral circulation [147-152].
Many types of ROS- superoxide, hydroxyl radicals, and peroxides- as well as reactive
nitrogen species such as peroxynitrite have been implicated within the cerebral vasculature [23,
114, 152, 153]. Several hypotheses have been tested to elucidate the source of ROS in the
cerebrovasculature, as well as to investigate potential treatments for restoring cerebrovascular
reactivity in models of diabetes and metabolic syndrome. One theory is that angiotensin II,
through its binding of angiotensin type I (AT1) receptors and activation of NAD(P)H oxidase,
increases generation of superoxide in the cerebrovasculature [113, 153-155]. Studies showing
ROS-associated dysfunction of endothelial-dependent dilatory responses in aged mice [153,
154], renin-angiotensin system (RAS) activation and endothelial dysfunction in LPS treated mice
[156], and improvement of vasodilation in losartan-treated type 1 diabetic rats [157] and
enalapril-treated type 1 diabetic rats [158] all support this theory. RAS is upregulated in both
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hypertension and diabetes, and RAS inhibitors have been shown to significantly lower long-term
risks of vascular complications in metabolic syndrome patients [159].
Figure 5: Reactive Oxygen Species Impair Nitric Oxide Bioavailability in the
Cerebrovascular Endothelium and Induce Vascular Dysfunction

Cerebral production of superoxide is generated from several sources, including NAD(P)H
oxidases, especially isoforms Nox2 and Nox4 [160, 161], endothelial and smooth muscle
mitochondria [162], xanthine oxidase, uncoupled eNOS, and other less common oxygenase
enzymes [23, 107, 150, 152, 163]. Superoxide (O2∙) especially has been effectively targeted in
24

pre-clinical models, improving NO•-mediated responses in several models, including: elderly
animals [153, 154, 164], hypertensive [165, 166], hypercholesterolaemic [167, 168], diabetic
[149, 157, 169], and stroke patents [114, 170, 171]. Use of apocynin, a broad inhibitor of
NAD(P)H oxidases, was able to restore reactivity of pial vessels in diabetic rats [152, 155, 166],
while another study found that Rosuvastatin treatment improved dilator reactivity of basilar
arteries in obese Zucker rats by reducing NAD(P)H-produced O2∙ [152, 166]. While NAD(P)H
oxidases are widely accepted as a major source of cerebral ROS [169, 172], some debate remains
as to whether Nox2 or Nox4 is the primary source of NAD(P)H oxidase generated ROS [161,
164, 165, 168, 173] Nox4 is highly expressed in endothelial cells of cerebral arteries in rats [160,
173-175], while Nox2 is highly expressed in mice MCAs as well as in circulating leukocytes
[107, 161, 164, 168, 174, 176]. Nox2 has been linked to cerebrovascular dysfunction in dietinduced obese mice [161, 165, 166, 177], while Nox4 was recently shown to increase ROS
production in cerebral endothelial cells in response to TNF-α [173]. Elevated levels of ROS can
also lead to endothelial cell mitochondrial dysfunction, and induce further overproduction of
ROS within the mitochondria [155, 178]. Metabolic syndrome has also itself been associated
with increased mitochondrial production of ROS [162, 169, 179]. Lastly, ROS can lead to
uncoupling of eNOS from its cofactor BH4 [180]. Uncoupled eNOS will reduce NO production,
despite continued high protein expression of eNOS, and instead generate superoxide.
Chronic inflammation is also strongly linked to vascular dysfunction.

TNF-α, an

inflammatory cytokine strongly linked to obesity, metabolic syndrome, depression, and many
other chronic disease states, stimulates production of NF-kB, a critical mediator of inflammatory
responses, apoptosis, and expression of growth factors. NF-kB stimulates pro-inflammatory
cytokines and adhesion molecules, such as MCP-1 [181] and ICAM-1 [182], and is implicated in
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endothelial dysfunction as well as arterial stiffening and plaque formation. While plaque
formation is uncommon in pial and parenchymal arterioles, TNF-α has been linked to activation
of Nox4 and subsequent generation of ROS [173].

IL-6, another inflammatory mediator

associated with metabolic syndrome, is the primary regulator of C-reactive protein (CRP);
increased CRP infiltration of the vasculature, results in inhibition of eNOS and angiotensinstimulated ROS production [183]. IL-6 has also been linked to mediating the endothelial effects
of angiotensin II [165]. Studies in the peripheral circulation have shown that reducing
inflammation with statins can improve NO bioavailability [184, 185], and a study in the cerebral
circulation found that Rosuvastatin can reduce cerebral ROS via mechanisms independent of
lipid-lowering effects [150]. The intersection between inflammatory mediators and ROS
production have clear implications for endothelial dysfunction in the cerebral circulation and
presents an array of potential targets for developing therapeutics to improve cerebral blood flow.
In humans, type 2 diabetes has been linked to impaired reactivity of MCAs to
hypercapnia, as assessed by trans-cranial Doppler ultrasound. This effect was linked to increased
arterial stiffening [186] and endothelial dysfunction associated with hyperglycemia. Building on
studies that demonstrated increased basal cerebral blood flow in healthy older adults, Wong et al
have shown that resveratrol supplementation was efficient at improving flow-mediated dilation
in brachial arteries of diabetic patients [187], and were further able to demonstrate a similar
improvement in MCA vasodilator responsiveness to a hypercapnic stimulus [187]; they then
demonstrated improvements in flow-mediated dilation in obese adults, and hypertensive obese
adults [188, 189]. Resveratrol, a polyphenol molecule which upregulates SOD2 in vitro, is a
controversial antioxidant [190], but these results are in accordance with findings that antioxidant
therapies consistently improve vascular reactivity in models of metabolic syndrome.
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Metabolic syndrome and diabetes are also linked to structural and mechanical changes in
the cerebrovasculature. In diabetic rats, the basement membrane of cerebral microvessels is
thickened, and swelling occurs in the pericytes and astrocytic end feed [120, 121, 126, 191].
Increased collagen can build up in the vessel wall, and degeneration of endothelial cells may also
develop[45]. Additionally, the BBB may become more permeable, leading to risk of edema and
transport of pathogens or harmful molecules into the cerebrum. Several studies have reported an
increase in myogenic tone in both T1D [128] and T2D [171, 192] rat models. In the GK rat,
increased myogenic tone was associated with elevated levels of peroxynitrite, and animals
exhibited impaired functional hyperemia and reduced regulation of CBF [121, 171].
While diabetes/metabolic syndrome are associated with rarefaction and decreased
angiogenesis in the periphery [42, 184, 193, 194], a recent slate of studies from Dr. Fagan’s
laboratory reported neovascularization and angiogenesis increasing vessel density in the cortex
of non-obese, type 2 diabetic GK rats [120-122, 145]. In contrast, Beauquis et al reported a
reduction in microvessel density in the hippocampus of the same rat model [195]. Interestingly,
the Fagan studies reported that the new vessels were often tortuous, non-viable, and nonperfused, suggesting that a functional hypo-perfusion could result. A thickening of cerebral
vessel walls also is known to occur in hypertension [196, 197], as is rarefaction of human
peripheral microvessels [198] and rodent cerebral cortical microvessels [124]. Work from
Munzenmaier and Green supports that blockage of AT1 receptor increases cortical microvessel
density concomitant to blood pressure changes, but could also be due to reduction of AT1associated ROS production [124]. Clearly, further study is needed to interrogate
angiogenesis/rarefaction in the cerebral circulation and what impacts this may hold for
cerebrovascular disease.
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Metabolic Syndrome, Diabetes, and Ischemic Stroke
As detailed above, rodent models of metabolic syndrome, diabetes, and hypertension all
develop pathologies of cerebrovascular vascular function and structure, with obvious
implications for outcomes of ischemic stroke. Indeed, ischemic stroke studies in diabetic mice
report increased infarct size, edema, and risk of hemorrhagic transformation. Pre-treatment of
these mice with peroxisome proliferator-activated receptor (PPAR)-γ agonists darglitazone,
rosiglitazone, and pioglitazone is neuroprotective in stroke, leading to smaller infarcts and better
functional outcomes [45, 126]. These studies support that acute usage of (PPAR)-γ agonists may
have clinical utility, especially in hyperglycemic patients.
The literature is somewhat more conflicting in rats: in the GK rat, ischemic
stroke/reperfusion resulted in smaller infarcts, but increased incidence of hemorrhage and
increased neurological deficits, as the infarction was more localized to the striatum, compared to
the cortex in controls [45, 121, 122, 145, 171, 191]. In OZR, stroke caused significantly larger
infarcts and MCA remodeling compared to control, which could be mitigated by chronically
controlling blood pressure prior to the stroke [199, 200]. One potential explanation may be that
neovascularization and angiogenesis is increased in the cortex of GK, but not in deeper brain
regions; therefore, the newer, underdeveloped vessels can perfuse the cortex better during stroke,
but are more prone to rupture and hemorrhage, while deeper brain regions are under-perfused,
leading to infarcts and more severe neurological deficits. If the OZR has reduced vessel density
in both the cortex and striatum, then larger infarcts and increased impairment would be the
expected outcome. Additionally, GK is non-obese and non-hypetesnive, both of which are risk
factors for rarefaction. A recent study by Abdelsaid et al found that peroxynitrite production is
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elevated following ischemia-reperfusion in GK rats, and that treatment with metformin
immediately after stroke can reduce nitrative-stress related damages and promote angiogenesis in
infarcted regions of the brain in this model [145], suggesting it may be a hyperglycemia-specific
pathology.
Ischemic stroke and reperfusion have a litany of pathophysiological effects on pial artery,
penetrating arteriole, and parenchymal arteriole function, which are further confounded by preexisting cerebrovascular dysfunction. During stroke and reperfusion, there is a sharp increase in
circulating superoxide and peroxynitrite, which can negatively impact myogenic tone in both
large and small arteries, as well as reduce NO bioavailability in the cerebral endothelium [36, 37,
170, 172, 200]. Endothelial NO is an important mediator of the protective response to stroke, as
NO improves dilation of conduits and collaterals, as well as inhibits platelet aggregation and
leukocyte adhesion. Reduced NO bioavailability therefore reduces collateral flow, and leads to
increased risk of further blockages in cerebral arterioles by small clots and platelet plugs [2, 117,
201, 202]. In metabolic syndrome, NO bioavailability is already reduced, and levels of oxidative
stress are elevated; further ROS and RNS production may lead to a near-total loss of NO
bioavailability during ischemia-reperfusion, severely impairing collateral flow and increasing
infarct size through poor perfusion and further aggregation of platelets [41, 42, 149, 193]. While
hypoxia can lead to dilation of MCAs and other conduits, this response is impaired in metabolic
syndrome [203-205], and does not appear to be present in parenchymal vessels. Dilation of
parenchymal vessels to NO, EDHF, or other hyperpolarizing factors is therefore critical during
stroke, yet these responses are already impaired in many stroke comorbidities. Many of the
pathological effects of ischemic stroke are a result of the inflammatory response and oxidative
stress that develops during ischemia/reperfusion [202]. These same mechanisms are already
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dysfunctional in diabetes and metabolic syndrome, which are both prevalent risk factors for
ischemic stroke. Further research is certainly needed to investigate how these diseases affect
stroke outcomes, and consideration of their complications towards of any new stroke therapy is
of critical importance.
Metabolic Syndrome, Vascular Dysfunction, and Neurologic Function
A recent study reported that the onset of MetSyn in OZR was associated with cognitive
impairments in memory testing, likely through hippocampal-dependent pathways [206]. Similar
impairments in cognitive function and memory recall have been observed in other rat strains fed
high-fat Western diets [207-209]. Rats which underwent mild disruption of cerebral blood flow
through a transient ischemia model developed cognitive decline and memory impairments [210],
and rats exposed to elevated oxidative stress developed cognitive deficits with direct implications
for health of the hippocampus and frontal cortex [211]. Viewed as a whole, these studies provide
evidence that the vascular pathologies inherent to MetSyn (and other types CVD) contribute
directly to cognitive decline. Similarly, cognitive impairments in aged rats have been directly
linked to regional changes in brain glucose availability and metabolism [212]. With a growing
body of clinical and epidemiological literature implicating MetSyn as a contributing factor
towards cognitive impairment [27], and high-fat diets with cognitive decline later in life [213]
and cognitive changes in older adults [214], the OZR-specific structural and physiological
vascular impairments that are highlighted in this study may provide a novel pathway for
preventing or treating cognitive impairments in at-risk adults.
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Figure 6: Inflammation and ROS from Metabolic Syndrome and Depression Impairs
Cerebrovascular Blood Flow with Implications for Ischemic Stroke

Part 5: Summary and statement of aims for writing the dissertation
As summarized above, endothelial vascular dysfunction is known to play a critical in the
pathophysiology of many disease states including hypertension, diabetes, dyslipidemia, and
metabolic syndrome.

When coupled

with

evidence of cerebral

rarefaction

and/or

neovascularization of non-viable vessels, such deficits in regulating cerebral perfusion have clear
implications for outcomes in ischemic stroke, and in the brain’s long-term ability to match blood
supply with increased demand by metabolically active regions of the brain. The literature thus far
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represents a diversity of rodent models, but two themes remain clear: oxidative stress impairs
vasodilation and vascular reactivity in the cerebral circulation, and cerebral perfusion and disease
outcome are significantly linked.
By utilizing a highly translational rodent model of metabolic syndrome- the obese Zucker
rat- this dissertation aims to more fully interrogate the mechanisms through which metabolic
syndrome, and its constituent pathologies, contribute to cerebrovascular dysfunction and
perfusion impairments. This model will then be used to study how environmental perturbations
effect alterations in cerebrovascular function: the effects of chronic stress and depression, a
common comorbidity of metabolic syndrome, are evaluated to further define the relationship
between depression and vascular disease, and an exercise training regime is implemented to
investigate how the anti-oxidant/pro-angiogenic effects of exercise impact cerebrovascular
dysfunction from stress/depression in the OZR. Lastly, OZR is presented as a novel model for
studying vascular dysfunction and oxidative stress during ischemic stroke.
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ABSTRACT
Objective: Chronic presentation of the MS is associated with an increased likelihood for stroke
and poor stroke outcomes following occlusive cerebrovascular events. However, the
physiological mechanisms contributing to compromised outcomes remain unclear, and the
degree of cerebral cortical MVD may represent a central determinant of stroke outcomes.
Methods: This study used the OZR model of MS and clinically relevant, chronic interventions to
determine the impact on cerebral cortical microvascular rarefaction via immunohistochemistry
with a parallel determination of cerebrovascular function to identify putative mechanistic
contributors.
Results: OZR exhibited a progressive rarefaction (to ~80% control MVD) of the cortical
microvascular networks vs. lean Zucker rats. Chronic treatment with antihypertensive agents
(captopril/hydralazine) had limited effectiveness in blunting rarefaction, although treatments
improving glycemic control (metformin/rosiglitazone) were superior, maintaining ~94% control
MVD. Chronic treatment with the antioxidant TEMPOL severely blunted rarefaction in OZR,
although this ameliorative effect was prevented by concurrent NOS inhibition.
Conclusions: Further analyses revealed that the maintenance of glycemic control and vascular
NO bioavailability were stronger predictors of cerebral cortical MVD in OZR than was
prevention of hypertension, and this may have implications for chronic treatment of CVD risk
under stroke-prone conditions.
Key Words: obesity, capillary density, rodent models of cardiovascular disease risk, perfusion
Abbreviations used: CVD, cardiovascular disease; eNOS, endothelial nitric oxide synthase; LNAME, L-NG-nitroarginine methyl ester; MCA, middle cerebral artery; MS, metabolic
syndrome; MVD, microvascular density; NO, nitric oxide; OZR, obese Zucker rat; PSS,
physiological salt solution.
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INTRODUCTION
With the increasing prevalence of overweight and obesity in developed economies, and
the ensuing elevations to the risk for development of other associated systemic pathologies (e.g.,
impaired glycemic control, hypertension, atherogenic dyslipidemia), the aggregate risk for
developing peripheral vascular disease is continuing at alarmingly high levels (3, 10, 29). Even
more concerning is that the incidence and prevalence of these conditions is continuing to rise in
our pediatric populations (34), thus resulting in the earlier development of increased risk and the
elevated likelihood of poor cardiovascular outcomes at younger ages. These negative outcomes
can include episodes of intermittent or chronic ischemia, poor perfusion distribution within
afflicted organs or tissues (13), and acute events including myriad thromboembolytic events
(e.g., stroke; 7, 25). As such, the effective interrogation and use of appropriate animal models to
fully understand the organ-specific vasculopathies that are associated with the development of
the metabolic syndrome is critical.
The obese Zucker rat (OZR; fa/fa) represents an animal model for the study of the
cardiovascular outcomes of the metabolic syndrome with excellent utility. Similar to that in
many afflicted humans, OZR develop metabolic syndrome as a result of a chronic hyperphagia
and excess caloric intake based in leptin resistance and impaired satiety (1), and sequentially
develop the systemic phenotype listed above to appropriate levels of severity (43).
Given the devastating potential for poor stroke outcomes on both patient quality of life
and economic costs that must be borne by society, an accurate understanding of the alterations to
the cerebral circulation and perfusion within the environment of the metabolic syndrome is
critical. Two recent studies by Stepp and colleagues have provided initial evidence that the
severity of poor stroke outcomes in the OZR was elevated as a result of the presence of the
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metabolic syndrome (32) and that this could be blunted somewhat through effective management
of hypertension (31). However, these were initial studies and did not provide significant insight
into the contributing elements to the poor stroke outcomes.
A critical element underlying tissue/organ viability is microvessel density (MVD), owing
to its central importance in terms of maintaining an optimal environment for effective mass
transport and exchange. However, recent evidence provided by our laboratory studying skeletal
muscle (12, 14, 15) and by others studying myocardium (42) and the kidney (18) provide
compelling evidence that microvessel density is significantly reduced in the OZR manifesting the
metabolic syndrome and that this can represent a key contributor to poor tissue/organ function
and outcomes. The general purpose of this study is to not only determine the extent to which this
rarefaction of the microvascular networks in the cerebral cortex is present in the OZR
manifesting the full metabolic syndrome, but also to gain insight into its temporal development
and the key contributing mechanisms that warrant further interrogation. Given previous results
cited above, the hypothesis tested in this study was that the cerebral microcirculation of OZR
undergoes a progressive reduction to microvessel density that tracks the severity of the metabolic
syndrome, and that controlling hypertension in the OZR would at least partially alleviate the
severity of this rarefaction.

MATERIALS AND METHODS
Animals: 6 week old male lean Zucker rats and OZR, purchased from Harlan (Indianapolis, IN),
were fed standard chow and tap water ad libitum were used for all experiments unless otherwise
stated (see below). Rats were housed in animal care facility at the West Virginia University Health
Sciences Center to the appropriate age range, and all protocols received prior IACUC approval. At
the time of final usage, rats were anesthetized with injections of sodium pentobarbital (50 mg/kg
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i.p.), and received tracheal intubation to facilitate maintenance of a patent airway. In all rats a
carotid artery and an external jugular vein were cannulated for determination of arterial pressure and
for intravenous infusion of additional substances as necessary (e.g., anesthetic, heparin, etc.).
LZR and OZR were used at three distinct age groups, 7-8 weeks, 12-13 weeks and 16-17
weeks of age. These age ranges were chosen to encompass the significant phases of development of
the metabolic syndrome in OZR (4). At 7-8 weeks, OZR are obese, and exhibit a moderate degree
of insulin resistance
with minimal fasting hyperglycemia or elevated mean arterial pressure. At 12-13 weeks, OZR
experience a pronounced insulin resistance and manifest a mild elevation in mean arterial pressure.
By 16-17 weeks of age, OZR are severely insulin-resistant, begin to demonstrate moderate fasting
hyperglycemia and exhibit a moderate hypertension.
Starting at 7 weeks of age, rats were placed in one of several groups to the time of final
usage:
1. Time control (normal food and water ad libitum)
2. Anti-hypertensive treatment with captopril (angiotensin converting enzyme inhibitor; 60
mg/kg/day; drinking water; [14, 20])
3. Anti-hypertensive treatment with hydralazine (systemic vasodilator; 50 mg/kg/day; drinking
water; [14, 20])
4. Anti-diabetic treatment with metformin (hepatic gluconeogenesis inhibitor; 300 mg/kg/day;
drinking water; [20, 45])
5. Anti-diabetic treatment with rosiglitazone (insulin sensitizing agent; 10 mg/kg/day; mixed with
food; [20, 37])
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6. Inhibition of endothelial nitric oxide synthase (eNOS) with L-NG-Nitroarginine Methyl Ester (LNAME; 100 mg/kg/day; drinking water; [15])
7. Anti-oxidant treatment with TEMPOL (10-3 M; drinking water [15])
8. Combined inhibition of eNOS (L-NAME) and anti-oxidant (TEMPOL) treatment
Investigation of Isolated Vessels: Following the initial surgery, each rat was decapitated and the
brain removed from the skull case and placed in cold physiological salt solution (PSS; 4ºC).
Subsequently, a middle cerebral artery (MCA) was dissected from its origin at the Circle of
Willis, as described previously (5, 8). Arteries were placed in a heated chamber (37 ºC) that
allowed the lumen and exterior of the vessel to be perfused and superfused, respectively, with
PSS equilibrated with 21% O2, 5% CO2; 74% N2 from separate reservoirs. Vessels were
cannulated at both ends with glass micropipettes and were tied (10-0 nylon suture) to the inflow
and outflow pipettes which were connected to a reservoir perfusion system that allowed
intralumenal pressure and gas concentrations to be controlled. Any side branches were ligated
using a single strand teased from 6-0 suture. Vessel diameter was measured using television
microscopy and an on-screen video micrometer. Arteries were extended to their in situ length
and were equilibrated at 80% of the animal's mean arterial pressure (~82 mmHg for LZR; ~100
mmHg for OZR).

Active tone for pressurized MCA in the present study, calculated as

(D/Dmax)100, where D is the diameter increase from rest in response to Ca2+-free PSS, and
Dmax is the maximum diameter measured at the equilibration pressure in Ca2+-free PSS, averaged
313% in LZR and 324% in OZR. The reactivity of isolated arteries was assessed in response
to increasing concentrations of acetylcholine (10-10 M – 10-6 M). To determine the extent to
which vascular nitric oxide bioavailability contributes to responses to acetylcholine in the MCA
at the different ages and under the differed conditions of the present study, all vessels were
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treated acutely with L-NAME (10-4 M; Sigma) following their responses under control
conditions to abolish the contribution of nitric oxide synthase.
Measurement of Vascular NO Bioavailability: From each rat, the abdominal aorta was removed
and vascular nitric oxide (NO) production was assessed using amperometric sensors (World
Precision Instruments, Sarasota, FL). Briefly, aortae were isolated, sectioned longitudinally,
pinned in a silastic coated dish and superfused with warmed (37C) PSS equilibrated with 95%
O2 and 5% CO2.

An NO sensor (ISO-NOPF 100) was placed in close apposition to the

endothelial surface and a baseline level of current was obtained. Subsequently, increasing
concentrations of methacholine (10-10–10-6 M) were added to the bath and the changes in current
were determined. To verify that responses represented NO release, these procedures were
repeated following pre-treatment of aortic strip with L-NAME (10-4 M).
Determination of Microvessel Density: Following removal of the MCAs from the Circle of
Willis on the base of the brain, the brain was placed within Tissue-Tek OCT compound and
frozen. Brains were then sliced into 5 m cross sections and where then stained using the
established approach developed by Munzenmaier and Greene (30) using primary anti-CD-31
antibody. Under microscopy, localization of labeled microvessels was performed with a Nikon
E600 upright microscope with a 20x objective lens. The microscope was coupled to cooled CCD
camera (Micromax; Princeton Instruments Inc, Trenton, NJ). Five nearby 1 mm 2 images were
taken from each of three sections in the frontal cortex of each brain, and the mean microvessel
density within these 15 images was taken to represent cortical MVD in that animal. All acquired
images from individual sections were analyzed for number of microvessels using MetaMorph
Imaging software (Universal Imaging Co., Downingtown, PA).
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Data and Statistical Analyses: All data are presented as mean±SEM. Statistically significant
differences in microvessel density measurements, slope coefficients, and measurements of plasma
biomarkers were determined using analysis of variance (ANOVA). In all cases, Student-NewmanKeuls post hoc test was used when appropriate and p<0.05 was taken to reflect statistical
significance. The mechanical responses of isolated MCA following acetylcholine challenge were fit
with the three-parameter logistic equation:
 max  min 
y  min  
log ED50 x 
1  10


where y represents the change in arteriolar diameter, “min” and “max” represent the lower and
upper bounds, respectively, of the change in arteriolar diameter with increasing acetylcholine
concentration, x is the logarithm of the acetylcholine concentration and log ED50 represents the
logarithm of the acetylcholine concentration ( x ) at which the response ( y ) is halfway between the
lower and upper bounds.
Vascular NO bioavailability measurements were fit with a linear regression equation
(𝑦 =∝0 + 𝛽1 𝑥); where y represents the NO concentration, ∝0 represents an intercept term, 𝛽1
represents the slope of the relationship, and 𝑥 represents the log molar concentration of
methacholine.

RESULTS
Data describing the baseline characteristics of LZR and OZR under the conditions of the
present study are presented in Table 1. Throughout the age ranges used in the present study, OZR
were heavier than LZR and also demonstrated a progressive worsening of glycemic control and an
elevation in mean arterial pressure. Chronic treatment with captopril and hydralazine was effective
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at preventing the development of hypertension and captopril was also marginally effective at
improving insulin resistance.

Treatment with either metformin or rosiglitazone significantly

improved glycemic control, and had modest effects on blunting the development of elevated blood
pressure. Chronic antioxidant therapy also had modest effects on reducing hypertension and insulin
resistance.
Figure 1 presents the changes in cerebral cortical MVD in LZR and OZR over the age
ranges of the current study. While there was no evidence for microvascular rarefaction at 7-8 weeks
of age, and a modest, but statistically significant, reduction in MVD by 12-13 weeks, cortical MVD
was reduced by approximately 20% in 16-17 week old OZR as compared to levels in age-matched
LZR.
The effects of chronic anti-hypertensive treatment on the changes in cortical MVD are
summarized in Figure 2. While both captopril and hydralazine were comparable in terms of their
efficacy in preventing the development of hypertension, only treatment with captopril resulted in
a significant improvement to the levels of cerebral MVD in OZR as compared to levels in the
untreated control animals.
Figure 3 presents the data describing the effects of chronic treatments to improve
glycemic control on cerebral MVD in LZR and OZR. Treatment with either metformin or
rosiglitazone resulted in a significant improvement to MVD in OZR as compared to responses in
untreated controls. No differences between metformin and rosiglitazone treatment in terms of
the impact on rarefaction were evident in OZR.
Data describing the effects of chronic eNOS blockade and/or antioxidant treatment on
cerebral cortex MVD in LZR and OZR are summarized in Figure 4. Chronic treatment with LNAME appeared to accelerate the cerebrovascular rarefaction in OZR, but did not result in a
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significant change in the final magnitude of the reduced MVD. In contrast, chronic treatment
with TEMPOL significantly reduced the severity of the rarefaction in OZR, such that the only
significant reduction to MVD occurred at 16-17 weeks of age. Combined treatment with LNAME and TEMPOL resulted in a similar change in MVD as with L-NAME alone, abolishing
the beneficial impact of the chronic TEMPOL treatment.
Figure 5 summarizes the vascular NO bioavailability, assessed using conduit arteries and
the amperometric NO sensors following challenge with increasing concentrations of
methacholine. At the youngest age range, vascular NO bioavailability was very comparable
between LZR and OZR, and the brief imposition (~1 week) of the pharmacological regimens,
with the singular exception of L-NAME, did not have a significant impact of methacholineinduced NO bioavailability (Panel A). At 12-13 weeks of age, vascular NO bioavailability was
significantly reduced in OZR as compared to LZR, although this loss was blunted by treatment
with captopril, metformin, rosiglitazone or TEMPOL (Panel B). These effects were mirrored in
OZR at 16-17 weeks of age, although the reduction to NO bioavailability in untreated OZR was
more pronounced, such that the relative degrees of drug treatment-induced improvements was
increased (Panel C).
The dilator reactivity of isolated MCA from rats in each group in response to challenge
with increasing concentrations of acetylcholine are summarized in Figure 6. At the youngest age
group, dilator responses of MCA to acetylcholine were not different between LZR and OZR and
the impact of the chronic drug treatment groups, except for L-NAME, was negligible. Acute
treatment with L-NAME severely abolished dilator responses to acetylcholine in all groups at the
age range (Panel A).

At the 12-13 weeks age range, MCA from OZR exhibited a significant

reduction in their acetylcholine-induced dilation as compared to LZR, and impaired response
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was largely prevented by treatment with captopril, TEMPOL and the agents targeted at
improving glycemic control (Panel B). In the older cohort of animals, the dilator responses of
MCA to acetylcholine were severely attenuated in OZR as compared to LZR and all drug
treatments, with the exception of chronic L-NAME, resulted in a significant improvement to
reactivity, with TEMPOL, metformin and rosiglitazone being most effective (Panel C). In all
cases, at all ages, acute administration of L-NAME (10-4 M) to the vessel nearly abolished
reactivity of MCA to acetylcholine (data not shown).
Figure 7 presents the correlation between group aggregate vascular NO bioavailability
(from Figure 5) and group aggregate MVD (from Figures 1-4). These data suggest that there is a
clear, positive correlation between estimated vascular NO bioavailability and cerebral cortex
MVD across the age ranges and conditions of the present study. In LZR and OZR at 7-8 weeks
of age (black), there was minimal disparity in either parameter and, as such, the data clump
together. With increasing age, the progressive loss in NO bioavailability and MVD in OZR
cause the data to distribute, although a clear correlation is still present, under both control
conditions and following pharmacological intervention.

DISCUSSION
With the increasing incidence of the constituent pathologies of the metabolic syndrome,
and the fact that this is occurring in younger individuals at a higher rate than ever before,
understanding the cardiovascular outcomes of these conditions, their mechanistic bases and the
potential for blunting their development or reversing their severity is a critical area for ongoing
investigation. The purpose of the present study was to use the OZR model of the metabolic
syndrome, which derives its origin in a severe systemic leptin resistance, to determine the extent
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to which cerebral cortical MVD is either maintained or degraded, what the fundamental
mechanisms underlying these responses are, and the efficacy of physiologically and clinically
relevant interventions might help to improve outcomes.
The primary observation of the present study was that, with the development of the
metabolic syndrome, the cerebral cortical MVD of OZR steadily fell as compared to levels in the
control LZR. Given the clear results presented in previous studies of the OZR myocardium (42),
kidney (18) and skeletal muscle (12), the progressive rarefaction of the cerebral cortical
microvascular networks clearly reflects a broad negative cardiovascular outcome that impacts
multiple diverse organs and tissues within the metabolic syndrome. However, this did not appear
to reflect the classic interpretation of microvascular rarefaction as the long term adaptation to
elevated perfusion pressure (23, 40), as treatment with captopril or hydralazine, to minimize the
development of elevated arterial pressure in OZR, had disparate effects on maintaining MVD
despite comparable effectiveness in preventing elevated pressure. As such, while elevated mean
arterial pressure within the metabolic syndrome in OZR may represent a significant contributor
to altered vascular wall mechanics (32, 39) or patterns of vascular reactivity (13), this does not
appear to be a major contributor to the evolving microvascular rarefaction.
Comparable to an observation made several years ago in the skeletal muscle of OZR with
regards to chronic treatments against the conditions of the metabolic syndrome (14), it was
determined that chronic captopril treatment had modest effects at improving glycemic control in
OZR in addition to its anti-hypertensive effects, and that this was associated with a blunted
severity of cerebral cortical microvascular rarefaction. This observation suggests that controlling
the severity of insulin-resistance and impaired glycemic control may be a more important
therapeutic target than controlling blood pressure alone for this outcome. As a result, OZR were
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chronically treated with two mechanistically divergent drugs for improving glycemic control,
metformin and rosiglitazone, to determine their effectiveness in terms of blunting the progressive
loss in cerebral microvessel density. Interestingly, both metformin and rosiglitazone were
comparably effective in improving glycemic control and in blunting the loss in MVD. This is an
observation that is consistent with those from previous studies in both relevant animal models (2,
6) and in human subjects afflicted with diabetes mellitus (16, 17), where superior maintenance of
insulin sensitivity and glycemic control where key variables associated with improving MVD
(where rarefaction had occurred) and attenuating its loss (where rarefaction was relatively mild).
Our previous investigative efforts into the physiological mechanisms contributing to
microvascular rarefaction in skeletal muscle (12, 15) and those of others focusing on other
tissues/organs (18, 42), has repeatedly implicated the balance between systemic vascular oxidant
stress and endothelial function (e.g., NO bioavailability, altered arachidonic acid metabolism) as
a key contributor to the progression and severity of microvascular rarefaction. The present study
uses two distinct measurements to assess vascular NO bioavailability, amperometric sensors for
methacholine-induced NO release and the mechanical responses of ex vivo cerebral microvessels
in response to an overwhelmingly NO dependent stimulus (acetylcholine, [41]). As shown in
figure 5 and 6, vascular NO bioavailability in young OZR (regardless of therapeutic intervention)
was very comparable to that determined in LZR, and this was the condition wherein no
significant reduction to cortical microvessel density was observed. As NO bioavailability began
to fall with increasing severity of the metabolic syndrome, the severity of the rarefaction
followed this, to the point where the lowest levels of cortical MVD were identified in the oldest
cohort of OZR with no therapeutic intervention. Interventions that were associated with
improvements to vascular NO bioavailability (e.g., captopril, metformin, rosiglitazone) were the
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ones most effective at blunting the severity of the cortical microvascular rarefaction in OZR. As
a further support to this concept, chronic treatment of OZR with the anti-oxidant TEMPOL
resulting in a superior maintenance of vascular NO bioavailability also exhibited a superior
maintenance of microvessel density. However, any protective effect of TEMPOL was abolished
if NO bioavailability was lost (e.g., combined treatment with L-NAME). Clearly, under the
conditions of the present study, and for the cerebral cortical microvasculature, the levels of
vascular NO bioavailability are a powerful positive correlate with MVD under the conditions of
the metabolic syndrome.
Our recent study of the temporal characteristics of microvascular rarefaction in the
skeletal muscle of OZR provided evidence of an early phase of microvessel loss that was NOindependent and appeared to reflect events associated with the inflammatory signaling cascades
on the venular endothelium that were strongly dependent on the production and actions of
thromboxane A2 (TxA2) and post-capillary venular leukocyte adhesion/rolling events (12).
While the results from the current study do not rule out this possibility as a potential contributing
factor for the microvessel loss in the cerebral cortex of OZR, there was little evidence for the
“early phase” of rarefaction in this tissue that was identified in peripheral skeletal muscle.
However, future investigation into the specific initiating mechanisms for cerebral cortical
microvessel loss within the metabolic syndrome is clearly warranted.
Clinical and Translational Perspective
Not only is metabolic syndrome associated with increased cardiovascular disease events
and morality (27) but it is an established risk factor for cognitive decline, dementia, and stroke
(24, 35, 36, 44, 46). Although the mechanisms by which metabolic syndrome confers its risk
have not been determined, it has been proposed that the ill effects of metabolic syndrome on
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cerebral function are, in part, due to an oxidative stress imbalance, neuro-inflammation, and
impaired vascular reactivity (19, 28, 38). We suggest that the damaging effects of metabolic
syndrome on cerebral integrity are in part dependent on the progressive decline in MVD and
vascular reactivity, thereby limiting cerebrovascular reserve capacity. Microvascular rarefaction
affects spatial hemodynamics and induces a non-uniform blood flow distribution, and has been
implicated in reducing the capillary transport of small solutes and in enhancing the risk of target
organ damage (22, 26). Such pathological adaptations would damage cerebral auto-regulation
and blood flow reserve, favoring the occurrence of cognitive impairment, and ischemic stroke.
Ameliorating or delaying the onset of these cerebral vascular alterations in metabolic
syndrome would likely improve clinical outcomes. In OZR, the cerebrovascular changes
correlated with the development of hypertension and greater cerebral injury after a stroke (31,
32), which would suggest that blood pressure has a key role in the cerebral damage. While we
have shown that chronic blood pressure treatment with a systemic vasodilator (hydralazine) or an
angiotensin converting enzyme inhibitor (captopril) were equally effective in preventing the
development of hypertension, only captopril blunted the decline in cerebral cortical MVD and
vascular reactivity. Further, chronic blood pressure treatment (hydrochlorothiazide) during the
progression of metabolic syndrome improved vascular remodeling and prevented stoke injury
(31, 32). Similarly, in a randomized, non-blinded, multi-center trial that evaluated the effects of
intensive blood pressure lowering on cardiovascular risk in diabetic patients, identified that
intensive blood pressure control lowered secondary endpoints such as the annual rate of total
stroke and nonfatal stroke compared to standard therapy (21). Therefore it is possible that the
blunted cerebrovascular impairment with metabolic syndrome with blood pressure control
resulted in a more favorable clinical outcome.
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Interestingly, our study showed that glycemic control rather than blood pressure control
appeared to be a major contributor to the microvascular remodeling. Whereby chronic glycemic
control with metformin (or rosiglitazone) during the development of metabolic syndrome
improved cerebral microvessel density and reactivity to a greater extent that blood pressure
control. In humans, intensive glycemic control with metformin compared with conventional
therapy (diet alone), led to a significantly greater risk reduction of death due to stroke (9). While
metformin administered shortly after an ischemic stroke in diabetic rats improved cerebral
vascular repair and cognitive function (33). Metformin exerts its anti-hyperglycemic actions by
reducing hepatic gluconeogenesis and increasing peripheral glucose uptake, insulin sensitivity,
and fatty acid oxidation, but importantly metformin also improves antioxidant capacity (11).
Indeed chronic treatment with TEMPOL, an anti-oxidant, also improved cerebral angiogenesis
and vascular reactivity in our metabolic syndrome model. Therefore, chronic glycemic control
would seem to be an effective strategy that confers vascular protection, and perhaps should be
administered in individuals presenting with early signs of metabolic syndrome, rather than given
once full-blown metabolic syndrome or diabetes has developed. Future research should directly
compare between control glucose vs. blood pressure vs. a combination therapy on preventing
poor clinical outcome in the metabolic syndrome model.
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FIGURE LEGENDS
Figure 1. The change in skeletal muscle microvessel density in LZR and OZR between 7-8 and 1617 weeks of age. Data are presented as mean±SE, n=6 animals in each age group for LZR; n=7
animals in each age group for OZR. *; p<0.05 vs. LZR at that age. Please see text for details.

Figure 2. The change in skeletal muscle microvessel density in LZR and OZR between 7-8 and 1617 weeks of age. Data (mean±SE) are presented under control conditions (grey) and in response to
chronic treatment with either captopril or hydralazine as an anti-hypertensive therapy. n=6 animals
in each age group for LZR; n=5-6 animals in each age group for OZR. *; p<0.05 vs. LZR at that
age. †; p<0.05 vs. OZR at that age. Please see text for details.

Figure 3. The change in skeletal muscle microvessel density in LZR and OZR between 7-8 and 1617 weeks of age. Data (mean±SE) are presented under control conditions (grey) and in response to
chronic treatment with either metformin or rosiglitazone as therapy for improving glycemic control.
n=6 animals in each age group for LZR; n=5-6 animals in each age group for OZR.*; p<0.05 vs.
LZR at that age. †; p<0.05 vs. OZR at that age. Please see text for details.

Figure 4. The change in skeletal muscle microvessel density in LZR and OZR between 7-8 and 1617 weeks of age. Data (mean±SE) are presented under control conditions (grey) and in response to
chronic treatment with TEMPOL, L-NAME or both agents together as means for separating oxidant
stress from nitric oxide bioavailability. n=6 animals in each age group for LZR; n=5-6 animals in
each age group for OZR. *; p<0.05 vs. LZR at that age. †; p<0.05 vs. OZR at that age. Please see
text for details.
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Figure 5. Data describing the bioavailability of vascular-produced nitric oxide from ex vivo
segments of the abdominal aorta from LZR and OZR at 7-8 (Panel A), 12-13 (Panel B) and 16-17
(Panel C) weeks of age.

Data are presented as the slope of the NO level with increasing

concentrations of methacholine pooled arteries under control conditions and following the
employed chronic interventions to the animal prior to use. Abbreviations: CAP (captopril), HDZ
(hydralazine), MET (metformin), RGZ (rosiglitazone), TEM (TEMPOL), LNM (L-NAME), TLN
(TEMPOL+L-NAME). Data are presented as mean±SE, n=6 animals in each age group for LZR;
n=5-6 animals in each age group for OZR. *; p<0.05 versus responses in LZR under control
conditions. †; p<0.05 versus responses in OZR under control conditions. Please see text for details.

Figure 6. Data describing the dilator reactivity of ex vivo middle cerebral arteries from LZR and
OZR at 7-8 weeks (Panel A), 12-13 weeks (Panel B) and 16-17 weeks of age (Panel C).

Data,

presented for the dilator responses of MCA in response to increasing concentrations of
acetylcholine, are shown as mean±SE, with n=arteries from 8-10 animals in for OZR; n=arteries
from 6-8 animals for LZR. *; p<0.05 in the upper bound vs. LZR. †; p<0.05 in the upper bound)
vs. OZR. Please see text for details.

Figure 7.

The correlation between vascular nitric oxide bioavailability and skeletal muscle

microvessel density for LZR and OZR at 7-10 (black), 12-13 (blue), and 16-17 weeks of age (red),
with the line of best fit through the aggregate data. Please see text for details.
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Table 1. Baseline characteristics of animal groups within the present study. Abbreviations: CAP (captopril), HDZ (hydralazine), MET
(metformin), RGZ (rosiglitazone), TEM (TEMPOL), LNM (L-NAME), TLN (TEMPOL+L-NAME); * p<0.05 vs. LZR; † p<0.05 vs. OZR.

Weeks LZR

OZR

OZR-CAP OZR-HDZ OZR-MET OZR-RGZ OZR-TEM OZR-LNM OZR-TLN

Mass

7-8

148±7

340±8*

338±9*

(g)

12-13

222±8

16-17
MAP
(mmHg)

348±7*

331±8*

344±6*

351±6*

349±8*

346±10*

458±11* 444±12*

446±10*

455±6*

448±8*

452±7*

455±10*

449±9*

308±9

688±14* 680±10*

679±12*

672±12*

681±7*

690±8*

684±11*

679±12*

7-8

104±4

102±5

98±4

102±6

97±6

100±5

102±6

100±5

99±6

12-13

106±5

112±6

99±5

100±6

103±5

105±4

106±5

128±5*†

125±7*

16-17

105±6

134±7*

104±6†

101±5†

128±7*

120±5*

114±6*†

151±6*†

144±7*

Glucose

7-8

84±5

88±5

92±6

91±6

88±7

92±6

92±4

92±4

87±5

(mg/dl)

12-13

92±5

101±6

105±6

104±7

101±6

94±5

99±5

110±6*

109±7*

16-17

94±4

128±7*

111±9

125±7*

106±5†

99±6†

119±6*

138±7*

135±10*

Insulin

7-8

0.9±0.2 5.8±0.5* 5.5±0.4*

5.4±0.7*

5.4±0.5*

5.6±0.5*

5.2±0.4*

4.9±0.4*

5.4±0.3*

(ng/ml)

12-13

1.2±0.2 6.9±0.6* 5.7±0.7*

6.6±0.5*

5.2±0.5*†

4.7±0.4*†

6.4±0.5*

7.4±0.5*

7.0±0.6*

16-17

1.3±0.2 8.4±0.5* 6.2±0.6*†

8.0±0.7*

4.7±0.7*†

4.2±0.5*†

6.8±0.5*†

9.0±0.6*

8.5±0.6*

8±3

17±3*

16±5

17±4

15±5

16±5

17±4

15±5

17±4

12-13

11±2

31±5*

25±5*

29±4*

22±5

21±6

20±5

47±6*†

25±4*

16-17

14±4

54±8*

40±7*

47±7*

26±4*†

24±5†

22±6†

72±7*†

32±5*†

N-tyrosine 7-8
(ng/ml)
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Chapter 2: Conceptual Framework
This chapter quantified the progressive decline in microvascular density in the frontal cortex of OZR
which results from the development of MetSyn in this model. This study utilized clinically relevant antihypertensives and glycemic control agents to assess the contribution of underlying hypertension and
hyperglycemia/insulin resistance on the development of cerebral cortical rarefaction. Microvascular
density (MVD) was measured in LZR and OZR at 7-8 weeks (when symptoms of MetSyn first begin to
appear), 12-13 weeks, and 16-17 weeks (consider full maturation of MetSyn vascular phenotype). A
significant, progressive decline in cortical MVD in OZR was documented at each time point. OZR were
then chronically treated from 7 weeks of age with an anti-hypertensive drug or a glycemic control agent,
and evaluated for MVD at the same time points. Neither captopril nor hydralazine was able to prevent
cerebral cortical rarefaction at 17 weeks, although captopril did delay onset and reduced rarefaction by
almost half. In contrast, both metformin and rosiglitazone significantly improved MVD at 17 weeks,
preventing the vast majority of rarefaction compared to untreated OZR.
The preliminary conclusion of these results was that management of hyperglycemia/insulin resistance is
critical to preventing MetSyn-induced cortical rarefaction. However, treatment with TEMPOL
completely prevented rarefaction in OZR, making it the most effective intervention, while treatment
with L-NAME/TEMPOL resulted in the same progression of rarefaction as OZR control. These results
are likely due to management of oxidant load in the cerebral circulation. A large body of literature has
linked both type 1 and type 2 diabetes to cerebrovascular dysfunction, and identified reactive oxygen
species (ROS) as the leading mechanisms. Additionally, angiotensin signaling in the brain is directly
linked to generation of ROS, so treatment with an ACE inhibitor like captopril would be expected to
reduce oxidative stress and thereby improve MVD. That TEMPOL was the most effective, and LNAME eliminated 100% of its benefit, supports this hypothesis. The measurements of NO
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bioavailability confirm this hypothesis, and a strong, linear relationship is evident between NO
bioavailability and cerebral cortical MVD.
This chapter establishes that progression of MetSyn in ORZ leads to loss of NO bioavailability, with
direct consequences for cerebral MVD. The next step was to investigate if impairments in
cerebrovascular reactivity, and alterations in cerebral vessel wall mechanics, would also develop in OZR
as a result of impaired NO bioavailability. The next chapter of this dissertation directly assessed this
question using a similar experimental approach as this chapter, but expanding the scope of vascular
outcomes.
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ABSTRACT
The metabolic syndrome (MetS) is highly prevalent in the North American population, and is
associated with increased risk for development of cerebrovascular disease. This study determined
the structural and functional changes to the middle cerebral arteries (MCA) during the
progression of MetS, and the effects of chronic pharmacological interventions on mitigating
vascular alterations in obese Zucker rats (OZR), a translationally-relevant model of MetS. The
reactivity and wall mechanics of ex vivo pressurized MCA from lean Zucker rats (LZR) and OZR
was determined at 7-8, 12-13 and 16-17 weeks of age under control conditions and following
chronic treatment with pharmacological agents targeting specific systemic pathologies.

With

increasing age, control OZR demonstrated reduced nitric oxide bioavailability, impaired dilator
reactivity (acetylcholine), elevated myogenic activation, structural narrowing and wall stiffening
versus LZR.

Anti-hypertensive therapy starting at 7-8 weeks of age (e.g., captopril or

hydralazine) blunted the progression of arterial stiffening compared to OZR controls, while
treatments that reduced inflammation and oxidative stress (e.g., atorvastatin, rosiglitazone,
captopril) improved NO bioavailability and vascular reactivity compared to OZR controls with
mixed impacts on structural remodeling. These data show the functional and structural cerebral
adaptions that limit cerebrovascular blood flow in MetS patients, contributing to increased risk of
cognitive decline, cerebral hypoperfusion, and ischemic stroke; however, these pathological
adaptations could potentially be blunted if treated early in the progression of MetS.

Keywords: Metabolic Syndrome, Cerebral vascular remodeling, arterial stiffness, reactive
oxygen species.
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INTRODUCTION
The metabolic syndrome (MetS), a clustering of metabolic abnormalities such as obesity,
impaired glycemic control, atherogenic dyslipidemia, hypertension, with the additional
contributing conditions of a pro-oxidant, -thrombotic and -inflammatory state, is prevalent in ~56
million US adults [1]. Correspondingly, MetS is associated with a 3-fold increased risk of
cardiovascular mortality [1], a 50% increased risk of stroke [2], and is a known risk factor for
cognitive decline with aging [3]. It is therefore imperative that translationally relevant models of
MetS be effectively interrogated to guide our understanding of the cerebral vascular adaptations
that are associated with the development of MetS, its physiological, molecular and genomic
mechanistic underpinnings, and the effectiveness of established and novel therapeutic agents in
either blunting or ameliorating MetS-associated cerebrovascular dysfunction.
The obese Zucker rat (OZR; fa/fa) represents a translationally relevant animal model for
the MetS in humans with high utility for studying negative cerebrovascular outcomes as a result
of the constellation of systemic pathologies [4]. We have previously reported that cerebral
resistance arteries from OZR develop significant alterations to vascular reactivity [5], and have
demonstrated a progressive rarefaction of cerebral cortical microvessels with the progression of
MetS. Of relevance, recent data suggest that cerebral infarct size in OZR is greater than in agematched control lean Zucker rat (LZR) [6] following ischemic stroke, and that this disparity in
infarct severity with MetS development could be blunted with improved control of the chronic
hypertension that develops [7]. While these are compelling initial observations regarding the
impact of MetS on outcomes subsequent to ischemic stroke and the potential for risk factor
control to lessen stroke severity following an ischemic episode, further information is necessary

84

to discern the role for altered cerebrovascular function as a contributing factor for compromised
outcomes.
The MetS in OZR is embodied by a few consistent overarching characteristics. Among
these are a global reduction in the bioavailability of vascular-derived nitric oxide (and the
associated alterations to vascular reactivity that this entails), the genesis of a systemic proinflammatory condition, and a progressive remodeling of the resistance and exchange
microvasculature at multiple levels of resolution, including a change in the mechanics of the
vascular wall and a reduction in tissue capillarity that have the potential to elevate perfusion
resistance and impair processes of mass transport and exchange.

However, the temporal

development of these adaptations to the cerebral circulation throughout the progression of the
MetS is not well understood and our ability to blunt them with relevant interventions remains
virtually unknown. As such, the purpose of the present study was to: 1) study OZR at key age
ranges throughout the development of the MetS to gain a fuller understanding of the temporal
development of cerebrovascular adaptation/dysfunction with the evolution of the systemic
pathologies and 2) to determine the extent to which interventions against the major constituent
pathologies of the MetS are effective at blunting the development of alterations to vascular
reactivity and vascular wall mechanics in the middle cerebral arteries of OZR.

MATERIALS AND METHODS
Animals: Male LZR and OZR (Harlan) arrived at the West Virginia University Health Sciences
Center at 6-7 weeks of age and, after one week of acclimation to the local environment, were placed
into a specific protocol cohort for the subsequent 9-10 weeks. Unless otherwise stated, animals were
fed standard chow and tap water ad libitum for all experiments. All rats were housed in the animal
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care facility at the WVU HSC, and all protocols received prior IACUC approval. At 7-8 weeks of
age, LZR (n=6; time control groups only) and OZR (n=6 for each group, at each age) were
randomly placed into one of the following treatments for the subsequent 9-10 weeks:
1. Time control (normal food and water ad libitum).
2. Anti-hypertensive treatment with captopril (angiotensin converting enzyme inhibitor; 60
mgkg-1day-1; drinking water) [8].
3. Anti-hypertensive treatment with hydralazine (systemic vasodilator; 50 mgkg-1day-1;
drinking water) [8].
4. Anti-diabetic treatment with metformin (hepatic gluconeogenesis inhibitor; 300 mgkg1

day-1; drinking water) [8, 9].

5. Anti-diabetic treatment with rosiglitazone (insulin sensitizing agent; 10 mgkg-1day-1;
mixed with food) [8, 10].
6. Anti-dyslipidemia treatment with atorvastatin (HMG Co-A reductase inhibitor; 25 mgkg1

day-1; mixed with food) [11].

7. Anti-dyslipidemia treatment with gemfibrozil (peroxisome proliferator-activated receptor
alpha (PPAR) activator; 100 mgkg-1day-1; mixed with food) [11].
8. Anti-oxidant treatment with TEMPOL (10-3 M; drinking water) [12].
9. Nitric oxide synthase (NOS) inhibition with L-NG-Nitroarginine Methyl Ester (L-NAME,
10-4 M; drinking water) [12].
Following completion of the treatment period, each rat was anesthetized with injections of sodium
pentobarbital (50 mgkg-1 i.p.), and received tracheal intubation to facilitate maintenance of a patent
airway. In all rats, a carotid artery and an external jugular vein were cannulated for determination of
arterial pressure and for infusion of additional substances, respectively, as necessary (e.g.,
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anesthetic, heparin, etc.). While under anesthetic, an aliquot of blood was drawn from the jugular
vein to be used for the subsequent determination of plasma insulin, tumor necrosis factor-α
(TNF-α) and nitrotyrosine concentrations from each animal using commercially available kits
(Millipore, Billerica, MA.
While deeply anesthetized, each rat was decapitated, after which the brain was removed
from the skull case and placed in cold physiological salt solution (PSS; 4ºC). Subsequently, a
middle cerebral artery (MCA) was dissected from its origin at the Circle of Willis. Each MCA
was doubly cannulated within in a heated chamber (37C) that allowed the lumen and exterior of
the vessel to be perfused and superfused, respectively, with PSS from separate reservoirs. The
PSS was equilibrated with a 21% O2, 5% CO2, and 74% N2 gas mixture and had the following
composition (mM): 119 NaCl, 4.7 KCl, 1.17 MgSO4, 1.6 CaCl2, 1.18 NaH2PO4, 24 NaHCO3,
0.026 EDTA, and 5.5 glucose. Any side branches were ligated using a single strand teased from
6-0 suture. Vessel diameter was measured using television microscopy and an on-screen video
micrometer.
Measurements of Vascular Reactivity in Isolated MCA: Following cannulation, MCA extended
to their in situ length and were equilibrated at 80% of the animal's mean arterial pressure (884
mmHg for LZR; 1095 mmHg for OZR) to approximate in vivo perfusion pressure [13]. Any
vessel that did not demonstrate significant active tone at the equilibration pressure was discarded.
Active tone at the equilibration pressure was calculated as (D/Dmax)100, where D is the
diameter increase from rest in response to Ca2+-free PSS, and Dmax is the maximum diameter
measured at the equilibration pressure in Ca2+-free PSS. Active tone for vessels in the present
study averaged 352% in LZR and 323% in OZR.
Following equilibration, the dilator reactivity of MCA was assessed in response to increasing
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concentrations of acetylcholine (10-10 M–10-6 M). Vascular responses to acetylcholine (ACh)
were also measured following acute incubation (45-60 minutes) with L-NAME (10-4 M) and
TEMPOL (10-4 M), to assess the contributions of nitric oxide (NO) and oxidative stress,
respectively, in modulating vascular reactivity.
Myogenic activation was assessed in MCA over the range of 40-140 mmHg, in 20 mmHg
increments. Pressure was changed non-sequentially, and vessels were allowed 10 minutes to
equilibrate at each pressure before arterial inner and outer diameters were recorded.
Following the experimental procedures for measuring ex vivo vascular reactivity, the
perfusate and superfusate PSS were replaced with Ca2+-free PSS containing the metal ion
chelators EDTA (0.03mM) and EGTA (2.0mM). Vessels were challenged with 10-7 M serotonin
until all active tone was lost. Subsequently, intralumenal pressure within the isolated vessel was
altered, in 20 mmHg increments, between 0 mmHg and 160 mmHg. To ensure that a negative
intralumenal pressure was not exerted on the vessel, 5 mmHg was used as the “0 mmHg”
intralumenal pressure point; all other values of intralumenal pressure were multiples of 20 mmHg
up to 160 mmHg. After 7 minutes at each intralumenal pressure, the inner and outer diameter of
the passive MCA was determined.
Measurement of Vascular NO Bioavailability: From each rat, the abdominal aorta was removed
and vascular NO production was assessed using amperometric sensors (World Precision
Instruments, Sarasota, FL). Briefly, aortae were isolated, sectioned longitudinally, pinned in a
silastic coated dish and superfused with warmed (37C) PSS equilibrated with 95% O2 and 5%
CO2. An NO sensor (ISO-NOPF 100) was placed in close apposition to the endothelial surface
and a baseline level of current was obtained.

Subsequently, increasing concentrations of

methacholine (10-10–10-6 M) were added to the bath and the changes in current were determined.
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To verify that responses represented NO release, these procedures were repeated following pretreatment of the aortic strip with L-NAME (10-4 M).
Data and Statistical Analyses: Mechanical responses following challenge with logarithmically
increasing dosages of acetylcholine were fit with the three-parameter logistic equation:

 max  min 
y  min  
log ED x
1  10 50 
where y represents the vessel diameter, “min” and “max” represent the lower (minimum) and
upper (maximum) bounds, respectively, of the change in diameter with agonist concentration, x is
the logarithm of the agonist concentration, and logED50 represents the logarithm of the agonist
concentration ( x ) where the response ( y ) is halfway between the bounds. For the presentation of
results, we have focused on the changes in the upper bounds as a representation of vessel
reactivity, as lower bound remained consistent between all groups (defined as the pre-challenge
diameter), and we did not determine a consistent or significant change to the logED50 values
between treatment groups.
The myogenic activation for each experimental group was plotted as mean diameter at
each intraluminal pressure and fitted with a linear regression (𝑦 = 𝛼0 + 𝛽𝑥), where the slope
coefficient β represents the degree of myogenic activation (diameter/ pressure). Increasingly
negative values of β therefore represent a greater degree of myogenic activation in response to
changes in intralumenal pressure. A similar analysis was used to determine the nitric oxide
bioavailability in response to increasing concentrations of methacholine, where β represents the
rate of change of nitric oxide released by the vessels in response to agonist challenge.
All calculations of passive arteriolar wall mechanics (used as indicators of structural alterations
to the individual microvessel) are based on those used previously [14], with minor modification.
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Vessel wall thickness was calculated as:

WT 

OD  ID
2

where WT represents wall thickness (m) and OD and ID represent arteriolar outer and inner
diameter, respectively (m).
Incremental arteriolar distensibility (DIST INC; % change in arteriolar diameter/mmHg) was
calculated as:
DISTINC  ID

ID  PIL   100

where ΔID represents the change in internal arteriolar diameter for each incremental change in
intralumenal pressure (ΔPIL).
For the calculation of circumferential stress, intralumenal pressure was converted from
mmHg to N/m2, where 1 mmHg=1.334102 N/m2.

Circumferential stress () was then

calculated as:

  PIL  ID 2WT 
Circumferential strain () was calculated as:

  ID  ID5  ID

5

where ID5 represents the internal arteriolar diameter at the lowest intralumenal pressure (i.e., 5
mmHg). The stress versus strain relationship from each vessel was fit (OLS, r2>0.85) with the
following exponential equation:

   5 e 
where 5 represents circumferential stress at ID5 and  is the slope coefficient describing arterial
stiffness. Higher levels of  are indicative of increasing arterial stiffness (i.e., requiring a greater
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degree of distending pressure to achieve a given level of wall deformation).
All data are presented as mean±SE. Differences in passive mechanical characteristics, slope
coefficients describing vascular reactivity or NO bioavailability, or descriptive characteristics
between LZR and OZR groups were assessed using analysis of variance (ANOVA), with StudentNewman-Keuls-test post-hoc, as appropriate. In all cases, p<0.05 was taken to reflect statistical
significance.

RESULTS
Table 1 presents body mass, mean arterial pressure, and plasma biomarker data for each of
the animal groups in the present study at three time points: 7-8 weeks, 12-13 weeks, and 16-17
weeks of age. With increasing age, control OZR developed characteristic symptoms of MetS
compared to LZR control, including elevated MAP, hyperglycemia and elevated plasma insulin.
Chronic treatment of OZR with specific pharmacological agents improved the expected outcomes
for each drug’s targeted risk factors. Specifically, treatment with captopril or hydralazine abrogated
the development of hypertension, treatment with metformin or rosiglitazone improved glycemic
control, treatment with atorvastatin or gemfibrozil blunted the severity of the developing
dyslipidemia in OZR, and chronic treatment with TEMPOL blunted the oxidant stress levels in
OZR versus LZR. Conversely, chronic NOS inhibition by treatment with L-NAME accelerated the
development of hypertension and resulted in an increased level of oxidant stress.
Figure 1 presents mechanical properties for arterial inner diameter (ID) and circumferential
stress vs. strain relationships, reactivity data for vasodilation to ACh and myogenic activation for
OZR and LZR control at all three age ranges points, as well as arterial NO bioavailability under LNAME treated, TEMPOL treated, and control conditions. By 16-17 weeks, both LZR and OZR
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demonstrated a significant decrease in inner diameter at elevated intraluminal pressure as compared
to their values at 7-8 weeks, with OZR also exhibiting a decreased inner diameter by 12-13 weeks
of age (Panel A), with a significant left-shifting of the circumferential stress vs. strain relationship at
both age groups in OZR as compared to values from the young age group (Panel B). LZR exhibited
a robust vasodilation in response to ACh at each age group, while reactivity to ACh was steadily
reduced with increasing age (Panel C). The slope of myogenic activation did not change between
age groups in LZR, while the β coefficients became increasingly negative with increasing age in
OZR (Panel D). NO bioavailability did not change with age in LZR, while it decreased steadily in
OZR at both 12-13 weeks and again at 16-17 weeks (Panel E). Treatment with TEMPOL did not
significantly alter NO bioavailability in LZR, but did improve NO bioavailability in OZR at both
12-13 weeks and 16-17 weeks. At all ages, in both LZR and OZR, treatment with L-NAME was
able to nearly eliminate NO bioavailability.
The impact of chronic treatment of OZR with the anti-hypertensive agents captopril or
hydralazine on arterial wall mechanics, reactivity, and NO bioavailability at 12-13 and 16-17 weeks
are presented in Figure 2. Generally, chronic treatment with either agent blunted remodeling of the
MCA wall in OZR, blunting changes to the MCA inner diameter (Panel A) and the stress vs strain
relationship (Panel B). The effect on vascular reactivity was heterogeneous, as captopril treatment
better maintained dilator reactivity to ACh versus OZR control, while the hydralazine-treated cohort
showed only minimal improvements (Panel C). Both anti-hypertensive treatments reduced the β
coefficient of myogenic activation to levels comparable to LZR (Panel D). Captopril significantly
improved NO bioavailability at 12-13 weeks and 16-17 weeks, while hydralazine had no effect at
12-13 weeks and only a modest improvement in NO bioavailability at 16-17 weeks.
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Data describing impact of chronic treatment of OZR with the anti-diabetic treatments
rosiglitazone or metformin on vessel wall mechanics, vascular reactivity, and NO bioavailability at
12-13 and 16-17 weeks are presented in Figure 3. While neither rosiglitazone nor metformin
resulted in significant alterations in MCA inner diameter at 12-13 weeks, both showed small but
significant improvements at 16-17 weeks of age (Panel A). Treatment with rosiglitazone reduced
the changes to the stress vs strain β coefficient primarily at 16-17 weeks; metformin had only a
slight effect at 16-17 weeks (Panel B). Both metformin and rosiglitazone exhibited moderately
improved reactivity to ACh at 16-17 weeks (Panel C), and both drugs were also able to improve the
β coefficient of the myogenic response at 16-17 weeks (Panel D). While both metformin and
rosiglitazone significantly improved NO bioavailability at 12-13 weeks, only rosiglitazone remained
effective at 16-17 weeks of age (Panel E)
The impact of chronic treatment of OZR with the anti-dyslipidemia treatments atorvastatin
or gemfibrozil on arterial wall mechanics, reactivity, and NO bioavailability at 12-13 and 16-17
weeks are presented in Figure 4. As with the glycemic control agents described above, chronic
treatment with the dyslipidemia agents did not significantly alter the inner diameter of the MCA
from OZR in response to elevated intraluminal pressure compared to LZR control (Panel 4A).
However, atorvastatin was able to significantly reduce the stress vs strain β coefficient at both 12-13
weeks and 16-17, while gemfibrozil had no effect at the younger age and only a small impact at 1617 weeks (Panel 4B). Similarly, atorvastatin was highly effective at improving reactivity to ACh
(Panel 4C) and NO bioavailability (Panel 4E) at both ages, while gemfibrozil had no effect on either
metric at any age. Both agents were able to significantly improve the β coefficient of the myogenic
response at 12-13 weeks and 16-17 weeks (Panel 4D).
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Figure 5 presents the impact of chronic treatment with the anti-oxidant agent TEMPOL, and
of chronic treatment with the competitive NOS-inhibitor L-NAME, on arterial wall mechanics,
reactivity, and NO bioavailability in OZR at 12-13 and 16-17 weeks. TEMPOL, which targets the
increases in oxidant stress that accompany the onset of metabolic syndrome in OZR, reduced the
narrowing of the MCA inner diameter to levels matching LZR control (Panel A), and showed the
greatest reduction in stress vs strain β coefficients of all treatment groups (Panel B). In contrast,
chronic treatment with L-NAME exacerbated arterial remodeling, and had no effect on stress vs
strain β coefficient at either age (Fig. 5 B). Chronic treatment with TEMPOL resulted in the most
robust dilation to ACh of any treatment group, while L-NAME nearly abolished all responses to
ACh across both strains and all ages (Panel C). While TEMPOL improved the β coefficient of the
myogenic response of MCA from OZR at both older ages, L-NAME negatively increased the β
coefficient, as was in fact the only treatment to do so (Panel D). In agreement with the reactivity
data, TEMPOL significantly improved NO bioavailability from OZR at both older ages, while LNAME severely reduced NO bioavailability to levels even lower than OZR control (Panel E5E).
The relationship between NO bioavailability, β coefficients from the stress vs. strain curves,
and the upper bound of ACh-induced vasodilation for each animals at each of the three age ranges
are displayed in Figure 6. At 7-8 weeks, OZR has not yet fully developed the metabolic syndrome
pathologies, which is reflected by the clustering of data points into one small area (Panel A). By 1213 weeks, OZR have developed MetS and demonstrate increased stress vs strain β coefficients
along with reduced NO bioavailability and decreased ACh upper bounds (Panel B). In panel B,
atorvastatin and TEMPOL-the treatments which best preserved NO bioavailability and ACh upper
bound, while mitigating increases in stress vs strain β coefficients with increasing severity of MetS.
In contrast, gemfibrozil and metformin, which were overall two of the least effective treatments,
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already demonstrated significant movement in the relationship at only 12-13 weeks of age. This
trend continues at 16-17 weeks, where the OZR controls are now extremely divergent from LZR,
representing significantly increased stress-strain β coefficients and poor NO bioavailability/vascular
reactivity. Gemfibrozil and metformin have similarly dropped as well, as has hydralazine,
suggesting that while hydralazine was able to delay the deleterious effects of MetS at 12-13 weeks,
it is no longer able to do so by 16-17 weeks. Atorvastatin and TEMPOL still remain towards the
upper right quadrant, while captopril and rosiglitazone populate the middle quadrants (Fig. 6C).
Figure 7 plots the stress vs. strain β coefficients against mean arterial pressures at 16-17
weeks. The four treatments which most effectively controlled hypertension in OZR- TEMPOL,
atorvastatin, hydralazine, and captopril- also exhibited β coefficients in the stress vs. strain curve
that were most similar to that for LZR control MCA. These treatment groups with the lowest β
coefficients, all had a final MAP at 17 weeks that was not significantly different from LZR control.
The other 4 treatments all had β coefficients>2.2 and had significantly higher MAP compared to
LZR control.

DISCUSSION
In the absence of intervention, OZR experience a progressive decline in vascular
structure, mechanics, and reactivity in the MCA, associated with the progressing MetS state.
However, changes in mechanical properties (i.e. distensibility) precede that of changes in lumen
diameter and wall thickness in MetS. At 7-8 weeks of age, OZR are significantly heavier and
have elevated levels of TNF-α and insulin; but show minimal changes to markers of oxidant
stress and blood pressure, and minor changes to vascular reactivity. The MCAs of OZR and LZR
remain dimensionally similar at 7-8 weeks, but substantial arterial stiffening is already present as
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reflected by the left-shifted stress-strain curve and increased β coefficient. At 12-13 weeks of age,
inflammation and insulin levels have risen further, while substantial oxidative damage has
accumulated, along with increased blood pressure. This is reflected in further mechanical
stiffening of the MCA, likely through increase deposition, and crosslinking of collagen, plus
fragmentation of elastin shift load to collagen at lower pressures, thereby making the vessel less
distensible [15]. Oxidative and inflammatory damage have negatively impacted the endothelium
and reduce NO bioavailability, resulting in impaired dilator reactivity, which is alleviated by
acute treatment with the antioxidant TEMPOL. Additionally, eutrophic structural remodeling
(lumen and outer diameters decrease with little change in wall thickness) of the MCA is present
in OZR, and stiffness of the MCA continues to worsen as measured by increased β coefficients of
the stress-strain relationship. By 16-17 weeks, as inflammation, oxidative stress, and blood
pressure have all increased with age and severity of the MetS, the degree of arterial dysfunction,
remodeling, and stiffening continue to worsen. It is possible that the progressive loss of vascular
wall distensibility may have contributed to the reduction of dilator reactivity between LZR and
OZR and across the different interventions. However, the extent to which wall distensibility
contributed to impaired reactivity is difficult to assess owing to the concurrent impairment of the
mechanisms of dilator reactivity (i.e., loss of NO bioavailability).
The increase in arterial stiffness was closely associated with the onset of hypertension,
indicative of the well-established relationship between elevated arterial pressure and vascular
remodeling[16]. In the present study, the use of atorvastatin, TEMPOL, captopril, or hydralazine
blunted the onset of hypertension, and were most effective at mitigating the increased arterial
stiffness. While atorvastatin, tempol, and captopril reduced inflammation and oxidative stress, as
well as blood pressure, hydralazine had minimal effects on inflammation and oxidative stress,

96

suggesting that efficacy for controlling arterial stiffness may be primarily related to the antihypertensive actions of atorvastatin, TEMPOL or captopril rather than any pleiotropic effect. Of
particular relevance, clinical observations in hypertensive human subjects have shown that chronic
treatment with ACE inhibitors can reduce the severity of large artery stiffness with prolonged
hypertension[17]. However, it should be noted that a limitation of the present study is that we do
not have chronic measurements of arterial pressure under the different conditions of the study
and only present data from the three age ranges.
While the relationship between the onset of MetS in OZR and the presence of arterial
dysfunction has been well established, this study found that four of the interventions
(atorvastatin, TEMPOL, captopril, and rosiglitazone) improved NO bioavailability and
endothelium-dependent dilation in 16-17 week old OZR. As shown in Table 1, these
pharmacological interventions reduces levels of TNF-α, MCP-1, and nitrotyrosine, suggesting
that treatments conferring both anti-inflammatory and anti-oxidant benefits are most effective at
improving NO bioavailability and arterial function in OZR. Atorvastatin for example, has welldefined roles in improving endothelial function, increasing NO bioavailability, reducing MAP,
and anti-inflammatory/anti-oxidant effects in addition to its cholesterol-lowering mechanism [18,
19].
In order to assess the effects of impaired glycemic control on arterial remodeling and
dysfunction, OZR were treated with metformin or rosiglitazone. Both drugs improved insulin
resistance, with minimal effects on arterial pressure. Although metformin had little effect on the
remodeling or stiffness of the MCA in OZR, rosiglitazone did blunt both structural narrowing
and the loss of MCA elasticity. Additionally, rosiglitazone was more effective at improving
dilator responses to ACh and arterial NO bioavailability than metformin. The divergence in the
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effectiveness of these anti-diabetic agents for MCA structure and function may lie within the
additional effects of rosiglitazone on improving endothelial function, inflammation, remodeling
and blood pressure, that do not appear to be as robust with metformin[20, 21]. It is possible that
metformin may be more effective at preventing remodeling at later stages of insulin
resistance/type II diabetes after prolonged treatment, when it shows greatest cardiovascular risk
reduction clinically[22], although this speculation is beyond the scope of the present study.
Dyslipidemia is common in MetS, and statins are the most popular front line
pharmacological agents in treatment of this condition. As stated above, atorvastatin has
numerous pleotropic effects in the context of cardiovascular disease, such as improving
endothelial function via increasing NO bioavailability, and boosting the innate anti-oxidant
system [23]. In this study, atorvastatin imparted significant improvements to arterial reactivity,
and coupled a decrease in oxidative load with a robust anti-inflammatory effect. These effects
corresponded with limited remodeling of the MCA and reduced arterial stiffness compared to
OZR control.

These observations support those from previous studies demonstrating that

atorvastatin treatment improved endothelial function in diabetes and cardiomyopathy [24, 25].
In contrast, gemfibrozil, a peroxisome proliferator-activated receptor agonist with potent
triglyceride lowering actions [26], had little effect on arterial stiffness, distensibility, or
reactivity, especially at 16-17 weeks of age in OZR. This disparity provides additional support
for the concept that the beneficial effects of atorvastatin stem not necessarily from management
of cholesterol, but rather from its pleotropic cardiovascular benefits [11, 27]. Similarly,
gemfibrozil alone or in combination with niacin did not significantly improve endothelial
function in patients with normal or elevated cholesterol levels [28].
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TEMPOL was included in this study as a positive treatment standard for treating chronic
low-level inflammation and oxidative stress associated with MetS [29]. Oxidative stress is
known to play an important role in the pathogenesis of vascular dysfunction [30]. Not only does
a pro-oxidative stress (ROS) environment impact the NO pathway and its regulation of arterial
remodeling, but ROS can independently interact with the components of the perivascular matrix
and can drive collagen cross-linking, collagen deposition, and the fracturing of elastin [31].
Previous evidence suggests that eutrophic inward remodeling was dependent on ROS activation
of specific matrix metalloproteinases (that degrade and reorganize the extracellular matrix of the
vessel wall) [32]. Importantly, TEMPOL was highly effective at lowering nitrotyrosine, TNF-α,
and MCP-1 concentrations in the OZR (Table 1), in addition to improving arterial reactivity,
reducing stiffness, and restoring NO bioavailability. It is important to note that all measurements
of NO bioavailability were made using conduit artery segments (aorta), and not harvested MCA.
As such, results should be interpreted appropriately.
The observation of increased myogenic properties of ex vivo MCA in the present study is
consistent with previous observations and across multiple tissues and organs from OZR and
other similar models of MetS [17, 22, 24, 43, 49]. While mechanistic contributors to increased
pressure-induced constriction remain to be fully elucidated, it does appear that the progressive
dysfunction of the vascular endothelium may act to remove a “buffer” on the robustness of the
constrictor response and contribute to the enhanced myogenic properties. It is unclear if this
reflects the loss of vascular NO bioavailability or a broader condition involving other
mechanisms of endothelial dysfunction and alterations in vascular smooth muscle responses per
se. However, on the basis of the results from the interventional procedures in the present study,
this appears to be more complicated than a simple “recovery of endothelial function,” as
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correlations between improvements in vascular NO bioavailability (Figs. 2E, 3E, 4E, and 5E)
were not perfectly associated with normalization of myogenic constriction in treated OZR (Figs.
2D, 3D, 4D, and 5D). This suggests that there may be alterations in vascular smooth muscle
itself and responses to intraluminal pressure with the development of the MetS [23, 37, 44] that
are not as readily correctable by improved endothelial function alone.
Translational Relevance: In addition to the work from Stepp’s group demonstrating increase
stroke infarct severity in OZR [39, 40]. Given that cognitive impairments and vascular dementia
have been linked to impairments of blood flow regulation and cerebral perfusion control, the
cerebrovascular adaptations occurring in MetS may represent key contributors to multiple
cerebral pathologies[33-35]. We have previously reported a decrease in cerebral cortical
microvascular density associated with MetS, and suggested that this rarefaction may contribute
to either accumulated stroke risk or poor health outcomes in afflicted individuals[36]. In the
present study, we have further added to the potential mechanisms by which MetS may contribute
to impaired cerebral perfusion and increased risk of ischemic stroke by describing
cerebrovascular dysfunction along with reduced cerebral arterial wall distensibility. In
combination with microvessel rarefaction, these additional alterations may serve as physiological
contributors to significant impairments in cerebral blood flow regulation and perfusion, which
have been linked to cognitive decline with aging. Indeed, provocative recent work by Tucsek et
al[37], who found that aging in combination with high-fat diet induced obesity in mice led to an
exacerbation of cerebrovascular rarefaction and neurovascular uncoupling previously observed
in obese mice and associated cognitive impairments, may provide additional insight. MetSassociated cerebrovascular changes can also lead to elevated risk for ischemic stroke in MetS, as
well as worsened stroke outcomes in patients suffering from a MetS as a pre-existing condition
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through compromised processes of mass transport and exchange, leading to an increased risk for
areas of ischemic damage.
Previous research has demonstrated that MetS in OZR is associated with cognitive impairments
in memory testing through hippocampal-dependent pathways [38], and similar impairments in
cognitive function and memory recall have been observed in other rat strains fed high-fat
Western diets [39] [40, 41]. Furthermore, rats experiencing mild disruption of cerebral blood
flow through a transient ischemia model developed cognitive decline and memory impairments
([42]), while rats exposed to elevated oxidative stress developed cognitive deficits as a result of
direct implications in the hippocampus and frontal cortex ([43]). Taken together, these findings
suggest that the cerebral vasculopathies resulting from MetS and its underlying conditions can
contribute to impairments in cerebral blood flow regulation and to an ensuing cognitive decline.
Similarly, cognitive impairments in aged rats have been directly linked to regional changes in
brain glucose availability and metabolism ([44]). With a growing body of clinical and
epidemiological literature implicating MetS and other cardiovascular disease risk factors with the
development of cognitive impairment [3][45][46], the structural and functional impairments in
the cerebral vasculature highlighted in this study may provide novel insight for preventing or
treatment of cognitive impairments in at-risk patients.
Thus, early recognition of MetS and therapeutic intervention targeted at protecting the
cerebral vasculature is critical. Although blood pressure control alone was effective in
dampening arterial stiffening, in the present study we found atorvastatin to be the most effective
treatment for ameliorating cerebrovascular dysfunction. It is noteworthy that there is substantial
evidence to support the beneficial effect of statins on limiting infarct size as a result of stroke and
improving recovery[47].

It has also been demonstrated that the use of statins during

101

hospitalization is associated with improved survival and a better discharge disposition among
patients following ischemic stroke [48]. This cumulative evidence would suggest that early
treatment with 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors to utilize their
pleiotropic effects on blood pressure, inflammation, and oxidative stress might be a useful
clinical tool for combating MetS-related cerebrovascular disorders.
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Table 1. Baseline characteristics of animal groups at 7-8, 12-13 and 16-17 weeks of age. Abbreviations: CAP (captopril), HDZ (hydralazine),
MET (metformin), RGZ (rosiglitazone), ATOR (atorvastatin), GEM (gemfibrozil), TEM (TEMPOL), TLM (L-NAME); MAP (mean arterial
pressure); TNF- α (tumor necrosis factor); N-tyr (Nitrotyrosine) * p<0.05 vs. LZR; † p<0.05 vs. OZR.
LZR

OZR

OZR-

OZR-

OZR-

CAP

HDZ

MET

OZR-RGZ

OZR-

OZR-

OZR-

OZR-

ATOR

GEM

TEM

LNM

7-8W

145±6

339±11*

335±7*

344±9*

338±11*

342±9*

331±11*

345±9*

350±10*

338±11*

12-13W

224±6

452±10*

454±9*

450±10*

448±8*

456±9*

453±11*

454±9*

450±10*

458±9*

16-17W

365±9

691±13*

685±10*

683±11*

692±13*

685±9*

681±12*

685±12*

690±11*

678±12*

MAP (mmHg) 7-8W

104±4

103±7

102±6

99±5

101±8

103±5

101±4

105±6

104±6

106±4

12-13W

105±5

114±5

98±5†

97±5†

113±4

112±4

106±5

109±6

100±4†

131±6*†

16-17W

103±6

135±5*

107±6†

101±6†

129±6*

130±6*

114±6†

119±5*†

109±6†

142±6*

Gluc (mg/dl) 7-8W

84±5

99±6

94±4

94±5

88±7

84±6

90±5

88±5

90±5

94±6

12-13W

92±5

121±5*

116±6*

120±7*

101±4†

94±6†

119±5*

121±6*

112±5*

123±5*

16-17W

94±4

148±8*

141±9*

147±7*

116±5*†

114±5*†

145±6*

139±6*

134±6*

151±6*

Insulin (ng/ml) 7-8W

0.9±0.3

5.4±0.5*

5.2±0.4*

5.5±0.5*

5.3±0.6*

5.1±0.7*

5.5±0.6*

5.4±0.5*

5.5±0.6*

5.4±0.4*

12-13W

1.2±0.2

6.9±0.5*

5.5±0.5*

6.8±0.6*

5.0±0.6*†

4.8±0.5*†

6.3±0.5*

6.5±0.6*

5.2±0.6*†

7.1±0.4*

16-17W

1.4±0.4

8.8±0.6*

6.8±0.5*†

8.4±0.6*

5.5±0.6*†

5.2±0.4*†

7.3±0.6*†

7.7±0.6*

6.5±0.5*†

9.4±0.5*

7-8W

76±6

84±8

88±7

94±11

83±8

90±9

79±5

82±7

79±8

84±8

12-13W

81±5

104±6*

106±5*

105±7*

110±9*

109±9*

89±5†

86±5†

98±6*

106±6*

16-17W

86±6

134±9*

130±6*

134±11*

133±10*

129±11*

96±5†

102±7†

129±9*

138±11*

N-tyr (ng/ml) 7-8W

8±3

15±4

13±4

16±5

15±4

17±5

14±4

15±5

13±4

16±5

12-13W

11±3

34±5*

29±4*

33±5*

24±4*

22±5*†

15±4†

23±4*†

13±4†

36±5*

16-17W

15±4

56±6*

42±5*†

49±7*

46±7*

39±5*†

38±4*†

46±7*

27±4*†

66±8*

Mass (g)

Chol (mg/dl)
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TNF- (pg/ml) 7-8W

1.1±0.4

3.4±0.5*

3.2±0.6*

3.5±0.5*

2.9±0.5*

3.1±.4*

3.2±0.4*

3.5±0.5*

2.8±0.4*

3.3±0.6*

12-13W

1.8±0.2

10.4±1.0*

9.4±0.8*

9.5±0.6*

7.2±0.5*†

8.0±0.4*†

6.2±0.5*†

7.5±0.5*†

5.8±0.5*†

10.8±0.6*

16-17W

2.6±0.4

13.1±1.0*

10.2±0.6*†

12.5±0.7*

9.2±0.6*†

8.6±0.7*†

7.2±0.6*†

9.5±0.5*†

5.0±0.6*†

14.3±1.1*

MCP-1 (pg/ml) 7-8W

29±4

35±6

34±5

37±4

30±5

31±6

34±6

33±5

30±4

36±5

12-13W

30±5

90±10*

68±6*†

87±5*

74±6*†

71±5*†

64±6*†

73±5*†

54±6*†

96±6*†

16-17W

38±6

104±8*

80±5*†

90±9*

84±8*

71±7*†

64±6*†

93±9*

58±6*†

116±10*
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FIGURE LEGENDS
Figure 1. Ex vivo middle cerebral artery wall mechanics and reactivity in LZR and OZR at 7-8 weeks, 1213 weeks and 16-17 weeks of age. Data are presented for MCA inner diameter with passive expansion
(Panel A) and circumferential stress versus strain relationships (Panel B), dilator responses to increasing
concentrations of acetylcholine (Panel C), myogenic activation (Panel D) and vascular nitric oxide
bioavailability with increasing concentrations of methacholine (Panel E).

All data are presented as

mean±SE. For Panels A – D, * p<0.05 versus responses in LZR at 7-8 weeks of age; † p<0.05 versus
responses in LZR at 12-13 weeks of age. ‡ p<0.05 versus responses in OZR at 7-8 weeks of age; # p<0.05
versus responses in OZR at 12-13 weeks of age.Please see text for additional details and formulae. For
Panel E, * p<0.05 versus responses in LZR at that age; † p<0.05 versus responses in OZR at that age.

Figure 2. Ex vivo middle cerebral artery wall mechanics and reactivity in LZR and OZR at 7-8 weeks, 1213 weeks and 16-17 weeks of age. Data are presented for responses following treatment with antihypertensive agents: captopril (CAP) or hydralazine (HDZ) starting at 8 weeks of age. Data are presented
for MCA maximum inner diameter with passive expansion (Panel A) and the slope () coefficient for
circumferential stress versus strain relationships (Panel B), the upper bound of the acetylcholine
concentration-response relation (Panel C), the slope () coefficient for myogenic activation (Panel D) and
the slope () coefficient for vascular nitric oxide bioavailability with increasing concentrations of
methacholine (Panel E). All data are presented as mean±SE. * p<0.05 versus responses in LZR at that
age; † p<0.05 versus responses in OZR at that age; ‡ p<0.05 versus responses under that condition at 1213 weeks of age. Please see text for additional details and formulae.

Figure 3. Ex vivo middle cerebral artery wall mechanics and reactivity in LZR and OZR at 7-8 weeks, 1213 weeks and 16-17 weeks of age. Data are presented for responses following treatment with anti-diabetes
agents: rosiglitazone (ROSI) or metformin (MET) starting at 8 weeks of age. Data are presented for MCA
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maximum inner diameter with passive expansion (Panel A) and the slope () coefficient for circumferential
stress versus strain relationships (Panel B), the upper bound of the acetylcholine concentration-response
relation (Panel C), the slope () coefficient for myogenic activation (Panel D) and the slope () coefficient
for vascular nitric oxide bioavailability with increasing concentrations of methacholine (Panel E). All data
are presented as mean±SE. * p<0.05 versus responses in LZR at that age; † p<0.05 versus responses in
OZR at that age; ‡ p<0.05 versus responses under that condition at 12-13 weeks of age. Please see text for
additional details and formulae.

Figure 4. Ex vivo middle cerebral artery wall mechanics and reactivity in LZR and OZR at 7-8 weeks, 1213 weeks and 16-17 weeks of age. Data are presented for responses following treatment with antidyslipidemia agents: atorvastatin (ATOR) or gemfibrozil (GEM) starting at 8 weeks of age. Data are
presented for MCA maximum inner diameter with passive expansion (Panel A) and the slope () coefficient
for circumferential stress versus strain relationships (Panel B), the upper bound of the acetylcholine
concentration-response relation (Panel C), the slope () coefficient for myogenic activation (Panel D) and
the slope () coefficient for vascular nitric oxide bioavailability with increasing concentrations of
methacholine (Panel E). All data are presented as mean±SE. * p<0.05 versus responses in LZR at that age;
† p<0.05 versus responses in OZR at that age; ‡ p<0.05 versus responses under that condition at 12-13
weeks of age. Please see text for additional details and formulae.

Figure 5. Ex vivo middle cerebral artery wall mechanics and reactivity in LZR and OZR at 7-8 weeks, 1213 weeks and 16-17 weeks of age. Data are presented for responses following treatment with the antioxidant TEMPOL (TEM) or the nitric oxide synthase inhibitor (NOS) starting at 8 weeks of age. Data are
presented for MCA maximum inner diameter with passive expansion (Panel A) and the slope () coefficient
for circumferential stress versus strain relationships (Panel B), the upper bound of the acetylcholine
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concentration-response relation (Panel C), the slope () coefficient for myogenic activation (Panel D) and
the slope () coefficient for vascular nitric oxide bioavailability with increasing concentrations of
methacholine (Panel E). All data are presented as mean±SE. * p<0.05 versus responses in LZR at that age;
† p<0.05 versus responses in OZR at that age; ‡ p<0.05 versus responses under that condition at 12-13
weeks of age. Please see text for additional details and formulae.

Figure 6. Relationships between vascular nitric oxide bioavailability, dilator reactivity to acetylcholine and
wall mechanics in LZR and OZR at 7-8 weeks (Panel A), 12-13 weeks (Panel B) and 16-17 weeks (Panel
C) of age. Data are presented for the results of individual experiments for LZR under control conditions
and OZR under control conditions and following treatment with captopril (CAP), hydralazine (HDZ),
rosiglitazone (ROSI), metformin (MET), atorvastatin (ATOR), gemfibrozil (GEM) and TEMPOL (TEM).
Vascular nitric oxide bioavailability is presented as the slope () coefficient for vascular nitric oxide
concentration with increasing concentrations of methacholine, dilator reactivity is presented as the upper
bound of the acetylcholine concentration-response relationship for ex vivo MCA, and wall mechanics are
presented as the slope () coefficient for the stress versus strain relationship. Please see text for additional
details and formulae.

Figure 7.

Relationships between the slope () coefficient for circumferential stress versus strain

relationships and the mean arterial pressure for LZR and OZR at 16-17 weeks of age. Data are presented as
the aggregate for the results from LZR under control conditions and OZR under control conditions and
following treatment with captopril (CAP), hydralazine (HDZ), rosiglitazone (ROSI), metformin (MET),
atorvastatin (ATOR), gemfibrozil (GEM), TEMPOL (TEM) and L-NAME (LNM). All data are presented
as mean±SE, and the linear regression equation of best fit is represented as: y=-0.259+0.021x; r2=0.724.
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Chapter 3: Conceptual Framework
The most significant finding of this chapter was that interventions which increased NO
bioavailability also significantly improved vascular reactivity, reduced inflammatory biomarkers (TNFα and MCP-1), and reduced nitrotyrosine, a plasma biomarker for oxidative stress. Rosiglitazone,
atorvastatin, captopril, and TEMPOL were the most effective interventions at achieving these outcomes,
with TEMPOL and atorvastatin having the largest benefit. Chronic treatment with L-NAME,
conversely, resulted in the most severe manifestation of each of the vascular pathologies. Temporal
analysis of the interaction between NO bioavailability, vascular reactivity, and vascular stiffness reveal a
progressive and concurrent decrease in each of these metrics from 7 to 17 weeks in OZR; animals from
each treatment group fit neatly into the three-dimensional model, with the most efficacious treatments at
preserving NO bioavailability trending towards values for LZR, while the least efficacious treatments
trended towards values for untreated OZR. As was found in chapter 1, the increase in oxidative stress
and inflammation that occurs with the onset of MetSyn in OZR significantly impaired functional and
structural components of the cerebral circulation.
he second and third chapters of this dissertation provide a substantial body of evidence that
development of MetSyn leads to structural and functional impairments in the middle cerebral arteries, as
well as a progressive loss of penetrating and parenchymal arterioles and capillaries within the cortex.
The next step was to evaluate how these cerebrovascular impairments, inherent in OZR, would impact
the pathophysiology of prevalent cerebrovascular diseases. The next chapter of this dissertation
investigates the vascular and neurological outcomes to ischemic stroke in LZR and OZR, and attempts
to elucidate distinct mechanisms contributing to both the acute stroke injury as well as the long-term
vascular complications from ischemic stroke.
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ABSTRACT
Objective: Metabolic syndrome (MetSyn) may exacerbate ischemic stroke-induced vascular
dysfunction and reduce vascularization, leading to larger infarcts and poor long term recovery.
This study sought to evaluate vascular and neurological impairments from transient middle
cerebral artery occlusion (tMCAO) in obese Zucker rats (OZR), a model of MetSyn, and
investigate acute inhibition of NAD(P)H oxidase 2 (NOX2) with gp9ds-tat as a candidate for
reducing oxidative injury during stroke.
Methods: 17 weeks old OZR were sacrificed at 24 hours or 15 days following tMCAO. A
separate cohort received infusion of gp91ds-tat (10mg/kg body weight) during tMCAO and was
sacrificed at 15 days. Reactivity of ipsilateral (IL) and contralateral (CL) middle cerebral arteries
(MCA) was assessed by ex vivo pressure myography. Nitric oxide (NO) production was
measured by DAF assay and infarct size by TTC straining. Cerebral microvessel density was
measured by staining with anti-CD31 antibody
Results: Dilation to acetylcholine of lean Zucker (LZR) MCAs was reduced 50% compared to
sham LZR at 24 hours, and another 20% in IL MCA at 15 days. In OZR, IL-MCA reactivity was
reduced 50% compared to OZR sham at 24 hours. By 15 days, OZR IL-MCA reactivity was
completely ablated, while CL-MCA reactivity had decreased 30%. NO bioavailability in LZR
and OZR at 24 hours was reduced 35%, and fell 50% further in OZR at 15 days. Rates of
mortality and infarct size were higher for OZR at both time points. Treatment of OZR with
gp91ds-tat completely blocked the progressive loss of IL/CL MCA reactivity from 24 hrs-15
days, improved post-stroke cerebral blood flow, and reduced mortality. At 15 days after stroke,
both LZR and OZR showed significant rarefaction of microvessels in the ischemic core, but only
OZR showed rarefaction of cerebral microvessels in the penumbra.
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Conclusions: MetSyn increases infarct size and mortality, and progressively exacerbated strokeinduced vascular dysfunction in a preclinical model of ischemic stroke. The worsened vascular
and neurological outcomes reflect oxidative injury during ischemia/reperfusion, and were
successfully prevented via treatment with gp91ds-tat during tMCAO. Inhibition of Nox2 during
stroke to control oxidative damage may therefore present a novel therapeutic opportunity for
improving ischemic stroke outcomes.
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INTRODUCTION
Ischemic Stroke is among the leading causes of death and disease burden worldwide.
According to the AHA’s 2016 Heart Disease and Stroke Statistics update, around 800,000 people
will experience a stroke every year in the US; a stroke occurs on average every 40 seconds, and
approximately 15 people die every hour from stroke [1-4](AHA). Stroke is one of the leading
causes of serious long-term disability and decreased quality of life, and alone is responsible for a
disease cost burden of over $34 billion in the US annually [4, 5](CDC). Despite its prevalence,
treatment options for patients are very limited. Currently, there are only two FDA-approved
treatments for ischemic stroke[3]. The “gold standard” treatment is intravenous recombinant
tissue plasminogen activator (IV tPA), first approved for use in 1996, which works to dissolve
the blood clot and restore blood flow to the ischemic area [6, 7]. However, IV tPA usage is
restricted by a narrow treatment window (0 to 3-4.5 hours after symptom onset), as well as
contra-indicated for use in many patients due to elevated hemorrhage risk. As a result, IV tPA is
vastly under-utilized, with estimates of usage ranging from only 3%-7.0% [3, 8] of stroke
patients.
The US Centers for Disease Control names high blood pressure, high cholesterol, heart
disease, and diabetes as significant independent risk factors for stroke, and over 40% of stroke
patients are hyperglycemic at time of event [5, 9-14]. The metabolic syndrome (MetSyn), which
encompasses each of these risk factors as constituents, is itself a significant risk factor [10, 1517]. MetSyn is defined clinically as the comorbid presence of three or more risk factors,
including:

central

obesity,

hypertriglyceridemia,

high

cholesterol,

hypertension,

and

hyperglycemia [15, 16]. Data from the NHANES study reveals that over 35% of all adults, and
over 50% adults aged 60 or older, are estimated to have the metabolic syndrome [16].
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The obese Zucker rat (OZR; fa/fa) is a translationally relevant rodent model for MetSyn,
with demonstrated history for studying cerebrovascular consequences of MetSyn and its
underlying network of systemic pathologies [18-20]. We have previously reported that middle
cerebral arteries (MCA) from OZR develop significant alterations in myogenic tone [21],
vascular reactivity [22], and vessel wall mechanics [22, 23]. We also recently reported a
progressive rarefaction of cerebral cortical microvessels in OZR that was correlated with insulin
resistance and nitric oxide (NO) bioavailability [23]. These combined pathologies should
theoretically seriously impair blood flow during and after ischemic stroke[24-26]; indeed the
only previous studies on stroke in OZR found that ischemic stroke results in increased infarct
size, elevation of MCA myogenic tone, and inward vascular remodeling of MCAs at 24 hours
following ischemic stroke [27] through hypertension-dependent mechanisms [28]. Additionally,
stroke in diabetic mice [24] and rats [29-33] have shown increases in infarct size, edema, and
hemorrhage.
The mechanisms through which cerebrovascular dysfunction develops in MetSyn are
largely mediated by oxidative stress and inflammation [22, 25, 33-39]. Reactive oxygen species
(ROS), which are associated with hypertension, diabetes, and dyslipidemia, react with and
reduce the bioavailability of NO, impairing reactivity of pial and parenchymal arterials[40-43].
Inflammation can exacerbate ROS generation, increase neurovascular permeability, and increase
neurotoxicity following stroke [44-50],). During stroke, ROS have been shown to cause neuronal
death and increase the size of the ischemic core [43, 51-53]. The main sources of ROS in the
cerebral circulation are NAD(P)H oxidase enzymes [53-56], especially isoforms Nox2, present
in the cerebrovascular endothelium [50, 53, 57-60] and Nox4 [55, 61-64]. Nox2 is also prevalent
in leukocytes [65], specifically neutrophils and macrophages [58], which are elevated during and
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immediately following ischemic stroke [35, 45, 66, 67]. The presence of Nox2 in both the
cerebrovascular endothelium, and within the primary immune cells responding acutely to
ischemic stroke, implies that it may be a critical source of ROS during ischemia-reperfusion, and
may therefore be an ideal therapeutic target.
Maintenance of cerebral blood flow during and after ischemic stroke is essential to
prevent neuronal death and limit spread of injury, and following ischemia/reperfusion, increased
blood flow and angiogenesis are necessary to promote recovery and rehabilitation [25, 68-71].
As most patients admitted for stroke exhibit one or more of the constituent underlying
pathologies of MetSyn [10, 15-17, 72], it is critical that we refine our understanding of how the
pre-existing cerebrovascular impairments associated with MetSyn influence vascular and
neurological outcomes following ischemic stroke. To address this issue, this study sought to
characterize vascular dysfunction and neurological impairments in OZR following 60 minute
experimental ischemic stroke, and evaluate the therapeutic benefits of reducing acute oxidative
injury during ischemia-reperfusion by inhibiting Nox2 with the peptide gp91ds-tat during stroke.
Please note: The data and analysis presented within this manuscript reflect a pilot study only,
and are not to be evaluated as a completed, fully powered study.

MATERIALS AND METHODS
Animals: Male LZR and OZR (Harlan) arrived at the West Virginia University Health Sciences
Center at 10 weeks of age and were allowed to mature to 17 weeks. Animals were fed standard
chow and tap water ad libitum for all experiments. All rats were housed in the animal care
facility at the WVU HSC, and all protocols received prior IACUC approval. At 17 weeks of age,
LZR (n=4 for each group) and OZR (n=4 for each group) underwent either 60 minutes of
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transient middle cerebral artery occlusion (tMCAO) or a sham surgical procedure. Animals were
sacrificed at 24 hours post-stroke or 15 days post stroke. A separate cohort of OZR (n=3)
received an infusion of gp91ds-tat (10mg/kg body weight) at exactly 30 minutes into 60 minute
tMCAO, and were sacrificed at 15 days post-stroke.
Experimental tMCAO: Ischemic stroke was performed using the transient middle cerebral artery
occlusion protocol. Briefly, animals were sedated by inhalational isoflurane and maintained on a
warming pad. A laser Doppler flowmetry probe (LDF; Moor Instrument) was affixed to the skull
over the perfusion territory of the right Middle Cerebral Artery (MCA) to monitor blood flow.
The bifurcation of the common carotid artery was isolated, and blood flow temporarily stopped
by vessel clamps. The external carotid was dissected, and a 3-0 monofilament was inserted
distally. The filament was then extended via internal carotid into the Circle of Willis, and
advanced until a minimum 70% reduction of blood flow in the MCA region was measured by
LDF. At 30 minutes into tMCAO, select OZR received either gp91ds-tat (10mg/kg body weight)
by IV infusion, or vehicle saline infusion. After 60 minutes of occlusion, the monofilament was
removed; restoration of blood flow was confirmed by LDF. The external carotid was then ligated
and cauterized, and the surgical opening was sutured shut. 4 hours post tMCAO onset, the animal
was evaluated behaviorally for stroke severity
Animals were sacrificed at 24 hours of 15 days post-stroke. Prior to sacrifice, animals
were anesthetized with injections of sodium pentobarbital (50 mg/kg i.p.). While under
anesthesia, animals received tracheal intubation to facilitate maintenance of a patent airway. In
all rats, a carotid artery and an external jugular vein were cannulated for determination of arterial
pressure and for infusion of additional substances, respectively, as necessary (e.g., anesthetic,
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heparin, etc.). While under anesthetic, an aliquot of blood was drawn from the jugular vein to be
used for the subsequent determination of plasma biomarkers.
While deeply anesthetized, each rat was decapitated, after which the brain was removed
from the skull and placed in cold physiological salt solution (PSS; 4ºC). Both the ipsilateral (IL)
and contralateral (CL) middle cerebral arteries (MCA) were dissected from their origin at the
Circle of Willis and placed into clean dishes of cold PSS. The brains were then immediately
sectioned and stained with triphenyltetrazolium chloride (TTC) to assess the presence and size of
any infarction. Each MCA was subsequently doubly cannulated within in a heated chamber
(37°C) that allowed the lumen and exterior of the vessel to be perfused and superfused,
respectively, with PSS from separate reservoirs. The PSS was equilibrated with a 21% O2, 5%
CO2, and 74% N2 gas mixture and had the following composition (mM): 119 NaCl, 4.7 KCl,
1.17 MgSO4, 1.6 CaCl2, 1.18 NaH2PO4, 24 NaHCO3, 0.026 EDTA, and 5.5 glucose. Any side
branches were ligated using a single strand teased from 6-0 suture. Vessel diameter was
measured using television microscopy and an on-screen video micrometer.
Measurements of Vascular Reactivity in Isolated MCA: Following cannulation, MCAs were
extended to their in situ length and were equilibrated at 80% of the animal's mean arterial
pressure to approximate in vivo perfusion pressure (Lombard paper). Any vessel that did not
demonstrate significant active tone at the equilibration pressure was discarded. Active tone at the
equilibration pressure was calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase from
rest in response to Ca2+-free PSS, and Dmax is the maximum diameter measured at the
equilibration pressure in Ca2+-free PSS.
Following equilibration, the dilator reactivity of MCA was assessed in response to
increasing concentrations of acetylcholine (10-9 M–10-5 M). Vascular responses to acetylcholine
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(ACh) were also measured following acute incubation (45-60 minutes) with L-NAME (10-4
M)(results not shown here) and TEMPOL (10-4 M), to assess the contributions of nitric oxide
(NO) and oxidative stress, respectively, in modulating vascular reactivity. [21]
Measurement of Vascular NO Bioavailability: From each rat, the abdominal aorta was removed
and sectioned into rings, and vascular NO production was assessed using a DAF assay.
Measurement of Cerebral Microvessel Density: Following TTC staining, coronal brain slices
(20 um thickness for histology) were flash-frozen in OCT immersed in supercooled isopentane
and stored at -80. Samples were prepared with a cryotome (Leica CM3050S; Leica
Microsystems) from bregma -1 using a standard Rat Brain Atlas and transferred to charged
microscope slides for histological analysis.
Cerebral microvessel and capillary density was evaluated by fluorescence immunohistochemistry
using a rat anti-CD31 antibody (BD Biosciences, San Diego, CA) as described preciously [90].
Briefly, brain sections were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton
X-100, and blocked with block solution (5% BSA in PBS) and then incubated with anti-CD31
(1:100) for 1 h at room temperature in a humidified chamber. Following three washes with PBS,
cells were incubated with Alexa Fluor 555-conjugated anti-mouse IgG (1:1000; Invitrogen) for 1
h at room temperature in a humidified chamber. After a final wash with PBS, cover glass was
placed on mounting medium with DAPI (Vector Laboratories, Burlingame, CA) on a slide.
Negative control was performed with the same procedure without primary antibody. Images
were obtained with an epifluorescence microscope and a SPOT RT camera (Diagnostic
Instruments). The microvessels density was analyzed in 6 region of interest (3 in cortex and 3 in
striatum) in the MCA territory using ImageJ, as described previously [90].
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Data and Statistical Analyses: Mechanical responses following challenge with logarithmically
increasing dosages of acetylcholine were fit with the three-parameter logistic equation:

 max  min 
y  min  
log ED x
1  10 50 
where y represents the vessel diameter, “min” and “max” represent the lower (minimum) and
upper (maximum) bounds, respectively, of the change in diameter with agonist concentration, x is
the logarithm of the agonist concentration, and logED50 represents the logarithm of the agonist
concentration ( x ) where the response ( y ) is halfway between the bounds.

For statistical

evaluation of results, we have focused on the changes in the upper bounds as a representation of
vessel reactivity, as lower bound remained consistent between all groups (defined as the prechallenge diameter); we did not determine a consistent or significant change to the logED50
values between treatment groups. All other statistical analyses utilized Student's t-test or analysis
of variance (ANOVA) with Student-Newman-Keuls test post-hoc. Statistical significance is
represented by p< 0.05.

RESULTS
Figure 1 presents representative brain slices from each experimental group following
staining with TTC. Cortical and striatal areas in the perfusion territory of the right MCA that are
stained white in the TTC stain represent the ischemic core of the stroke. The area of neuronal
tissue immediately surrounding the ischemic core is characterized as the penumbra. The average
total percentage of the right hemisphere stained white during the TTC stain is presented in Figure
1H. LZR showed significantly lower average TTC infarct volume at 24 hrs compared to OZR; at
15 days post stroke, very little or no TTC stained infarct volume was detected in LZR, while
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significant infarcts were measured in OZR. In OZR treated with gp91ds-tat, no TTC infarct
volume was measured at 15 days post-stroke.
Figure 2 presents the laser Doppler Flowmetrey (LDF) and mortality data for all animals.
To be included in this study as a stroke, cerebral blood flow as measured by LDF must have
decreased by at least 70%; the animals from all three groups averaged 80% reduction of blood
flow (Figure 2A). LZR and OZR from both time course groups are reported as one metric, as all
LDF recordings occurred immediately following tMCAO. Reperfusion of cerebral blood flow
compared to baseline was measured by LDF immediately following withdrawal of the
monofilament (Fig 2B). LZR recovered on average 95% of cerebral blood flow, with a range of
75-130% of baseline flow, while OZR only recovered on average ~80% of cerebral blood flow,
with a range of 50-90% of baseline, and two high/two low outlier points. OZR treated with
gp91ds-tat, in contrast, all recovered ~95% of cerebral blood flow, comparable to LZR animals.
Trends in recovery of cerebral blood flow collated with TTC infarct volume size (p=.0038)
(Figure 2C). Of all groups, only non-treated OZR animals died as a complicated after tMCAO.
Survival was 100% with exception of OZR, which had a mortality rate of 45% (Figure 2D). Due
to variability in time of death, mortality from both the 24 hour and 15 day treatment groups are
presented; of note, while data from these animals was included in analysis of cerebral blood flow
and infarct size, they were not included in analysis of vascular reactivity to avoid confounding
data points with respect to vascular dysfunction developing over time.
Figure 3 presents vasodilator reactivity to ACh in isolated IL and CL MCAs from LZR
and OZR at 24 hours and 15 days post stroke. In LZR, at 24 hours post-stroke, dilation to ACh
was significantly reduced (~50% reduction to LZR sham MCA) in both IL and CL MCA (Figure
3A). At 15 days post-stroke, reactivity in IL MCA continued to significantly worsen, while
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reactivity in CL-MCA was unchanged compared to reactivity at 24 hours (Figure 3B). Dilator
reactivity was reduced about 50% in OZR sham MCA compared to LZR sham MCA (Figure
3C); this is consistent with our previously published data for vascular dysfunction in 17 week old
OZR (Brooks et al). At 24 hours, the CL MCA from OZR was not significantly different from
OZR sham MCA, while dilator reactivity in the IL MCA was reduced an additional 50%
compared to CL and sham MCA (Figure 3C). By 15 days post-stroke, OZR CL MCA reactivity
had decreased 30% compared to OZR sham MCA, while dilator reactivity to ACh in IL MCA
was completely ablated (Figure 3D).
Figure 4 presents vasodilator reactivity of MCAs from LZR and OZR at 24 hours poststroke, and in gp91ds-tat-treated OZR, following incubation with the reactive oxygen species
scavenger TEMPOL. In LZR, reactivity in neither sham MCA, nor IL or CL MCA, significantly
changed in the presence of TEMPOL (Figure 4A, 4B). In contrast, sham, IL and CL MCA from
OZR all showed significant improvement in dilator reactivity to ACh after treatment with
TEMPOL, as both CL-MCA and sham MCA averaged ~40% increase in dilation (Figure 4C).
TEMPOL treatment on IL MCA from OZR at 24 hours showed a significant increase as well,
returning reactivity to levels comparable to untreated sham MCA (Figure 4D). At 15 days poststroke, IL MCA of OZR, TEMPOL treatment was able to partially rescue dilator reactivity to
ACh (Figure 4E); CL MCA of 15 day animals showed no significant difference to TEMPOL
treatment (Figure 4F). In OZR treated with gp91ds-tat, reactivity was significantly improved in
IL MCA, and trended towards improvement in CL MCA, following incubation with TEMPOL
(Figure 4E, 4F).
`Figure 5 presents dilator reactivity of IL and CL MCA from OZRs treated with gp91dstat prior during tMCAO, at 15 days following post-stroke. Dilation to ACh at 15 days in IL MCA
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was significantly improved, increasing from completely non-reactive to levels comparable to 24
hour IL MCA in OZR (Figure 5A). In CL MCA, a small non-significant increase was observed
in dilator reactivity compared to 15 day untreated CL MCA (Figure 5B). Changes in maximal
dilation were most pronounced at 15 days in IL MCA from OZR treated with gp91ds-tat. This
improvement was similar to that observed in other groups following treatment with TEMPOL
(Figure 4), suggesting a ROS-mediated mechanism may be partly responsible.
Figure 6 presents NO bioavailability data from isolated aortic ring segments. NO was
measured by DAF assay and reported in arbitrary units of fluorescence (AU). At baseline levels
of NO production, OZR 15 days post-stroke were the only group that showed a significant
decrease. Stimulated production of NO with methacholine (MCh) showed significant increases in
NO production in LZR sham animals only (Figure 6). NO bioavailability remained significantly
lower in 15 day post-stroke OZR for all treatments, including baseline and both stimulated MCh
treatments, while NO bioavailability in OZR 24 hour post-stroke remained comparable to LZR
24 hour and 15 day post-stroke.
Figure 7 presents cerebral microvessel density measured from the ischemic core and
penumbra of LZR and OZR at 15 days post-stroke. Microvessel density was consistent in the
contralateral hemispheres between LZR and OZR, and both groups experienced a similar,
significant decrease in microvessel density within the ischemic core following stroke (Figure 7).
Only in OZR, however, was there also a significant decrease in microvessel density measured in
the penumbra at 15 days post stroke. Contralateral brain regions were selected for structural
homology with the each brain’s designated ischemic core and penumbra areas.
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DISCUSSION
We present here for the first time detailed descriptions of the progressive nature of
cerebrovascular dysfunction in the major resistance arteries of both hemispheres following
ischemic stroke in a rodent model of MetSyn, as well as novel findings regarding
vasculoprotective and neuroprotective benefits of acute treatment with the selective Nox2
inhibitor gp91ds-tat during ischemic stroke. Cerebrovascular dysfunction in MetSyn impairs
regulation of cerebral blood flow, and we demonstrate here that ischemic stroke induces
significant impairments in vasodilatory reactivity of MCAs, the major conduits most commonly
implicated in ischemic stroke. We further report impairment in MCA vasoreactivity in both LZR
and OZR, but found that comorbid presence of MetSyn in OZR increased stroke severity and
drove progressive decline of cerebrovascular reactivity following ischemic stroke. Additionally,
while oxidative stress has long been considered a major pathological influence on ischemic
stroke outcomes, we show that acutely inhibiting Nox2 during the ischemia-reperfusion injury
period is sufficient to improve post-stroke vascular reactivity and reduce infarct size in OZR.
Our results are consistent with the theory that ischemic stroke causes severe attenuation
of NO bioavailability and cerebrovascular reactivity in the cerebrovasculature following
ischemic stroke [27, 28, 73-75]. We show that vasoreactivity is impaired in both the IL and CL
hemispheres of LZR and OZR at 24 hrs post-stroke, with reactivity being poorest in IL MCA of
OZR. Furthermore, we show a progressive loss of reactivity from 24 hours to 15 days that was
most significant in IL MCA of OZR. OZR IL MCA completely lost all vasodilator reactivity to
ACh, and indeed became slightly vasoconstrictive to ACh, by 15 days post-stroke. While
TEMPOL was able to rescue vasodilatory function at 24 hrs, it was ineffective at improving
dilation at 15 days in the CL MA of OZR; this suggests that acute oxidative injury during
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ischemic stroke in OXR may lead to more severe impairments in endothelial function.
Vasoconstriction of resistance arteries to ACh is consistent with severe injury to the vascular
endothelium [76], indicating a progression of endothelial dysfunction stemming from ischemic
stroke. While not shown in this paper, we also have data suggesting that myogenic tone and
constriction to 5-hydoxytryptamine are increased in MCA of OZR, but not LZR, following
ischemic stroke. These data support that pre-existing cerebrovascular dysfunction inherent to
MetSyn indeed influences an exacerbation of vascular impairments following ischemic stroke.
Superoxide and other ROS are known to cause vascular and neurological impairments
during ischemic stroke. While ROS such as superoxide can directly react with, and neutralize,
NO, they can also uncouple eNOS from BH4 and lead to eNOS generation of additional ROS
[38, 54, 77]. Previous work from our laboratory has shown a significant, systemic reduction in
NO bioavailability in the peripheral and central circulation in MetSyn [19, 22, 78-81]. Here, we
show that systemic NO bioavailability is further reduced in LZR and OZR at 15 days following
ischemic stroke, indicating that oxidative injury sustained during this event can have long-lasting
effects on endothelial dysfunction. Beyond limiting NO bioavailability, ROS can further impair
myogenic reactivity [21, 75, 82, 83] and can lead to endothelial cell death and compromise of the
cerebral blood brain barrier [7, 61, 84, 85]. Additionally, elevated levels of ROS during stroke
are implicated in exacerbating neuronal cell death and oxidative injury, leading to neuronal
apoptosis in the ischemic core and penumbra and increasing glutamate-induced excitotoxicity
within the brain [7, 29, 43, 84-86]. Limiting levels of ROS during stroke has been suggested to
be neuroprotective [68, 70, 72, 87] and several studies have sought to identify the most
prominent sources of ROS during cerebral ischemia [53, 55, 59, 60].
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Our results suggest that the NAD(P)H oxidase isoform Nox2 is a major source of ROS
during ischemic stroke. Nox2 is highly expressed in the cerebrovascular endothelium of both pial
and parenchymal vessels [50, 57-59], as well as in activated neutrophils and macrophages [58],
which are amongst the first immune cells to respond to ischemic injury in the brain [22, 45]. By
inhibiting Nox2 during ischemia-reperfusion in OZR with a one-time infusion of the Nox2selective peptide gp91ds-tat, we were able to significantly improve vascular reactivity of the IL
MCA at 15 days post-stroke. Of interest, we observed a significantly larger impairment of
vasoreactivity in the IL MCA vs CL MCA at 15 days post stroke in OZR, and correspondingly
saw improvement only in the IL MCA, and not CL MCA, of OZR treated with gp91ds-tat. One
potential explanation for these observations is that oxidative injury is increased in the IL MCA
due to the localized incident of ischemia-reperfusion, while oxidative injury in the CL MCA is a
reflection of circulating oxidative and inflammatory factors. Hypoxia-induced activity of Nox2
in the cerebrovascular endothelium of IL MCA, and/or activation of Nox2 in the neutrophils and
macrophages that migrate to the location of stroke injury, could account for why acute inhibition
of Nox2 during stroke was not more protective throughout the entire cerebrovasculature.
Accordingly, chronic treatment with gp91ds-tat or with a broad spectrum NAD(P)H oxidase
inhibitor such as apocynin prior to, during, or after ischemic stroke may indeed result in
improved cerebrovascular reactivity throughout the brain. Additionally, Nox2 inhibition during
stroke resulted in a significant reduction of infarct size in OZR at 15 days post-stroke. This
finding is consistent with studies showing that antioxidant neuroprotective agents can reduce
infarct size in preclinical models of stroke (source) and further suggests that inhibition of Nox2
during the acute stroke injury may help to limit the damage occurring during ischemia and
subsequent reperfusion in human patients. Our results suggest that one enzyme, Nox2, could be
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an effective target for improving both cerebrovascular and neurological outcomes during
ischemic stroke.
Lastly, we show that ischemic stroke reduces microvascular density in ischemic core 15
days post-stroke in both LZR and OZR. This finding is consistent with previous studies showing
impaired neovascularization following stroke in a model of non-obese diabetes [29, 31, 88, 89].
We have previously reported that cortical rarefaction in MetSyn is associated with insulin
resistance and loss of NO bioavailability [23]; results of the present study support that loss of NO
bioavailability due to oxidative injury could indeed explain vessel rarefaction observed in the
ischemic core. The aforementioned study of Fagan et al also found that treatment with metformin
is sufficient to restore neovascularization after stroke, suggesting that regulation of plasma
glucose may also play an important role [29]. Significantly, we also report rarefaction of cerebral
microvessels in the penumbra of OZR, but not LZR, at 15 days following stroke. This novel
finding may be the result of increased cerebrovascular dysfunction and oxidative injury during
ischemic stroke; poor collateral flow and increased ROS production could lead to expansion of
the penumbra and influence a cerebrovascular microenvironment conducive to rarefaction of
small vessels in the affected tissue.

Clinical Implications
Impaired regulation of cerebral blood flow during ischemic stroke is widely recognized
as among the most important pathophysiological drivers of neuronal death and stroke severity
[25, 26, 71]. While the primary ischemic injury during stroke occurs due to physical blockage of
blood flow, neuronal and vascular injuries are greatly exacerbated by oxidative stress during
periods of hypoxia. Additionally, several studies have shown that additional injury and neuronal
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death can occur after dissolution of the clot during reperfusion [44, 52, 75], indicating that
treatments could be administered during an active stroke to improve outcomes beyond simple
restoration of blood flow. Often, the vascular health of the individual, or indeed the preclinical
model, is overlooked when considering therapies for ischemic stroke. Cerebrovascular
dysfunction is hallmark of MetSyn and other types of cardiovascular disease, and is itself an
important risk factor for developing stroke; therefore, it is important to factor in pre-existing
mechanisms of cerebrovascular dysfunction when studying the pathological outcomes of
ischemic stroke or evaluating novel therapeutics. To this end, we conducted experimental strokes
in OZR, a well-established model of MetSyn and cerebrovascular disease, and would encourage
other groups to consider a similar approach.
Reducing oxidative injury during ischemia-reperfusion has been proposed by several
groups as an important mechanism for improving outcomes of ischemic stroke. In this study, we
evaluated specific targeting of Nox2 during ischemia-reperfusion injury (as opposed to chronic
pre- or post- treatment with antioxidants) to assess potential benefits of reducing ROS during the
stroke itself. Our initial findings are encouraging, as we demonstrated that this strategy was
sufficient to prevent severe cerebrovascular dysfunction in the IL MCA and to reduce infarct size
and mortality. While we did not improve reactivity in CL MCA, this may be due to the acute
nature of our treatment period; the only injury we prevented was the acute injury from ischemiareperfusion, and not injury due to chronic oxidative and inflammatory conditions that persist
from MetSyn and ischemic stroke. Nevertheless, we report here that inhibition of Nox2 during
stroke may be a viable therapeutic pathway for improving outcomes to ischemic stroke. Our
future aims will include evaluating how chronic reduction of ROS following ischemia-
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reperfusion, either with gp91ds-tat or a more broad antioxidant, improves cerebrovascular
reactivity and neurological outcomes.

Limitations of present study:
This study is limited by the small sample size, due to its nature as a pilot study. Further
extrapolation of the results summarized here is therefore discouraged, and this study needs to be
completed in full with adequate animal numbers to confer statistical power. Another limitation of
this study is the lack of a dose-response experiment to determine ideal dosage of gp91ds-tat; a
high dose was selected based on the literature, but tolerance and efficacy of this drug in OZR
needs to be more fully established. Lastly, this study reflected only 1 time point for
administration of gp91ds-tat, and only two time outcome points; an expanded study looking at
the effects of pre-stroke and post-stroke administration, as well as chronic vs acute dosing, is
needed for this study. Comparison with a more broad Nox inhibitor, such as apocynin, may be
warranted as well.
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FIGURE LEGENDS

Figure 1. TTC stain of coronal brain slices to measure infarct area at 24 hrs or 15 days poststroke. Representative slices are shown for LZR- Sham (A), tMCAO 24 hrs (B), and tMCAO 15
days (E). As well as for OZR- Sham (D), tMCAO 24 hrs (C), and tMCAO 15 days (F), and OZR
treated with gp91ds-tat (G). Panel (H) shows a graphical representation of the average infarct
size per group. Given small sample size, statistical data not shown.

Figure 2. Trans-cranical Laser Doppler Flowmetrey (LDF) measurements of blood flow during
the tMCAO (A), and following reperfusion (B). The % of flow recovered was plotted against
infarct area to determine correlation (C). Mortality rates are presented in panel (D). In panel D,
the lines for LZR Sham, OZR Sham, LZR MCAO, and OZR MCAO all overlap at 100%.

Figure 3. Ex vivo IL and CL middle cerebral artery reactivity in LZR and OZR following
ischemic stroke. Panel (A): Dilation to acetylcholine for IL and CL MCA of LZR. 24 hours post
stroke. Panel (B): Dilation to acetylcholine for IL and CL MCA of LZR. 15 days post stroke.
Panel (C): Dilation to acetylcholine for IL and CL MCA of OZR. 24 hours post stroke. Panel
(D): Dilation to acetylcholine for IL and CL MCA of OZR. 15 days post stroke. All data are
presented as mean ± SE. * p<0.05 versus responses in LZR control at 17 weeks; † p<0.05 versus
responses in OZR control at 17 weeks. Please see text for more details.

Figure 4. Ex vivo middle cerebral artery reactivity in LZR and OZR following ischemic stroke.
Vessels were incubated with TEMPOL, rinsed thoroughly, and then incubated with L-NAME,
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and assessed for reactivity to acetylcholine. Panel (A): Dilation to acetylcholine for LZR IL
MCA at 24 hours post stroke. Panel (B): Dilation to acetylcholine for LZR CL MCA at 24 hours
post stroke. Panel (C): Dilation to acetylcholine for OZR IL MCA at 24 hours post stroke. Panel
(D): Dilation to acetylcholine for OZR CL MCA at 24 hours post stroke. Panel (E): Dilation to
acetylcholine for OZR IL MCA, treated with gp91ds-tat, at 24 hours post stroke. Panel (F):
Dilation to acetylcholine for OZR CL MCA, treated with gp91ds-tat, at 24 hours post stroke. All
data are presented as mean ± SE. * p<0.05 versus responses in LZR control at 17 weeks; †
p<0.05 versus responses in OZR control at 17 weeks. Please see text for more details.

Figure 5. Ex vivo middle cerebral artery reactivity for IL and CL MCA of OZR treated with
gp91ds-tat during tMCAO. Panel (A): Dilation to acetylcholine, comparing IL MCA of treated
and untreated OZR at 15 days post stroke. Panel (B): Dilation to acetylcholine, comparing CL
MCA of treated and untreated OZR at 15 days post stroke. Panel (C): Bar graph of maximum
dilation to acetylcholine [10-5] M for all time and treatment groups. All data are presented as
mean ± SE. * p<0.05 versus responses in LZR control at 17 weeks; † p<0.05 versus responses in
OZR control at 17 weeks. Please see text for more details.

Figure 6. Arbitrary fluorescence units representing nitric oxide produced from aortic ring
segments of LZR and OZR, at 24 hrs or 15 days post stroke. NO was measured at unstimulated
baseline, and after stimulation with Methacholine [10-5] M and [10-4] M. Fluorescence was
measured by DAF immunoassay. Due to small sample size, statistical analysis is not shown.
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Figure 7. Cortical and striatal measurements of microvessel density in the cortex and striatum of
the IL and CL MCA perfusion territories, taken 15 days post stroke. Microvessel density was
measured by staining arterioles and capillaries with anti-CD31 antibody. While a strong trend is
exhibited in this data, due to small sample size, statistical data is not shown.
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Chapter 4: Conceptual Framework
Chapter 4 established that ischemic stroke in rats with pre-existing MetSyn increased
infarct size and mortality rates, impaired recovery of cerebral blood flow following reperfusion,
and caused a progressive exacerbation of stroke-induced vascular dysfunction in both
hemispheres of the brain. At two weeks post-stroke, reactivity in OZR IL MCA was completely
eliminated, and vessels instead constricted to acetylcholine. Acute treatment with TEMPOL in
OZR IL MCA prevented vasoconstriction, but did not improve dilation. These findings indicated
that a specific injury, likely occurring during ischemia-reperfusion, was causing damage only to
the OZR IL MCA. Administering the NAD(P)H oxidase 2 (Nox2) inhibitory peptide gp91ds-tat
during ischemic stroke assessed whether oxidative stress generated during ischemia-reperfusion
injury could be the cause. Treatment with gp91ds-tat was able to improve OZR IL MCA
reactivity at 15 days post stroke to match OZR CL MCA, but had no effect on OZR CL MCA
function. Nox2 inhibition also improved post-stroke cerebral blood flow, and eliminated
infarction in the stroke territory. The conclusion of this part of the study was that acute inhibition
of Nox2, which is highly expressed on leukocytes that respond to ischemic injury, could prevent
oxidative damage to both the IL MCA and the ischemic core of the stroke during and
immediately following an ischemic event.
This chapter provided additional evidence that oxidative stress and ROS contribute to the
loss of NO bioavailability that defines cerebrovascular dysfunction in MetSyn. The next chapter
of this dissertation sought to establish whether chronic stress/depression, which is known to
impair peripheral vascular reactivity, would further exacerbate these pathologies in OZR.
Additionally, it investigates whether exercise training would prevent the onset of
stress/depression-induced vasculopathy in both LZR and OZR.
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ABSTRACT
Objective: Chronic stress/depression is a major risk factor for cardiovascular disease (CVD) and
impaired vascular function. The purpose of this study was twofold: first, to elucidate the
functional and structural cerebrovascular pathologies induced by chronic stress/depression in a
comorbid model of CVD/metabolic syndrome; second, to determine the efficacy of exercise
training as a prophylactic method for abrogating the onset of stress-induced vasculopathy in LZR
and OZR, and interrogate the mechanisms through which these benefits are conferred.
Methods: Eight weeks of an unpredictable chronic mild stress (UCMS) protocol was imposed
on 9 week old male lean and obese Zucker rats (LZR, OZR) to induce depressive behaviors.
Animals also underwent 8 weeks of daily treadmill exercise concurrent to the UCMS protocol.
After sacrifice, brains were removed and the middle cerebral artery (MCA) was isolated and
cannulated in an ex vivo microvessel preparation. Vascular reactivity was assessed to dilator and
constrictor agonists, and again following acute incubation with TEMPOL or L-NAME. Changes
in cerebral microvascular density were measured by fluorescence immunohistochemistry using a
rat anti-CD31 antibody.
Results: Vascular reactivity was impaired in MCAs from both UCMS-LZR and OZR compared
to non-stressed control. OZR-UCMS demonstrated near-total loss of reactivity to ACh, which
was rescued marginally by TEMPOL. Exercise training was able to completely reverse the
effects of UCMS in both LZR and OZR. Cerebral microvessel density did not vary significantly
except in the cortex of UCMS OZR; this deficit was not present in UCMS Exercise OZR,
however. Interestingly, both UCMS LZR and OZR showed a divergence in vascular benefit
between good and poor responders to exercise.
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Conclusions: Chronic stress induces severe cerebral vasculopathy and rarefaction in rats with
comorbid metabolic syndrome, but exercise training can protect the cerebrovasculature from the
detrimental effects of chronic stress/depression. Our findings suggest NO bioavailability and
levels of oxidative stress may be key factors in these pathologies. Patients suffering from chronic
stress/depression and with other CVD comorbidities may experience severe vascular
impairments and warrant further study.
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INTRODUCTION
Over 350 million people worldwide suffer from depression or a depressive disorder,
establishing depression as a leading cause of disease burden [1, 2]. The National Institute of
Mental Health (NIMH) reports that 15% of U.S. adults suffer from depression [1-3], accounting
for $150 billion in direct costs and an estimated $193 billion from lost earnings/lowered
productivity. While the causes of depression are multifactorial, chronic psychological stress is
recognized as a major factor contributing to the development of depressive episodes [4-10].
Glucocorticoid hormones, such as cortisol, become systemically elevated during periods of
chronic stress and cause increased inflammatory signaling, impairments in metabolic processes
[10-13], leading to dysregulation of the sympathetic-adrenalmedullary (SAM) and hypothalamicpituitary-adrenal (HPA) axes [8-10, 14-16]. Disruption of the normal homeostatic functions
mediated by the HPA axis leads to insulin resistance, cortisol insensitivity, hyperphagia
contributing to visceral fat, and systemic inflammation [9, 17-19].
Depression is an established independent risk factor for cardiovascular disease (CVD)
[17, 20-23]. Patients suffering from depressive episodes, and no prior history of CVD, exhibit
impaired flow-mediated dilation and endothelium-dependent dilation, as well as decreased
plasma nitric oxide (NO) and endothelial NO synthase (eNOS) activity [4, 20, 24, 25]. Obesity,
a major CVD risk factor, is also directly associated with depression [20]. Over a third of all US
adults meet the criteria for the metabolic syndrome (MetSyn) [26, 27], and due to the nationwide
prevalence of both MetSyn and depression- 35% and 15% incidence respectively [26, 27]-many
patients experience disease comorbidity. Dysregulation of the SAM and HPA axes have broad
systemic effects that both directly and indirectly link the pathological progression of MetSyn and
depression [14, 28-30], with implications for vascular function. The relationship between
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depression and CVD is compelling, indicating a critical need to evaluate the physiological
interactions in a combined model.
The unpredictable chronic mild stress (UCMS) protocol is used to generate stressinduced depressive symptoms following exposure to unpredictable mild exogenous stressors [10,
11]. The UCMS model is considered translationally relevant, as long-term application induces
symptoms similar to clinical depression [31-35]. Using the UCMS model, we [17, 32, 36] and
others [18, 37, 38], have demonstrated onset of symptoms, increases in systemic inflammation,
and development of vascular dysfunction in large and small arteries. Degree of depressive
symptom severity is significantly correlated with impairments to endothelium-dependent
vasomotor responses in the peripheral and cerebral vasculatures [17, 32, 36], characterized by
increases in inflammatory markers and ROS, and a reduction in NO and PGI2 bioavailability.
The impact of chronic stress and depression on aortic ring reactivity is mediated through
altered endothelial dysfunction, characterized by low nitric oxide [39] and prostacyclin
bioavailability [17, 32, 36]. Similar mechanisms, including impaired endothelium-dependent
reactivity and reduced NO bioavailability, as well as a pro-inflammatory [6, 18, 40] and prothrombotic [41] circulatory microenvironment, has been observed in mice models of depression
[6, 39, 42], as well as in depressed patients [24, 25]. These mechanisms of impaired vascular
function themselves represent an independent predictor of risk for the development of CVD [25,
43].
We have also observed similar mechanisms of peripheral and cerebral vascular
dysfunction in studies of the obese Zucker rat (OZR), an established model of MetSyn and its
underlying network of systemic pathologies [44-46]. The OZR has a mutation that causes leptin
insensitivity, leading to rapid onset of MetSyn from hyperphagia [44, 46]. We have previously
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reported that significant alterations in the regulation of blood flow in microvascular networks in
the periphery [45, 47-55], and recently reported that middle cerebral arteries (MCA) in OZR
develop significant alterations in myogenic tone [56], vascular reactivity [57], and vessel wall
mechanics [57, 58] due to their underlying MetSyn. We also recently reported a progressive
rarefaction of cerebral cortical microvessels in frontal cortex of OZR that was correlated with
insulin resistance and nitric oxide (NO) bioavailability [58]. By imposing UCMS on OZR, this
study aims to interrogate the functional and structural cerebrovascular impairments that develop
due to comorbid depression and MetSyn.
Exercise training is an effective therapy for improving depressive symptoms and
preventing recurrent episodes in patients suffering from depression [59]. Exercise training has
also been shown to improve MetSyn symptoms on OZR, as well as increase microvascular
perfusion and reduce vascular dysfunction [60, 61]. Exercise has anti-oxidant benefits, and is
known to increase NO bioavailability in both rats [60, 62] and humans [59, 63]. The secondary
aim of this study is to identify the prophylactic benefits of exercise training on cerebrovascular
function in lean and obese Zucker rats undergoing the UCMS protocol, and elucidate the
mechanisms through which protection is occurring.

MATERIALS AND METHODS
Animals: Male LZR and OZR (Harlan Laboratories) were fed standard chow and drinking water
ad libitum and were housed in the animal care facility at the WVU HSC. All protocols received
prior IACUC approval, and animals undergoing exercise training and/or chronic stress treatment
were handled and inspected daily, with regular supervision of the veterinary support staff. At
nine weeks of age, LZR and OZR were divided into four groups: age-matched control, UCMS
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(below), treadmill exercise, or UCMS with treadmill exercise. After eight weeks duration under
either control, UCMS, exercise, or UCMS/Exercise conditions, rats were anesthetized with
injections of sodium pentobarbital (50 mg•kg-1 i.p.) and a carotid artery was cannulated for
determination of mean arterial pressure. Venous blood aliquots were collected by venipuncture
for biochemical evaluation of plasma biomarkers of treatment outcomes and metabolic health
status of the rats.
Unpredictable Chronic Mild Stress Protocol: All rats were singly housed; control animals were
housed in a separate “quiet room” in close proximity to the room used for UCMS treatments.
Exercise training was performed in an adjacent room to minimize animal transport. In UCMS
groups, rats were randomly exposed to the following mild environmental stressors on multiple
occasions throughout each 24 hour period over the course of 8 weeks:
1.

Damp bedding – 10 oz. of water was added to each standard cage for the next 3 hours

2.

Water – all bedding was removed and ~0.5 inches of water was added to empty cage for

the next three hours. Water temperature was ~30°C and the room temperature was ~24°C
3.

Each cage was tilted to 45 degrees with or without bedding for 3 hours

4.

Social stress – each rat was switched into a cage of a neighboring rat for 3 hours

5.

No bedding lasting for 3 hours or, on two occasions each week, overnight.

6.

Succession of light/dark cycles, lasting 30 minutes throughout a 24 hour period

7.

Exposure to predator smells (e.g., cat fur) and/or sounds (e.g., cat growling) for 8 hours

8.

After eight weeks, all rats were subjected to a series of behavioral tests to evaluate the

outcomes of the UCMS procedures.
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Coat Status: This evaluation was done throughout the duration of the UCMS protocol. Each
week, every rat was weighed and inspected for grooming habits. The total cumulative score was
computed by giving an individual score of 0 (clean) or 1 (dirty) to eight body parts.
Exercise Training Protocol: LZR/OZR underwent 8 weeks of treadmill running, either
concurrent with UCMS or as a standalone treatment. Animals ran 5 days/week on a three-lane
motor driven treadmill set at a 4% grade. For the first 3 weeks, animals ran 20 min/day,
increasing by 5 min/day until sustainable duration of 60 minutes daily was achieved. The
following 15 min. exercise intensity cycles were used: 24 m/min for 10 minutes, 26 m/min for 3
min, and 28 m/min for 2 min. Mild electrical stimulation was used to encourage running; the
maximum current was no more than .300 milliamps. Work calculations were performed based on
animal body weight, and speeds/durations were adjusted to normalize work output between lean
and obese animals accordingly.
Euthanasia and Collection of Middle Cerebral Arteries: While deeply anesthetized, each rat
was decapitated, after which the brain was removed from the skull and placed in cold
physiological salt solution (PSS; 4ºC). Both middle cerebral arteries (MCA) were dissected from
their origin at the Circle of Willis and placed into an isolated microvessel chamber filled with
PSS. Each MCA was subsequently doubly cannulated within in this heated chamber (37°C) that
allowed the lumen and exterior of the vessel to be perfused and superfused, respectively, with
PSS from separate reservoirs. The PSS was equilibrated with a 21% O2, 5% CO2, and 74% N2
gas mixture and had the following composition (mM): 119 NaCl, 4.7 KCl, 1.17 MgSO4, 1.6
CaCl2, 1.18 NaH2PO4, 24 NaHCO3, 0.026 EDTA, and 5.5 glucose. Any side branches were
ligated using a single strand teased from 6-0 suture. Vessel diameter was measured using
television microscopy and an on-screen video micrometer.
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Measurements of Vascular Reactivity in Isolated MCA: Following cannulation, MCAs were
extended to their in situ length and were equilibrated at 80% of the animal's mean arterial
pressure to approximate in vivo perfusion pressure (Lombard paper). Any vessel that did not
demonstrate significant active tone at the equilibration pressure was discarded. Active tone at the
equilibration pressure was calculated as (ΔD/Dmax)•100, where ΔD is the diameter increase
from rest in response to Ca2+-free PSS, and Dmax is the maximum diameter measured at the
equilibration pressure in Ca2+-free PSS.
Following equilibration, the dilator reactivity of MCA was assessed in response to
increasing concentrations of acetylcholine (ACh, 10-9M– 10-5M), sodium nitroprusside (SNP 109

M– 10-5M), and serotonin (5-hydroxytryptamine, 5-HT 10-10M– 10-7M). Vascular responses to

acetylcholine (ACh) were also measured following acute incubation (45-60 minutes) with LNAME (10-4M) and TEMPOL (10-4M), to assess the contributions of nitric oxide (NO) and
oxidative stress, respectively, in modulating vascular reactivity. (Cite Butcher JOVE). Passive
vessel inner and outer diameters were measured at the end of experiments while vessel was
immersed in Ca2+-free PSS. Wall thickness was calculated as the difference in inner and outer
passive vessel diameters.
Plasma Clinical Biomarker Analyses: Levels of common clinical plasma biomarkers (e.g.
insulin, glucose, triglycerides, blood urea nitrogen (BUN)/creatinine, etc) were measured by the
clinical laboratory service at Ruby Memorial Hospital (Morgantown, WV). Blood was drawn
intravenously from anesthetized rats into lithium-heparin coated blood tubes and transported
immediately to the laboratory for analysis.
Immunohistochemistry and Western blot: After rats were euthanized and surface vessels
removed, brains were quickly saved in OCT and flash-frozen in super-cooled isopentane.
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Samples were stored at -80 until processing. Coronal brain slices (20 um thickness for histology)
and additional brain slices (100um thickness for protein and RNA analysis) were prepared with a
cryotome (Leica CM3050S; Leica Microsystems) from bregma -1 using a standard Rat Brain
Atlas and transferred to charged microscope slides for histological analysis.
Cerebral

microvessel

and

capillary

density

was

evaluated

by

fluorescence

immunohistochemistry using a rat anti-CD31 antibody (BD Biosciences, San Diego, CA) as
described preciously (23632977). Briefly, brain sections were fixed with 4% paraformaldehyde,
permeabilized with 0.2% Triton X-100, and blocked with block solution (5% BSA in PBS) and
then incubated with anti-CD31 (1:100) for 1 h at room temperature in a humidified chamber.
Following three washes with PBS, cells were incubated with Alexa Fluor 555-conjugated antimouse IgG (1:1000; Invitrogen) for 1 h at room temperature in a humidified chamber. After a
final wash with PBS, cover glass was placed on mounting medium with DAPI (Vector
Laboratories, Burlingame, CA) on a slide. Negative control was performed with the same
procedure without primary antibody. Images were obtained with an epifluorescence microscope
and a SPOT RT camera (Diagnostic Instruments). The microvessels density was analyzed in 6
region of interest (3 in cortex and 3 in striatum) in the MCA territory using ImageJ, as described
previously (23632977).
Semi-quantitative immunodetection was performed as detailed previously. Briefly, brain
tissues were homogenized in RIPA buffer (Thermo Fisher Scientific, Wiltham, MA)
supplemented with 1mM DTT, protease and phosphatase inhibitor cocktails (Thermo Fisher
Scientific, Wiltham, MA). Lysates were sonicated on ice and centrifuged at 10,000 x g at 4 °C
for 10 min. The supernatant was removed and protein concentration was determined by BCA
Protein assay (Thermo Fisher Scientific, Wiltham, MA). Samples were diluted to 1 mg ml-1 in
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Laemmli sample buffer and boiled at 70 °C for 15 min. Equivalent amounts of protein were
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed
by electroblotting onto nitrocellulose membranes. Membranes were blocked with 5% milk in
PBST for 1 h at room temperature, washed 3 times in phosphate buffered saline containing 0.1%
Tween (PBST), and incubated overnight at 4 °C in primary antibodies against CD31 antibody
(BD Biosciences, San Diego, CA), VEGF (1:250 SCRabbit. After washing 3 times in TBST, membranes were incubated with anti-species secondary
antibody conjugated with HRP and HRP-linked anti-biotin secondary antibodies for a
biotinlyated ladder (1:5000; Cell Signaling Technology) for 1 h at room temperature and then
washed again 3 times with TBST. An enhanced chemiluminescence detection system (ECL
Advance, Amersham Biosciences) was used to detect the antibodies and the lanes were analyzed
using a G:Box system (Syngene). The relative expression of each protein was quantified with
ImageJ.
Data and Statistical Analyses: Mechanical responses following challenge with logarithmically
increasing dosages of ACh, SNP, and 5-HT were fit with the three-parameter logistic equation:

 max  min 
y  min  
log ED x
1  10 50 
Where y represents the vessel diameter, “min” and “max” represent the lower (minimum) and
upper (maximum) bounds, respectively, of the change in diameter with agonist concentration, x
is the logarithm of the agonist concentration, and logED50 represents the logarithm of the
agonist concentration ( x ) where the response ( y ) is halfway between the bounds. For statistical
evaluation of results, we have focused on the changes in the upper bounds as a representation of
vessel reactivity, as lower bound remained consistent between all groups (defined as the pre-
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challenge diameter); we did not determine a consistent or significant change to the logED50
values between treatment groups. All other statistical analyses utilized Student's t-test or analysis
of variance (ANOVA) with Student-Newman-Keuls test post-hoc. Statistical significance is
represented by p< 0.05.

RESULTS
Clinical biomarkers from all animal groups were measured from plasma. As expected,
OZR control demonstrated elevated plasma glucose, insulin, triglycerides, and cholesterol
(especially LDL), as well as elevated alkaline phosphatase, blood urea nitrogen (BUN) and
BUN/creatinine ratio, AST, and ALT, when compared to LZR control. LZR UCMS developed
higher levels of plasma glucose, triglycerides, and AST, ALT compared to LZR control;
however, these biomarker levels were brought back to control levels in the exercise treated LZR
UCMS cohort. In OZR UCMS, plasma glucose, insulin, triglycerides, and cholesterol, as well as
BUN, BUN creatinine ration, alkaline phosphatase, ALT, and AST, all remained significantly
elevated compared to LZR control, but were not different from OZR control. Exercise treated
OZR UCMS had reduced cholesterol (including LDL) and improved insulin levels compared to
OZR control and OZR UCMS, while the other biomarkers remained unchanged. In exercise
treated non-stressed OZR, insulin was also lowered, as were cholesterol, LDL cholesterol, and
alkaline phosphatase, while glucose, BUN/creatinine, triglycerides, and AST, ALT remained
unchanged. (plasma results not shown due to unavailability of graph).
Vascular reactivity was measured first in MCA from UCMS and control LZR and OZR
to assess the effect of chronic stress on cerebrovascular reactivity. Figure 1 presents
endothelium-dependent vasodilation of ex vivo MCA to escalating doses of ACh. LZR control
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dilated most robustly at all doses compared to LZR UCMS, OZR control, and OZR UCMS
(Figure 1A). Maximum dilation (response to ACh [10-5]M) was reduced by ~30% in LZR
UCMS compared to LZR control, ~45% in OZR control, and more than 65% in OZR UCMS
(Figure 1B). MCA incubation was TEMPOL was able to almost completely rescue vasodilation
to ACh in LZR UCMS, while incubation with L-NAME eliminated ~80% of vasodilation
(Figure 1C). In OZR UCMS, TEMPOL incubation restored MCA dilation to that of OZR
control, while L-NAME incubation completely eliminated all reactivity to ACh in OZR UCMS
MCA (Figure 1D).
Figure 2 presents maximum dilation to the highest dose of ACh [10-5]M or SNP [10-5]M,
assessing

endothelium-dependent

and

endothelium-independent

vasomotor

responses

respectively in control and UCMS treated LZR and OZR. In LZR control, incubation with
TEMPOL did not improve vasodilation to ACh, and dilation to SNP was not significantly
different from ACh (Figure 2A). Incubation with L-NAME significantly reduced maximum
vasodilation to ACh. In LZR UCMS, max dilation to ACh was reduced ~30% compared to LZR
control, while dilation to SNP was not different from LZR control, indicating the difference in
vasoreactivity is largely attributable to endothelium-dependent mechanisms (Figure 2B).
Incubation with TEMPOL significantly improved maximum dilation to ACh, while L-NAME
reduced dilation consistent with its effect in LZR control MCA (Figure 2B). In OZR control,
maximum dilation to ACh was reduced ~45% compared to LZR control, and dilation to SNP was
reduced as well, by ~15% (Figure 2C). Treatment with TEMPOL improved dilation to ACh by
nearly 50%, increasing max dilation to 75% of LZR control; treatment with L-NAME nearly
ablated all vasodilation to ACh (Figure 2C). In OZR UCMS, max dilation to ACh was decreased
~70% or ~45% to LZR control/OZR control respectively, and dilation to SNP was reduced a
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further ~10% compared to OZR control (Figure 2D). Incubation with TEMPOL improved dilator
response to ACh by 75%, restoring lost reactivity between OZR and OZR UCMS, while
incubation with L-NAME totally elimination vasodilation to ACh, instead allowing
vasoconstriction in some vessels (Figure 2D).
Exercise training was then imposed on control and UCMS LZR and OZR over 8 weeks to
assess the effects of exercise on behavioral and vascular outcomes of UCMS, MetSyn, and
comorbid UCMS/MetSyn. Figure 3 presents the effects of exercise training on MCA
vasoreactivity in LZR control, LZR UCMS, OZR control, and OZR UCMS. Dilation to
escalating doses of ACh was not different between LZR control and LZR exercise, and dilation
in LZR UCMS Exercise was restored to LZR control levels (Figure 3A). In contrast, dilation to
ACh in OZR exercise was significantly improved compared to OZR control, recovering nearly
90% of dilation compared to LZR control (Figure 3B). Exercise training in OZR UCMS also
reversed the decline in dilation seen in OZR UCMS, improving dilation over OZR control by a
further ~15% (Figure 3B). Maximum dilation to SNP [10-5]M did not significantly differ
between any of the LZR treatment groups (Figure 3C), while dilation to SNP [10-5]M did
improve significantly in OZR exercise, returning it to levels comparable to LZR control (Figure
3D). Exercise training did not improve maximum dilation to SNP in OZR UCMS, however.
To account for whether structural changes in the vessels may account for differences in
maximal dilation, MCAs were allowed to equilibrate in a Ca2+ free PSS solution resulting in
passive dilation. These results are presented in Figure 4. Passive inner MCA diameter did not
change for LZR Exercise or LZR UCMS Exercise compared to LZR control; interestingly, a
significant increase in inner diameter was found in LZR UCMS (Figure 4A). However, this was
also reflected as a comparable significant increase in passive MCA outer diameter, indicating
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that this cohort of animals may have just genetically had slightly larger MCAs (Data not shown).
Passive inner diameters of OZR and OZR UCMS were both significantly reduced compared to
LZR control, while inner diameters of OZR Exercise and OZR UCMS Exercise were not
significantly different from LZR control (Figure 4B). The measured wall thickness for all LZR
groups (Figure 4C) and all OZR groups (Figure 4D) was not significantly different, meaning that
significant differences in passive inner MCA diameter were attributable to eutrophic inward (or
outward) remodeling, as opposed to hypertrophic remodeling.
To further interrogate the mechanisms governing endothelium-dependent vasodilation in
exercise treated animals, isolated MCA were incubated with either TEMPOL or L-NAME.
Maximum dilation to ACh in exercise-trained OZR is presented in Figure 5. As stated
previously, MCAs from OZR Exercise showed a significantly increased maximum dilation to
ACh [10-5]M compared to OZR control. Incubation with TEMPOL further increased dilation,
recovering it to levels equivalent of LZR control. Incubation with L-NAME reduced dilation by
~60%, which while significant, was less that the reduction measured in LZR control to the same
dose of L-NAME. Figure 6 presents maximum dilation in exercise trained LZR UCMS and OZR
UCMS. Incubation with TEMPOL did not have a significant effect on dilation to ACh in LZR
UCMS Exercise, while the effect of L-NAME was the same as LZR Control (Figure 6A). In
OZR UCMS Exercise, TEMPOL also did not improve dilation to ACh, in contrast to OZR
Exercise and OZR UCMS (Figure 6B). Similar to OZR UCMS, L-NAME completely ablated all
dilation to ACh, and allowed vasoconstriction in some MCAs.
Analysis of vasodilator responses in MCA of OZR Exercise, OZR UCMS Exercise, and
LZR UCMS Exercise groups revealed larger Standard Errors than any other treatment condition.
Subsequent analysis revealed that some OZR and UCMS MCAs were ‘poor’ responders while
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others were ‘good’ responders to ACh; evaluation of the training log revealed that these animals
were also ‘good’ or ‘poor’ performers on the treadmill, often requiring different levels of
encouragement to run. Analysis of each of these three groups was therefore further sub-divided
into ‘good’ responders (n=4 OZR Exercise, n=4 OZR UCMS Exercise, n=4 LZR UCMS
Exercise) and ‘poor’ responders (n=3 OZR Exercise, n=3 OZR UCMS Exercise, n=4 LZR
UCMS Exercise), which were presented in Figure 7. For OZR exercise, ‘good’ responders
showed maximum dilation responses to ACh on par with LZR control, while ‘poor’ responders
showed a much reduced, but still significant, benefit from exercise (Figure 7A). In OZR UCMS
Exercise, ‘good’ responders showed a significant improvement in vasodilation, while ‘poor’
responders did not significantly improve compared to OZR UCMS (Figure 7B). In LZR UCMS
Exercise, this trend continued, as ‘good’ responders demonstrated improved dilation to levels
comparable to LZR control, while ‘poor’ responders were not significantly different from LZR
UCMS (Figure 7C). Importantly, animals in the LZR exercise group did not develop divergent
dilatory responses, and training logs indicated universally ‘good’ performance during training.
Vasoconstriction of MCAs from control, UCMS, and UCMS Exercise LZR and OZR are
presented in Figure 8. Vasoconstriction to 5-HT was similar between LZR control and LZR
exercise. LZR UCMS constricted significantly more at the higher doses of 5-HT than LZR
control, which was recovered back to control responses in LZR UCMS Exercise (Figure 8A).
OZR control and OZR UCMS both showed significant, and comparable, increases in constriction
compared to LZR control, but exercise training was not able to significantly improve constriction
in OZR UCMS as it was in LZR UCMS (Figure 8B). Exercise was, however, able to restore
constriction in OZR to levels comparable to LZR control. Maximum constrictor responses to 5-
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HT [10-7]M are presented for LZR (Figure 8C) and OZR (Figure 8D) to allow visualization of
responses between LZR and OZR.
Figure 9 presents the results of fluorescence immunohistochemistry staining for anti-CD31 to measure microvascular density in the cortex and striatum of MCA perfusion territories, and
semi-quantitative immunodetection by western blot of these brain regions for CD-31 and VEGF.
CD-31+ vessel density in the cortex was not significantly different between LZR control, LZR
UCMS, and LZR UCMS Exercise, nor between LZR Control, OZR Control, and OZR Exercise
(Figure 9A). However, there is a sharp decline in microvessel density in OZR UCMS, which is
recovered fully in OZR UCMS Exercise (Figure 9A). No differences in microvessel density in
the striatum achieved significance between any groups, but OZR UCMS trended in that direction
(Figure 9B). Protein levels of CD31 were also significantly decreased in OZR UCMS (Figure
9C), but no other groups, while protein levels of VEGF trended towards increases in both LZR
UCMS Exercise and OZR UCMS Exercise compared to LZR UCMS and OZR UCMS
respectively (Figure 9D).

DISCUSSION
We present here novel findings that show cerebrovascular dysfunction in the MCAs of
LZR and OZR following eight weeks of UCMS. To our knowledge, this is the first such report of
stress/depression-induced cerebrovascular dysfunction in rats. The comorbid presence of chronic
stress and MetSyn resulted in a severe reduction to endothelium-dependent vasodilation of
MCAs, as well as impaired dilation to an exogenous donor of NO, significant eutrophic inward
remodeling, and a decrease in cortical microvessel density in the MCA perfusion territory. We
also report that exercise training, which recovers vascular function in OZR controls to levels
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comparable with LZR, is able to completely reverse the onset of vascular pathologies from
UCMS in LZR, and block vascular impairment present in control OZR from progressing in the
presence of UCMS.
These impairments, and subsequent improvements following exercise training, are likely
a function of limited NO bioavailability. This is supported through our observation of a decrease
in direct production of NO from conduit vessels, and improved MCA reactivity following
incubation with TEMPOL/ total loss of reactivity following incubation with L-NAME. Nitric
oxide has been extensively described in the literature as being the most influential vasodilatory
mediator produced in the cerebrovascular endothelium [64-71], and impairments in NO
bioavailability have been linked with cerebrovascular dysfunction in diabetes, metabolic
syndrome, hypertension, and stroke [72-76]. Reduced NO bioavailability has also been linked
with rarefaction in peripheral tissues [49], as well as with progressive increase in vascular
dysfunction of skeletal muscle arterioles [50, 51, 77]. Oxidant stress, which is exacerbated by
chronic stress, is well established as a leading cause of vascular dysfunction, and these results
support that it may indeed drive loss of NO bioavailability and the progression of cerebral
vasculopathy reporter here.
Chronic stress, which causes dysregulation of the SAM and HPA axes, has been linked
with a litany of metabolic [21, 39, 78] and vascular consequences. We previously reported loss
of NO bioavailability and increases in biomarkers of oxidant stress in a murine model of UCMS
[17, 36], which correlated with impaired endothelium-dependent mechanisms of vasodilation.
Our results in the present study confirm similar mechanisms of dysfunction in the
cerebrovasculature of LZR. Baseline impairments in reactivity of MCA from OZR are also
consistent with our previously published work, with further impairment resulting from the
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imposition of UCMS in OZR. Of concern, we did not see a decrease in microvessel density in
control OZR, as we have previously reported [58]; this may be a result of studying a different
region of interest in the brain- namely, the MCA perfusion territory (this study) as opposed to the
frontal cortex. The MCA perfusion territory is the largest and most well-perfused area of the
cortex, and is well-supplied with collateral flow. If the basal level of collateral flow is sufficient
to prevent rarefaction in this region even in OZR, then the sharp decline in microvessel density
seen in OZR UCMS is of great concern, as this region is the most commonly implicated in
ischemic stroke, and impaired perfusion/reduction of collaterals would worsen stroke outcomes.
The eutrophic inward remodeling reported here is also consistent with advanced vascular
dysfunction seen in OZR [57]. We previously reported that chronic anti-oxidant therapy was able
to prevent such structural alterations, lending further support for the argument that loss of NO
bioavailability and increased oxidant stress are driving the pathological changes in the
cerebrovascular circulation of OZR. Vessel diameter, functional hyperemic responses, and
vascular density all play a role in maintaining adequate blood flow to each region of the brain,
and must be able to response accordingly to accommodate increases in flow during periods of
higher neural activity. Impairments in any/all of these processes may have significant impacts on
neuronal metabolism and activity.
Exercise training has been extensively researched as a treatment for depression and major
depressive disorders [59]. Our results show that exercise training was able to improve
cerebrovascular outcomes in terms of vascular reactivity, remodeling, and microvessel density,
in both OZR and LZR following 8 weeks of UCMS. In humans, exercise has been found to be as
effective as SSRIs at improving depressive symptoms [59] and more effective than several
common drugs at preventing recurrent episodes of depression. Large meta-analyses have

176

determined that exercise programs of any kind- aerobic, weight training, walking, etc- were all
equally effective as treatments as long as it was 9 weeks or longer [59]. Clinical studies have also
shown that exercise is equally effective for men and women, as well as newly diagnosed or longterm diagnosed patients. The mechanisms through which exercise treats depression are currently
an area of debate. One theory is that improved bioavailability of mono-amine neurotransmitters,
including NE, dopamine, and serotonin, can lead to improved neurological function in the
affected areas of the brain [40, 79-81]. Alternatively, a reduction in oxidant stress, and increase
in overall body metabolism have been identified as ways exercise combats depression [59, 62,
68, 82].
Recent studies into the etiology of depression have linked molecular alterations in
hippocampal neurons with increases in oxidant stress [6, 83-85]. Two recent studies have shown
that culturing hippocampal neurons from depressed animals with TEMPOL can restore rates of
proliferation, and direct anti-oxidant treatment of the hippocampus in mice has been shown to be
anti-depressant. As reactive oxygen species (ROS) can cross the blood brain barrier, peripheral
sources of ROS may therefore contribute to the oxidative microenvironment driving loss of
neuronal proliferation and impaired neuronal function in the hippocampus. By this theory,
exercise training may be anti-depressant by its anti-oxidative effects, in addition to its effects on
mono-amine neurotransmitter production. This would provide evidence to the theory that
systemic oxidative stress and inflammation, both common consequences of MetSyn and most
types of CVD, contributes directly to the development of depression. Development of
physiological neuronal dysfunction may therefore share a common pathological etiology with the
vascular dysfunction, as both develop due to systemic oxidative stress. Furthermore, impairment
in delivery of blood to the hippocampus could cause hypoxia, inducing oxidative dysregulation
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within neurons and contributing to the pathology. Further work is certainly warranted to study
this link between CVD, vascular dysfunction, and the molecular origins of depression in the
hippocampus.
Clinical Implications
Impaired regulation of cerebral blood flow has significant implications for cognitive
function, as well as for risk and outcomes in disease such as mild cognitive impairment, vascular
dementia, and ischemic stroke. Mild cognitive impairments and vascular dementia have been
previously linked to poor regulation of cerebral perfusion. The cerebrovascular adaptations
occurring from MetSyn and UCMS may therefore represent key contributors to multiple cerebral
pathologies [70, 71, 86, 87]. We have previously reported a decrease in cerebral cortical
microvascular density associated with MetS, and report here that this rarefaction may increase in
the presence of chronic stress. In this study, we report that limited NO bioavailability and
oxidant stress, stemming from both MetSyn and UCMS,

contribute to impaired cerebral

perfusion by reducing endothelial-dependent dilation, inward remodeling of MCA, and reducing
density of microvessels. These mechanisms serve as physiological contributors to impairments in
cerebral blood flow regulation and perfusion, which have been linked to cognitive decline with
aging. Indeed, recent work by Tucsek et al [88-91] found that combining aging with high-fat diet
induced obesity in mice led to an exacerbation of cerebrovascular rarefaction and neurovascular
uncoupling which was directly associated with cognitive impairments. MetSyn- associated
cerebrovascular disease leads to elevated risk for ischemic stroke risk for patients with MetSyn.
Early recognition of stress/depression-associated vascular impairments, especially in
patients who concurrently suffer from MetSyn, may provide a valuable clinical time window to
treat patients to protect their cerebral vasculature. Prophylactically treating such patients with
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drugs that confer pleiotropic benefits- such as atorvastatin [52, 57, 92]- may limit the deleterious
impact of chronic stress on neurological and cerebrovascular health in patients with MetSyn,
potentially conferring the anti-depressant and vasculo-protective benefits of exercise in a patient
popular who may be unwilling or unable to exercise daily.
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FIGURE LEGENDS
Figure 1: MCA vasodilation to acetylcholine in LZR and OZR following 8 weeks of chronic
stress. Dose-response dilation to ACh for LZR control, LZR UCMS, OZR control, and OZR
UCMS (Panel A). Maximum dilation to ACh to each group (Panel B). Dilation to ACh for LZR
control and LZR UCMS after acute inbubation of vessels with TEMPOL or LNAME (Panel C).
Dilation to ACh for OZR control and OZR UCMS after acute inbubation of vessels with
TEMPOL or LNAME (Panel D). All data are presented as mean ± SE. * p<0.05 versus
responses in LZR control at 17 weeks; † p<0.05 versus responses in OZR control at 17 weeks.
Please see text for more details and formulae.
Figure 2: Maximum dilation of MCA to ACh and SNP in LZR and OZR following 8 weeks of
chronic stress. Maximum dilatory capacticity is shown for MCA to ACh, SNP, ACh after
incubation with TEMPOL, and ACh after incubation with L-NAME for LZR control (Panel A),
LZR UCMS (Panel B), OZR control (Panel C), and OZR UCMS (Panel D). All data are
presented as mean ± SE. * p<0.05 versus responses in LZR control at 17 weeks; † p<0.05 versus
responses in OZR control at 17 weeks. Please see text for more details and formulae.
Figure 3: Effects of 8 weeks of exercise training on vasodilatory responses to ACh and SNP in
LZR and OZR. Dose-response dilation to ACh for LZR control, LZR UCMS, LZR Exercise, and
LZR UCMS+Exercise (Panel A). Dose-response dilation to ACh for OZR control, OZR UCMS,
OZR Exercise, and OZR UCMS+Exercise (Panel B). Maximal dilation to SNP for LZR control,
LZR UCMS, LZR Exercise, and LZR UCMS+Exercise (Panel C). Maximal dilation to SNP for
OZR control, OZR UCMS, OZR Exercise, and OZR UCMS+Exercise (Panel D). All data are
presented as mean ± SE. * p<0.05 versus responses in LZR control at 17 weeks; † p<0.05 versus
responses in OZR control at 17 weeks. Please see text for more details and formulae.
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Figure 4: Effects of 8 weeks of exercise training on eutrophic remodeling of MCA in LZR and
OZR. Passive inner diameter as measured after incubation of vessel in a Ca++-free physiological
salt solution for LZR control, LZR UCMS, LZR Exercise, and LZR UCMS+Exercise (Panel A).
Passive inner diameter as measured after incubation of vessel in a Ca++-free physiological salt
solution for OZR control, OZR UCMS, OZR Exercise, and OZR UCMS+Exercise (Panel B).
Vessel wall thickness as measured after incubation of vessel in a Ca++-free physiological salt
solution for LZR control, LZR UCMS, LZR Exercise, and LZR UCMS+Exercise (Panel C).
Vessel wall thickness as measured after incubation of vessel in a Ca++-free physiological salt
solution for OZR control, OZR UCMS, OZR Exercise, and OZR UCMS+Exercise (Panel D). All
data are presented as mean ± SE. * p<0.05 versus responses in LZR control at 17 weeks; †
p<0.05 versus responses in OZR control at 17 weeks. Please see text for more details and
formulae.
Figure 5: Maximal Dilation of MCA to ACh from OZR control and OZR after 8 weeks of
exercise training. Dilation also shown for vessel after incubation in TEMPOL or L-NAME. All
data are presented as mean ± SE. * p<0.05 versus responses in OZR control at 17 weeks. Please
see text for more details and formulae.
Figure 6: Maximum Dilation of MCAs in Exercise-trained LZR and OZR after 8 weeks of
chronic stress. Maximal dilation to ACh, SNP, and ACh in the presence of TEMPOL or LNAME for LZR UCMS Exercise (Panel A). Maximal dilation to ACh, SNP, and ACh in the
presence of TEMPOL or L-NAME for OZR UCMS Exercise (Panel B). All data are presented as
mean ± SE. * p<0.05 versus responses in LZR control at 17 weeks; † p<0.05 versus responses in
OZR control at 17 weeks. Please see text for more details and formulae
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Figure 7: Maximal dilation of MCA to ACh in exercise trained LZR and OZR after 8 weeks of
UCMS based on exercise response. Maximum dilatory capacity is shown for MCA to ACh for
OZR control, OZR exercise, OZR exercise Good Responders, and OZR exercise Poor
Responders (Panel A). Maximum dilatory capacity is shown for MCA to ACh for OZR control,
OZR UCMS, OZR UCMS + Exercise, OZR UCMS + Exercise Good Responders, and OZR
UCMS + Exercise Poor Responders (Panel B).Maximum dilatory capacity is shown for MCA to
ACh for LZR control, LZR UCMS, LZR UCMS + Exercise, LZR UCMS + Exercise Good
Responders, and LZR UCMS + Exercise Poor Responders (Panel C). All data are presented as
mean ± SE. * p<0.05 versus responses in LZR control at 17 weeks; † p<0.05 versus responses in
OZR control at 17 weeks. Please see text for more details and formulae
Figure 8: Vasoconstriction to 5-HT in LZR and OZR after 8 weeks of exercise training and
UCMS. Dose-response constriction to 5-HT for LZR control, LZR UCMS, LZR Exercise, and
LZR UCMS+Exercise (Panel A). Dose-response constriction to 5-HT for OZR control, OZR
UCMS, OZR Exercise, and OZR UCMS+Exercise (Panel B). Maximal constriction to 5-HT for
LZR control, LZR UCMS, LZR Exercise, and LZR UCMS+Exercise (Panel C). Maximal
constriction to 5-HT for OZR control, OZR UCMS, OZR Exercise, and OZR UCMS+Exercise
(Panel D). All data are presented as mean ± SE. * p<0.05 versus responses in LZR control at 17
weeks; † p<0.05 versus responses in OZR control at 17 weeks. Please see text for more details
and formulae
Figure 9: Cerebral microvessel density and protein expression of CD-31 and VEGF in the cortex
and striatum of LZR and OZR following 8 weeks of exercise and UCMS. Semi-quantitative
analysis of microvessel density by immunostain for anti-CD-31 in the cortex of LZR and OZR
control, LZR and OZR UCMS, LZR and OZR Exercise, and LZR and OZR UCMS + Exercise

190

(Panel A). Semi-quantitative analysis of microvessel density by immunostain for anti-CD-31 in
the striatum of LZR and OZR control, LZR and OZR UCMS, LZR and OZR Exercise, and LZR
and OZR UCMS + Exercise (Panel B). Western blot quantification of CD-31 protein expression
in the brains of LZR and OZR control, LZR and OZR UCMS, LZR and OZR Exercise, and LZR
and OZR UCMS + Exercise (Panel C). Western blot quantification of VEGF protein expression
in the brains of LZR and OZR control, LZR and OZR UCMS, LZR and OZR Exercise, and LZR
and OZR UCMS + Exercise (Panel C). All data are presented as mean ± SE. * p<0.05 versus
responses in LZR control at 17 weeks; † p<0.05 versus responses in OZR control at 17 weeks.
Please see text for more details and formulae
Supplemental Figures: Data shown for average mean arterial pressure at 17 weeks of age as
measured by flow transducer placed into cannulated carotid artery (Supplemental Figure 1). Data
shown for average weekly food intake by group over 8 weeks (Supplemental Figure 2). Data
shown for average amount of work performed by each during exercise training (Supplemental
Figure 3). Data shown for average weekly body mass for each group of the 8 week time course
of these experiments (Supplemental Figure 4).
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Figure 1 (MCA Dilation in LZR and OZR after 8 Weeks of UCMS)
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Figure 2 (Maximum Dilation of MCA)
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Figure 3 (Effect of Exercise on Dilation of MCA following UCMS)
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Figure 4 (Effect of Exercise on Eutrophic Remodeling of MCA)
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Figure 5 (Maximum Dilation of MCA in Exercise-trained OZR)
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Figure 6 (Maximum Dilation of MCAs in Exercise-trained UCMS Animals)
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Figure 7 (Differential Responses of Good vs Poor Responders to Exercise Training)
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Figure 8 (MCA Constriction Responses Following UMCS)
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Figure 9 (Cerebrovascular Microvessel Density)
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Supplemental Figure 1 (Mean Arterial Pressures at 17 Weeks)
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Supplemental Figure 2 (Average Weekly Food Intake)
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Supplemental Figure 3 (Average Work Performed During Exercise)
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Supplemental Figure 4 (Change in Body Mass over 9 weeks of UCMS)
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Chapter 5: Conceptual Framework
This chapter investigated the effects of imposing the unpredictable chronic mild stress (UCMS)
protocol on LZR and OZR for 8 weeks to induce depression and vascular dysfunction. A separate cohort
of LZR and OZR received exercise training alone, or exercise training concurrent to UCMS, for the 8
week period. The main finding of this chapter is that UCMS induces vascular dysfunction in MCA of
LZR and OZR, as well as eutrophic remodeling and cortical rarefaction in UCMS treated OZR. Acute
incubation of vessels with TEMPOL and L-NAME revealed that these impairments largely stemmed
from alterations in NO bioavailability, with impairments being substantially greater in OZR than LZR.
Exercise training was able to improve each of these symptoms in both LZR and OZR. Interestingly,
exercise trained animals from the control OZR and UCMS OZR groups, as well as the UCMS LZR
groups, could be characterized as ‘good’ or ‘poor’ responders to exercise. ‘Good’ responding OZR
showed a dramatic improvement in MCA reactivity, restoring reactivity to LZR control, while ‘poor’
responders showed a much smaller, albeit significant, improvement over OZR control and OZR UCMS.
A similar dichotomy was seen for ‘good’ and ‘poor’ responders in LZR. These findings suggest that the
anti-depressive and vasculoprotective benefits of exercise training may be limited by individual factors.
While the finding that exercise improves depressive symptoms and vascular health is not itself
novel, this study was the first to conclusively link chronic stress/depression with cerebrovascular
dysfunction, in lean as well as MetSyn animals, and the exercise component helps establish the
mechanisms through which impairments occur and subsequently be treated. In sum, this chapter
provides a final examination of functional impairments that result when comorbid metabolic syndrome
is incorporated into a disease model. Considering the extremely high prevalence of MetSyn in the US,
and its link to stroke, myocardial infarction, atherosclerosis, dementia, and Alzheimer’s, it becomes
necessary to question how the comorbid presence of MetSyn directly impacts the pathophysiology of
these diseases. Incorporating MetSyn into preclinical models of these diseases may serve to enhance the
translational utility of these models and improve the clinical relatability of their findings.
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CHAPTER 6: DISSERTATION DISCUSSION
The purpose of this dissertation was to define and interrogate the mechanisms of
cerebrovascular dysfunction and remodeling that develop due to the underlying constituent
pathologies of the metabolic syndrome (MetSyn), and to evaluate the functional consequences of
these impairments on outcomes in ischemic stroke and stress-induced depression. Metabolic
syndrome is one of the most costly and prevalent conditions in the United States, and its
underlying pathological conditions- hypertension, hyperglycemia, insulin insensitivity, central
obesity, and dyslipidemia- each directly contribute to mechanisms of vascular dysfunction and
vascular remodeling. The obese Zucker rat (OZR) is a well-established model for studying the
vascular complications of MetSyn, especially with respect to the peripheral circulation. Prior to
these chapters written for this dissertation, however, very little was known about how MetSyn in
the OZR specifically impacted the cerebrovascular circulation, and how these impairments
would influence the physiologic responses to perturbations like ischemic stroke or stress-induced
depression. Ischemic stroke in particular is highly correlated with MetSyn, yet few studies into
the vascular responses to ischemic stroke have incorporated traditional stroke risk factors like
MetSyn in their study design. After defining and investigating the mechanisms of
cerebrovascular dysfunction in the OZR, this dissertation focuses specifically on how these
impairments change or exacerbate pathophysiological outcomes in cerebrovascular disease.
The second chapter of this dissertation focused on quantifying the progressive decline in
microvascular density in the frontal cortex of OZR, and utilized clinically relevant antihypertensives and glycemic control agents to assess the contribution of underlying hypertension
and hyperglycemia/insulin resistance on the development of cerebral cortical rarefaction.
Previous research from our laboratory and others had established that microvascular rarefaction
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occurs in the microcirculation of skeletal muscle, myocardium, and kidney. This study began by
measuring microvascular density (MVD) in LZR and OZR at 7-8 weeks (when symptoms of
MetSyn first begin to appear), 12-13 weeks, and 16-17 weeks (considered the age of full
maturation of MetSyn), and documented a significant, progressive decline in cortical MVD in
OZR. OZR were then chronically treated from 7 weeks of age with either an anti-hypertensive
drug (captopril, an ACE inhibitor; hydralazine, a systemic vasodilator), or a glycemic control
agent (metformin, hepatic gluconeogenesis inhibitor; rosiglitazone, insulin sensitizing agent),
and evaluated for MVD at the same time points. A separate cohort of OZR was treated with
TEMPOL to evaluate the effect of chronic anti-oxidant therapy on rarefaction, and/or L-NAME,
an endothelial nitric oxide synthase (eNOS) inhibitor. These treatments were selected to improve
NO bioavailability (TEMPOL), greatly reduce/inhibit NO bioavailability (L-NAME), and
evaluate potential non-NO related benefits of anti-oxidant therapy (TEMPOL+L-NAME).
Neither captopril nor hydralazine was able to prevent cerebral cortical rarefaction at 17
weeks, although captopril did delay onset and reduced rarefaction by almost half. In contrast,
both metformin and rosiglitazone significantly improved MVD at 17 weeks, preventing the vast
majority of rarefaction. The preliminary conclusion suggested by results is that management of
hyperglycemia and insulin resistance is critical to preventing cortical rarefaction. Treatment with
TEMPOL, however, completely prevented rarefaction in OZR at all time points, rendering it as
the most effective intervention. Treatment with L-NAME, both with and without TEMPOL,
resulted in the same temporal progression of rarefaction observed in OZR control, suggesting
that TEMPOL’s therapeutic benefit lays solely in its ability to increase NO bioavailability.
Mechanistically, these results suggest that management of oxidant load in the cerebral circulation
is the most important factor towards mitigating cortical rarefaction. A large body of literature has
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linked both type 1 and type 2 diabetes to cerebrovascular dysfunction, and identified reactive
oxygen species (ROS) such as superoxide as causative agents. Additionally, angiotensin receptor
signaling in the brain is directly linked to endothelial generation of ROS, so systemic treatment
with an ACE inhibitor like captopril should induce some reduction in oxidative stress. That
TEMPOL was the most effective, and L-NAME eliminated 100% of its benefit, supports this
hypothesis. The measurements of NO bioavailability further confirm this hypothesis, and a
strong, linear relationship is evident between NO bioavailability and cerebral cortical MVD.
The second chapter of this dissertation establishes clearly that progression of MetSyn in
ORZ lead to loss of NO bioavailability, with direct implications for MVD. It was therefore
hypothesized that impairments in cerebrovascular reactivity, and alterations in cerebral vessel
wall mechanics, would also develop in OZR. To test this hypothesis, the third chapter of this
dissertation investigated the structural and functional changes in middle cerebral arteries (MCA)
of OZR at 17 weeks, and utilized chronic treatment with pharmacological agonists targeted at
each of the constituent pathologies of MetSyn (anti-hypertensive, anti-diabetic, antidyslipidemic) to investigate how each of these cardiovascular phenotypes individually impact the
functional and structural alterations in the vasculature of the brain. Similar to Chapter 2, chronic
TEMPOL treatment and L-NAME treatment were utilized to directly assess what effect antioxidant therapy and elimination of NO bioavailability have on the progression of each functional
and structural outcome.
By 17 weeks of age, MCA of OZR had developed severe impairment to endotheliumdependent vasodilation, increased myogenic activation, significantly reduced NO bioavailability,
eutrophic inward remodeling, and increased mechanical stiffening. Plasma levels of biomarkers
for inflammation and oxidative stress were also elevated significantly. Stiffening of MCAs
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occurred earliest, and seemed to precede the other structural and functional deficits, and acute
incubation of isolated MCA with TEMPOL rescues some, but not all, dilatory capability and NO
bioavailability. Management of hypertension in OZR was most significantly related to changes
in arterial stiffening. The two anti-hypertensives, hydralazine and captopril, effectively mitigated
increase in arterial stiffness, as did atorvastatin and TEMPOL, which each independently caused
a reduction in blood pressure. In this study, the anti-diabetic agent rosiglitazone helped reduce
inward remodeling, and improved NO bioavailability and vasodilation to acetylcholine.
Rosiglitazone was more effective than metformin at improving NO bioavailability, and was also
more effective at improving vascular reactivity and reducing arterial stiffness. The effects of the
anti-dyslipidemia drugs were highly divergent; while both atorvastatin and gemfibrozil
effectively controlled plasma cholesterol levels, atorvastatin also conferred significant
improvements in NO bioavailability, vascular reactivity, and vascular stiffness, while
gemfibrozil did not. Atorvastatin is known to have anti-inflammatory and anti-oxidative
pleiotropic actions, providing a potential explanation for the difference from gemfibrozil.
The most significant finding of this chapter was that interventions which increased NO
bioavailability also significantly improved vascular reactivity, reduced inflammatory biomarkers
(TNFα, MCP-1), and reduced nitrotyrosine, a plasma biomarker for oxidative stress.
Rosiglitazone, atorvastatin, captopril, and TEMPOL were the most effective interventions at
achieving these outcomes, with TEMPOL and atorvastatin having the largest benefit. Chronic
treatment with L-NAME, conversely, resulted in the most severe manifestation of each vascular
pathology. Temporal analysis of the interaction between NO bioavailability, vascular reactivity,
and vascular stiffness reveal a progressive and concurrent decrease in each of these metrics from
7 to 17 weeks in OZR; animals from each treatment group fit neatly into the three-dimensional
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model, with the most efficacious treatments at preserving NO bioavailability trending towards
values for LZR, while the least efficacious treatments trended towards values for untreated OZR.
As was found in chapter 2, the increase in oxidative stress and inflammation that occurs with the
onset of MetSyn in OZR significantly impaired functional and structural components of the
cerebral circulation.
The second and third chapters of this dissertation provide a substantial body of evidence
that development of MetSyn leads to structural and functional impairments in the middle
cerebral arteries, as well as a progressive loss of penetrating and parenchymal arterioles and
capillaries within the cortex. The next step was to evaluate how these cerebrovascular
impairments inherent in OZR would impact the pathophysiology of prevalent cerebrovascular
diseases. Chapter 4 of this dissertation investigated the vascular and neurological outcomes to
ischemic stroke in LZR and OZR, and attempted to elucidate distinct mechanisms that contribute
to both the acute stroke injury as well as the long-term vascular complications from ischemic
stroke.
Chapter 4 established that ischemic stroke in rats with pre-existing MetSyn increased
infarct size and mortality rates, impaired recovery of cerebral blood flow following reperfusion,
and caused a progressive exacerbation of stroke-induced vascular dysfunction in both
hemispheres of the brain. While vascular reactivity was impaired in the ipsilateral (IL) MCA
(stroke side MCA) of both LZR and OZR at 24 hours post-stroke, the dysfunction was greater in
OZR. Two weeks post-stroke, reactivity remained constant in LZR IL MCA and contralateral
(CL) MCA, and was improved in both by acute treatment with TEMPOL; in OZR IL MCA
however, reactivity was completely eliminated, and vessels instead constricted to acetylcholine.
Acute treatment with TEMPOL in OZR IL MCA prevented vasoconstriction, but did not
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improve dilation, as was seen in OZR CL MCA. These findings indicated that a specific injury,
likely occurring during ischemia-reperfusion, was damaging the OZR IL MCA far worse than
LZR IL or CL MCA, or OZR MCA. It was hypothesized that oxidative injury specific to the site
of ischemia-reperfusion was the cause of this impairment. This hypothesis was tested by
administering the NAD(P)H oxidase 2 (Nox2) inhibitory peptide gp91ds-tat during ischemic
stroke in OZR. Treatment with gp91ds-tat was able to improve OZR IL MCA reactivity at 15
days post stroke to match OZR CL MCA, but had no effect on OZR CL MCA function. Nox2
inhibition also improved post-stroke cerebral blood flow, and eliminated infarction in the stroke
territory. The conclusion of this experiment was that acute inhibition of Nox2, a highly expressed
enzyme in leukocytes that respond to ischemic injury, could prevent oxidative damage to both
the IL MCA and the ischemic core of the stroke during and immediately following an ischemic
event.
Chapter 4 provided additional evidence that oxidative stress and ROS were contributing
to the loss of NO bioavailability that defines cerebrovascular dysfunction in MetSyn. The fifth
chapter of this dissertation sought to establish whether chronic stress/depression, which is known
to impair peripheral vascular reactivity, would further exacerbate these pathologies.
Additionally, chapter 5 investigated whether exercise training would prevent the onset of
stress/depression induced vasculopathy in both LZR and OZR, and establish whether the antioxidant, anti-depressant effects of exercise would be sufficient to treat stress-induced depression
in OZR.
The experiments in Chapter 5 involved imposing the unpredictable chronic mild stress
(UCMS) protocol, a translationally-relevant model of environmental stressors that reproducibly
induces depressive symptoms in rodents- on LZR and OZR for 8 weeks to induce depression and
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vascular dysfunction. Concurrently, a cohort of LZR and OZR received exercise training, or
exercise training with UCMS, for the 8 week period. The main finding of this chapter is that
UCMS induces vascular dysfunction in MCA of LZR and OZR, as well as eutrophic remodeling
and cortical rarefaction in UCMS treated OZR. Acute incubation of vessels with TEMPOL and
L-NAME revealed that these impairments largely stemmed from alterations in NO
bioavailability, with impairments being substantially greater in OZR than LZR. Exercise training
was able to improve each of these symptoms in both LZR and OZR. Interestingly, exercise
trained animals from control OZR and UCMS OZR groups, as well as the UCMS LZR groups,
could be characterized as ‘good’ or ‘poor’ responders to exercise training. ‘Good’ responding
OZR showed a dramatic improvement in MCA reactivity, restoring reactivity to the same as
LZR control, while ‘poor’ responders showed a much smaller, albeit significant, improvement
over OZR control and OZR UCMS. A similar dichotomy was seen for the ‘good’ and ‘poor’
responders in the LZR. These findings suggest that the anti-depressive and vasculoprotective
benefits of exercise training may be limited in many individuals. While the finding that exercise
improves depressive symptoms and vascular health is not itself novel, this study was the first to
conclusively link chronic stress/depression with cerebrovascular dysfunction, in lean as well as
MetSyn animals, and the exercise component helps to establish the causative mechanisms
through which these impairments occur and could subsequently be treated.
Each chapter of this dissertation used TEMPOL as a scavenger of ROS to reduce levels
of superoxide and improve NO bioavailability, either acutely on ex vivo vessels, chronically
through dietary administration, or both. TEMPOL is a mimetic of the enzyme superoxide
dismutase (SOD) and therefore will work to directly reduce superoxide levels; SOD itself
however turns superoxide into oxygen or hydrogen peroxide, which itself is a vasoactive
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metabolite that can contribute to vasodilation or potentially impact basal tone. In our
experiments, acute incubation of vessels with TEMPOL did not result in any change in resting
vessel diameter or tone. TEMPOL also had a negligible effect on reactivity in control LZR,
exercise LZR, and exercise OZR, indicating that conditions of healthy NO bioavailability were
significantly more important that the role of any SOD-produced peroxide at baseline or during
vasodilation. However, a specific significant role of hydrogen peroxide cannot be completely
ruled out by the methods presented in this dissertation, and is therefore a limitation of each study.
Future studies could control for this by specifically treating with catalase to directly evaluate the
role hydrogen peroxide plays in each of the pathways and conditions discussed here.
In conclusion, MetSyn in the OZR is associated with structural and functional
impairments in the cerebrovasculature. These MetSyn-induced impairments are significantly
driven by loss of NO bioavailability, and highly correlated with an increase in oxidative stress
and inflammation. As a consequence of poor perfusion and control of cerebral blood flow,
animals with MetSyn demonstrate significantly worse vascular and neurological outcomes to
ischemic stroke, and are more severely affected by vascular impairments from chronic
stress/depression. Treating underlying pathologies of MetSyn, such as hypertension, diabetes,
and dyslipidemia, has limited efficacy at improving cerebrovascular function. Instead, therapies
which focus on improving NO bioavailability by reducing inflammation and production of ROS
are the most effective option for reducing cerebrovascular dysfunction in MetSyn.
There are many clinical implications of these findings. When considering the extremely
high prevalence of MetSyn in the US and its link to diseases such as stroke, myocardial
infarction, atherosclerosis, dementia, and Alzheimer’s disease, it becomes necessary to question
how the comorbid presence of MetSyn directly impacts the pathophysiology of these diseases.
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Incorporating MetSyn into preclinical models of these diseases may serve to enhance the
translational utility of these models and improve the clinical relatability of their findings.
This dissertation provides preclinical evidence that targeting acute production of ROS
during ischemic stroke may substantially improve vascular reactivity and reduce oxidative injury
in the ischemic core, leading to better outcomes for stroke patients. Evidence is provided for
efficacy of exercise as an anti-depressant and anti-oxidant therapy; however, mechanisms are
also identified through which more targeted therapies can be designed, perhaps to capture
‘exercise in pill form’. More broadly, this dissertation provides a wide body of evidence that
severe, significant cerebrovascular dysfunction develops due to the underlying pathologies of the
metabolic syndrome.
Clinically, cognitive function is not often considered when diagnosing and treating
MetSyn and other forms of CVD; however, these impairments may be significant contributors to
the pathological development of vascular cognitive impairments, vascular dementia, and loss of
collateral reactivity that worsens outcomes in ischemic stroke. It is well-established that the
damages and deficits from dementia and mild cognitive impairments are permanent, and cannot
be reversed; the same goes for neuronal death in stroke. It is therefore of critical importance that
cerebrovascular health is considered, and potentially treated, well in advance of the manifestation
of cerebrovascular disease.
By reducing oxidant stress and improving NO bioavailability in the brain, healthy
regulation of blood flow can be ensured for functional hyperemic responses generated by
neurons, or for promoting collateral flow during cerebral ischemic events. While evaluating
efficacy of therapeutics to achieve such benefits was not the primary aim of this dissertation, the
results presented here show that drugs such as captopril, atorvastatin, and TEMPOL are effective
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at mitigated cerebrovascular dysfunction from MetSyn. Additionally, exercise was highly
effective in both regular OZR and UCMS-treated OZR. Of course, TEMPOL is not viable for
application in humans, and the compliance issues with prescribing exercise are well documented;
nevertheless, the mechanisms through which these treatments confer benefits to the
cerebrovasculature are defined within this dissertation, and future studies to identify more ideal
compounds for human use would be warranted. The therapeutics studied here would therefore
serve as a good starting place for the evaluation or development of novel compounds for treating
cerebrovascular dysfunction.
There are several future directions this work could take. Firstly, further evaluation and
characterization of gp91ds-tat as an acute inhibitor of Nox2 during ischemic stroke is warranted
and necessary to evaluate the clinical potential of this compound and this pathway for treating
stroke in human patients. The preliminary data of the pilot study presented within this
dissertation are promising, and offer a novel approach for limiting oxidative damage that occurs
in both the cerebral vasculature and within the infarcted tissue during and after ischemic stroke.
Dose-escalation should be conducted, as well as single vs multi-time point administration of
gp91ds-tat. Additionally, other Nox family inhibitors should be evaluated for their therapeutic
potential against gp91ds-tat specifically. Another immediate future direction for the work in this
study is to identify and characterize the distinct pathways through which microvascular
rarefaction occurs in the cerebrum. While it is likely that oxidative stress and reduced NO
bioavailability are causal factors in this rarefaction, the pathways through which vessels are
broken down and through which angiogenesis is regulated need to be characterized in order to
better understand these processes and consider therapeutic approaches for mitigating or reversing
cerebral rarefaction in patients.
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Long-term, this work has interesting implications for the study of MCI and dementia.
While preclinical models are not necessarily adequate for studying age-related cognitive
disorders, efforts could be undertaken to characterize vascular density in the brains of patients
with age and in clinical conditions such as MCI and dementia. Imaging studies to determine
overall basal metabolic activity of neurons could be performed to establish any relationships
between blood flow perfusion and neuronal activity, and correlations sought after between
impaired cerebral blood flow and the advancement of cognitive deficits and dementias.
Additionally, long term augmentation of NO bioavailability should be studied in patients taking
daily doses of drugs such as atorvastatin or captopril to determine whether they have lower risk
of MCI or dementia independently of the direct beneficial effects of the drug on cholesterol or
blood pressure, respectively. Such observational studies could offer insight as to the direct
translational relevance of the mechanisms of cerebrovascular disease presented herein, and offer
further justification for clinical trials to establish which means may be most effective at
preserving cerebrovascular health and function in humans.
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SHORT ABSTRACT:
The unpredictable chronic mild stress (UCMS) protocol is a validated method for
studying behavioral and physiological changes associated with chronic stress and depressive
symptoms. Eight weeks of imposition of the UCMS protocol induces behavioral changes and
poor health outcomes in rodents of either gender.
LONG ABSTRACT:
Chronic, unresolved stress is a major risk factor for the development of clinical
depression. While many preclinical models of stress-induced depression have been reported, the
unpredictable chronic mild stress (UCMS) protocol is an established translationally-relevant
model for inducing behavioral symptoms commonly associated with clinical depression, such as
anhedonia, altered grooming behavior, and learned helplessness in rodents. The UCMS protocol
also induces physiological (e.g., hypercortisolemia, hypertension) and neurological (e.g.,
anhedonia, learned helplessness) changes that are clinically associated with depression.
Importantly, UCMS-induced depressive symptoms can be ameliorated through chronic, but not
acute, treatment with common SSRIs. As such, the UCMS protocol offers many advantages over
acute stress protocols or protocols that utilize more extreme stressors. Our protocol involves
randomized, daily exposures to 7 distinct stressors: damp bedding, removal of bedding, cage tilt,
alteration of light/dark cycles, social stresses, shallow water bath, and predator sounds/smells. By
subjecting rodents 3-4 hours daily to these mild stressors for 8 weeks, we demonstrate both
significant behavioral changes and poor health outcomes to the cardiovascular system. This
approach allows for in-depth interrogation of the neurological, behavioral, and physiological
alterations associated with chronic stress-induced depression, as well as for testing of new
potential therapeutic agents or intervention strategies.
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INTRODUCTION:
Depressive mental illness is a complex neurological disorder that is currently recognized
as a leading cause of disability and disease burden worldwide. The NIMH reports that
approximately 12% of Americans suffer from clinical depression, with twice as many women
affected versus men1.

In the US alone, depression accounts for billions of dollars direct

healthcare costs and an estimated $193 billion more in indirect costs (lowered earnings and lost
productivity)2. Symptoms of depression include anhedonia, changes in weight and sleep cycles,
decreased physical activity and personal hygiene, feelings of hopelessness or guilt, and/or
reoccurring thoughts of death or suicide.

During the last decade, epidemiologic and clinical

studies have indicated that depression is an independent risk factor for cardiovascular disease
(CVD) morbidity and mortality3, and is predictive of more severe prognosis of cardiovascular
pathologies, including atherosclerosis, hypertension, myocardial infarction, and coronary artery
disease, regardless of prior history of overt CVD4. Despite the increasing prevalence and adverse
public health impact of depression, the etiology and related pathophysiology of this disease is
poorly understood and the heterogeneity of the disorder due to various factors (e.g. genetic,
biological, and environmental components) has made clinical diagnosis difficult to define.
Evidence indicates that irresolvable psychological stress is a major contributing factor for
developing depressive illnesses and may also be a potent pathogenic factor linking depression
and CVD, in part due to disruption and dysregulation of the hypothalamic-pituitary-adrenal
(HPA) axis5, 6. Dysfunction of the HPA axis is a major mechanism that has been linked to the
behavioral and physiological changes observed in depression and the development of several
CVD risk factors, including dyslipidemia, obesity, and diabetes7. Multiple preclinical models of
depression have been developed in attempt to replicate the mechanism of altered HPA axis
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activity characteristic of clinical depression; such models provide a validated means for
investigating the behavioral, neurological, and physiological changes associated with chronic and
acute stress in animals. The validity of an animal model of disease is based on the relevance of
the etiology and progression of the model design and its ability to recapitulate anatomical,
neurophysiological, and behavioral features observed in human disease. In addition, preclinical
responses to treatments (such as SSRIs) should yield similar results to those observed in clinical
settings.
Several animal models of stress-induced depression are currently utilized in research,
such as learned helplessness, early life stress, and social defeat stress. However, each of these
models has inherent disadvantages that lessen their translational efficacy8. Within the last
decades, the Unpredictable Chronic Mild Stress (UCMS) protocol has emerged as one of the
most translationally-relevant models for studying the pathophysiology of depression in rodents9.
This model is based on the fundamental concept that chronic exposure to stressors disrupts stress
response systems and ultimately leads to the development of depressive disorders. During the
UCMS protocol, animals are exposed to a randomized series of mild environmental and social
stressors on a daily basis. A crucial factor that enhances the relevance of this model to human
situations lies in the high degree of unpredictability and uncontrollability of the stressors, as well
as the time at which they are introduced. Additionally, the UCMS protocol uses only mild
stressors, instead of relying on early life or aggressive physical stimuli. Over a period of UCMS
exposure, depressive behaviors develop and are comparable to clinical symptoms, including
decreased responsiveness to rewards (anhedonia), changes in physical activity and investigative
behavior (helplessness and despair), deterioration of the coat state and altered sexual activity10.
Almost all demonstrable symptoms of depression have been reported using this model, and
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studies have demonstrated that these behaviors persist for several weeks following the cessation
of stress. In addition, these UCMS-induced depressive behaviors can gradually be revered by
chronic, but not acute, treatment with particular antidepressants, suggesting similar neurological
effects of therapeutic improvement that closely mirrors the clinical action and variable efficacy
of these agents in humans11, 14-18 . Here, we report a detailed description of the UCMS protocol
and describe typical behavioral and vascular outcomes in mice.

PROTOCOL:
All procedures described below have been reviewed and approved by the Institutional Animal
Care and Use Committee at the West Virginia University Health Sciences Center.

1. Selection of animal model.
NOTE: Most commonly used species in the UCMS model include Sprague Dawley, and Wistar
rats and the BALB/cJ mouse; other murine models have shown limited efficacy (DBA/2,
C57BL/6). However, careful consideration should be given to the particular mouse or rat strain
of choice, as the genetic background and susceptibility to environmental stressors vary widely
among species and have been shown to be critical factors affecting the outcomes of the study.11,
14, 15, 19

1.1)

The protocol takes at least 7-9 weeks to fully induce depressive symptoms, so animals of
the appropriate age must be utilized (e.g. if the desired endpoint is to be evaluated in a
17-week old rat, then the rats must start the UCMS protocol at ~9 weeks of age).

221

1.2)

Single-house animals undergoing UCMS in IACUC-approved cages and facilities, with
food and standard chow available ad libitum (unless otherwise required by specific
protocol).

1.3)

Take special care to ensure controls are housed in a quiet room with minimal activity to
reduce effects of any possible unknown environmental stressors.

2. Unpredictable Chronic Mild Stress Protocol.
NOTE: Animals undergoing UCMS are transported daily (>5 days per week) to a clean room
used for UCMS manipulations. Animals are exposed to 1 or 2 of the stressors listed below each
day. Stressors are performed on a randomized schedule, and each stress is administered for a
minimum of 3-4 hours (see Table 1).

2.1)

Dampen the bedding by pouring 10-20 oz. of clean water into each standard cage. Adjust
the amount of water accordingly to the size of the cage in order to fully dampen the
bedding but not to cause pooling of water. Reside the animals in damp cage for 3-4 hours.

2.2)

Remove bedding from each cage for 3-4 hours, after which animals are transitioned into
another stressor requiring an empty cage (shallow bath, cage tilt) or placed into a clean
cage with fresh bedding.
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2.3)

Tilt cages to approximately 45 degrees (without bedding) for 3-4 hours. Cages can be
tilted with a sturdy object that will remain in place as the animal moves around in the
cage.

2.4)

Alter normal 12 hour/12 hour light/dark cycles into successions of 30 minute periods
lasting for 8 hours. After, return animals to the normal cycle.

2.5)

Transfer each animal from its home cage to that of the cage of a neighboring animal that
has been removed for 3 hours.

2.6)

Remove all bedding from each cage and add water to a depth of ~0.25 inches for mice or
~0.5 inches for rats for approximately 4 hours. Use water that is warmer than room
temperature (~30° C) to minimize hypothermia potential. Briefly dry animals with a soft
towel at the conclusion of the water exposure prior to placement into clean cages.

2.7)

Expose animals to predator smells/sounds by adding randomly distributed sample tufts of
fur or urine (10-20 ml) from a natural predator species into the cage for 3-4 hours.
Alternatively, play growling or predatory noises from natural predator species in close
proximity to cages for 3 hours.

2.8)

At the end of each daily stress period, place all animals into clean cages and return them
to the housing facility.

223

3. Animal monitoring/grooming scores.
NOTE: Each animal is monitored daily for development of lesions or wounds, and weekly for
changes in weight and an overall grooming assessment.

3.1)

Inspect each animal daily for the development of wounds or sores that may require
veterinary treatment. Animals that develop mild injuries may continue in the UCMS
protocol on the consent of the veterinarian.

3.2.1) Two investigators trained in evaluating coat grooming inspect each animal and assign a
weekly coat score on a scale of 0-1. This score is determined by assigning individual
scores (0- clean, 1-dirty) to each of 8 body regions- head, neck, dorsal coat, ventral coat,
tail, forelimbs, hind limbs, and genital region. The same investigators are to perform this
task throughout the UCMS protocol to maintain consistency in assigning coat scores.
3.2.2) Any animal that experiences a sharp reduction in body weight (i.e., >15%) should be
reported to the veterinary staff and must be removed from the protocol.

4.

Behavioral testing and outcome measurements.

NOTE: Several methods of assessment can be used to quantify behavioral changes from the
UCMS protocol in rodents.

4.1)

Cumulative Coat Grooming Score.

4.1)1. As described above, a weekly coat grooming score is assigned for each animal.
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4.2)

Sucrose Splash Test:

4.2)1. Place the animal in a clean cage lined with an cotton pad or towel to prevent bedding
from adhering to its coat. Spray a 10% sucrose solution onto the head and dorsal coat of
each animal and record total grooming behavior for 5 minutes.

4.2)2. Grooming activity (defined as cleaning of the fur by licking or scratching) is measured by
latency (idle time between the first spray and initiation of grooming) and frequency
(number of times grooming a particular body part).

4.3)

Sucrose Preference Test:

4.3)1. Habituate animals to drink 1% sucrose solution (w/v) 72 hours before the test and then
provide exposure to two bottles (1% sucrose solution versus tap water in different
bottles). After habituation, provide animals with ad libitum access to sucrose solution
and tap water for 3 hours. After 3 h record the consumption volumes of sucrose solution
and tap water and calculate sucrose preference as: [(sucrose consumption)/(water
consumption + sucrose consumption)]×100.

4.4)

Tail Suspension Test (Mice Only):

4.4)1. Suspend mice by the tail from a stable rod (20 cm from the floor) using adhesive tape (2
cm from tip of tail). Record immobility time over 5 minutes. Mice are considered
immobile only when they hang passively and completely motionless.
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4.5)

The Forced swim Test:

4.5)1. Place animals in a container (~15-20 cm diameter for mice; ~55-60 cm diameter for rats)
filled with water at a temperature of 26 ± 0.5 °C. Record the latency to the first bout of
mobility and the time spent immobile during the 5-min testing period. At the end of a
test, place the wet animal in a holding cage on a heating pad (30–35 °C) with normal
bedding covered by an absorbent paper towel until dry.

4.6)

Elevated Plus Maze:

4.6)1. Allow each animal to explore the maze freely for 5 min. Record total entries into each
arm, and total time spent in each arm, according to a priori criteria20.

4.7)

Locomotor Activity:

4.7)1. Record activity levels, defined as overall movement, fine movements, rearing
movements, and inactivity, for both acute (30 minute) and/or chronic (12 hour) time
periods.

Do this using the home cage or a novel environment, depending on the

individual environment (although consistency should be maintained) in real time by an
observer or post-hoc by replaying and analyzing camera footage.

5.

Expansion/Variation of UCMS protocol:

5.1. Administer appropriate therapeutic agents or challenges to study their ability to either blunt
the development of UCMS-induced outcomes (if initiated early) or to reverse severity of
established UCMS-induced outcomes (if initiated late). This is dependent on the individual
laboratory or protocol11.
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6.

Final outcome assessments:

6.1. Following the conclusion of UCMS protocols and behavioral testing, utilize animals in
subsequent experiments in a manner that addresses the specific hypotheses, aims or goals
of the individual laboratory.

NOTE: As examples, this can include cardiovascular, inflammatory or endocrine responses to
chronic stress. Alternatively, therapeutic interventions can be introduced at this point to evaluate
their effectiveness and mechanistic underpinnings.

REPRESENTATIVE RESULTS:
An example of the schedule for one week following the UCMS procedure is shown in
Table 1. Each week, stressors were randomized to prevent acclamation and to ensure
unpredictability of the stress challenge each day.

Measures of Depressive like Behaviors: Following 8 weeks of UCMS, there were significant
alterations to both behavioral and physiological outcomes in chronically stressed rodents relative
to their non-stressed control strains. Development of depressive like symptoms following UCMS
was assessment via coat score, sucrose splash test, and tail suspension (mice only; references 12
and 13). A progressive decline in coat grooming scores was observed in all UCMS animals
(Figure 1, Panel A), and this marked degradation in the physical state of the coat suggests
decreased grooming activity. This behavior may parallel the lack of motivation to or loss of
interest in performing everyday tasks, such as the maintenance of minimal personal care.
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UCMS animals also demonstrated an increased latency to groom and reduced total
grooming time in the sucrose splash test (Figure 1, Panels B and C). Increased time to initiate
grooming behavior along with decreased time spent grooming is associated with reduced
motivation and a decline in self stimulatory behavior, or reduced sensitivity to pleasure. This is
representative of the core symptom of depression, anhedonia. In addition, there was a significant
increase in the immobility time during the tail suspension test in mice. As stated previously, this
behavior is a measure of behavioral despair with greater immobility representing a more severe
depressive like symptom.

Measures of Physiological Changes: MAP can be significantly elevated as a result of the
UCMS protocol, but this is not consistently observed (Table 1). A significant reduction in the
dilator response to methacholine was observed in the aortic rings of UCMS BALB/cJ mice
compared to controls (Figure 2). This increased shift towards blunted dilator responses is
observed in clinical cases of increased risk for development of cardiovascular disease.

UCMS mice manifested increased plasma levels of cortisol, a marker of chronic physiological
stress, and nitrotyrosine, a marker of chronic oxidative stress (Table 2).

Additionally, UCMS mice showed significantly elevated levels of the pro-inflammatory markers
TNF-α and MCP-1. Together, these results suggest that stressed animals develop a
pathophysiological disease profile following 8 weeks of UCMS (Table 2).
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Divergence with Sex: Recent evidence has suggested that there is a substantial quantitative
divergence in the responses to UCMS between male and female mice (13). Specifically, data
suggest that female mice, exposed to the identical UCMS protocol as age-matched males,
develop more severe behavioral responses to the protocol than do males (Table 3 and Figure 3),
with elevated levels of cortisol, nitrotyrosine and markers of inflammation.

However, despite this divergence between sexes following the UCMS protocol, the vasculopathy
that develops as a result appears to be blunted in the female sex as compared to the males,
strongly suggesting a superior maintenance of endothelial function, despite the compromised
environment (Figure 4).

For Figures 1 and 3, results were obtained using the techniques described above, with the
application of ANOVA and t-tests as appropriate. For Figures 2 and 4, results were obtained
using concentration-response relationships in ex vivo aortic ring preparations. Curves were fit
with a three parameter logistic equation, with ANOVA and t-tests as appropriate for the lower
bounds of the curves. Please see references12, 13 for details.

FIGURE LEGENDS:
Figure 1: Depressive Symptoms Following Eight Weeks of UCMS in Mice. Data are presented
for coat status (Panel A), the latency (Panel B) and frequency (Panel C) of facial grooming
following a 10% sucrose solution spray, and the total period of immobility during the tail
suspension test (Panel D) for control and UCMS mice. * p<0.05 versus control. Please see
reference12 for details.
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Figure 2. Vasodilator Responses to Methacholine from Mice Following Eight Weeks of
UCMS. Data are presented for mice under control conditions (control lower bound=10.3±2.4%)
and following eight weeks of the imposed UCMS protocol (UCMS lower bound=33.6±4.4%). *
p<0.05 versus responses in untreated vascular rings from control mice. Re-printed from reference12
with permission.

Figure 3. Differences in Depressive Symptoms Following Eight Weeks of UCMS in Male and
Female Mice. Data are presented for coat status (A), the latency (B) and frequency (C) of facial
grooming following a 10% sucrose solution spray, and the total period of immobility during the
tail suspension test (D) for control and UCMS mice. * p<0.05 versus Control in the sex; †
p<0.05 versus UCMS-Male. Re-printed from reference13 with permission.

Figure 4. Differences in Vasodilator Responses from Male and Female Mice Following Eight
Weeks of UCMS. Dilator responses of aortic rings to increasing concentrations of methacholine
(upper panel, A) and sodium nitroprusside (lower panel, B) from mice under control conditions and
after eight weeks of UCMS. * p<0.05 versus Control in the sex; † p<0.05 versus UCMS-Male.
Re-printed from reference13 with permission.

Table 1: Two sample weeks for imposition of unpredictable chronic mild stress (UCMS)
protocol.

Stressor 1

Sunday
Monday
Alter
Social
Light/Dark Stress

Tuesday
No
bedding

Wednesday
Damp
Bedding

Thursday
Alter
light/dark

Friday
Saturday
Predator Social
sounds
Stress
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Stressor 2

Alter
Cage Tilt
Light/Dark

Shallow
Bath

Cage Tilt

Social
Stress

Shallow
Bath

Table 2. Baseline characteristics between mouse groups under control conditions and following
8 weeks of UCMS. All mice are aged 17-18 weeks. * p<0.05 versus control. Modified from
reference 12.

DISCUSSION:
Extensive clinical and epidemiological evidence has indicated that chronic stress is one of
the most potent precipitating factors for depression. Repeated exposure to stressors may
potentiate individual vulnerability to depression and other neuropsychiatric disorders as a
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consequence of the psychological and physical demands within the body that accumulate over
time. The use of validated preclinical animal models offers a valuable translational tool for
studying depression and comorbid diseases. Firstly, an ideal animal model offers an opportunity
to understand molecular, genetic and epigenetic factors that may lead to depression. By using
such models, the underlying mechanisms and the causal relationship between genetic or
environmental alterations and depression can be investigated, potentially allowing a more
thorough insight into the pathophysiology of depression. Secondly, validated, improved models
of depression are an indispensable tool for identifying and evaluating novel therapeutics and
treatments, an essential first step towards developing improved diagnostic and treatment options.
For many years, the UCMS model has been validated for use in psychological and
behavioral studies as a translationally relevant rodent model for chronic stress, human depression
and depressive symptoms, as it does an excellent job at reproducing clinical symptoms of human
depression, including anhedonia and learned helplessness21.

In addition, the temporal

development of the depressive symptoms is also relevant for human disease conditions, as
animals experiencing UCMS develop depressive symptoms over time in response to stress,
which is considered to be more translationally relevant. The representative results reported here
showcase the ability of this model to generate a symptomatic profile of depression, including
both behavioral and physiological changes, in both a rat and mouse model. In addition, the
severity of behavioral and physiological outcomes shows sex-specific differences that could
potentially be used to study the pathological effects of stress on men and women21.

It should be pointed out that the outcome of stress exposure is influenced by several
variables under experimental conditions, including the nature of the stress (physical/systemic vs.
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cognitive/psychological), the severity of the stress, and exposure parameters. Different
techniques can be used to measure depression-like behaviors and physiological outcomes and
vary results among investigators21. For example, evaluation of the end points of behavioral tests
may be variable depending on the use of recording methods as well as inconsistent methodology
and bias amongst individual investigators. The particular strain/species used is also critical, as
they have been shown to possess differences in susceptibility to UCMS. Further, other issues,
such as the degree of control an animal has over stress exposure and the predictability of the
stressor have been demonstrated to be important to the outcomes of the UCMS model, as greater
unpredictability can reduce the probability of adaptive processes occurring upon repeated stress
exposure and promote the appearance of stress effects on physiological and behavioral
functions21.
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